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There is a dire need for next-generation approaches to treating autoimmune disease that 
can potently inhibit the autoreactive destruction of host tissue while conserving protective immune 
functions. Antigen-specific immunotherapies (ASIT) offer such promise by harnessing the same 
pathogenic epitopes attacked in autoimmunity to selectively suppress the autoreactive cells that 
cause disease. Formatting autoantigen for ASIT is not trivial, as no clinical immunotherapies of 
this class are currently approved for treating autoimmune disease despite decades of attempts. This 
dissertation sought to explore physical and chemical determinants of efficacy in ASITs as a 
contribution toward fostering a future of precisely tailored autoimmune interventions. In these 
works, three autoantigen formats are explored: soluble, particulate, and surface delivery – each 
within the context of murine experimental autoimmune encephalomyelitis (EAE). In chapter 2, the 
soluble antigen array (SAgA) was adopted as a platform to investigate the role of antigen valency 
in evoking B cell anergy to promote tolerance among mixed splenocytes. Analysis of SAgAs 
presenting discrete autoantigen valencies revealed that low-valency (but not monovalent) 
autoantigen was most capable of inhibiting B cell calcium mobilization, and this inhibition 
predicted tolerogenic effects in a mixed population of splenocytes. In chapter 3, particulate 
autoantigen delivery was explored by formulating a “functional” delivery system consisting of an 
antioxidant vitamin E emulsion. This formulation proved capable to suppress EAE in vivo, but 
mechanistic analyses suggested a driver of effect that differed from the originally hypothesized 
antioxidant function. These results motivated the invention of the antigen-specific immune decoys 
(ASIDs) reported in chapters 4 and 5. ASIDs were comprised of autoantigen restricted onto the 
surface of microporous collagenous biomaterials. Peptide-epitope decorated constructs prevented 
EAE in vivo by intercepting and exhausting autoreactive cells. Chapter 5 was an extension of this 
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work, where polyantigenic ASIDs were fabricated to present a comprehensive palette of 
autoantigens and account for the heterogeneity of authentic disease. Though capable of amplifying 
discrete antigen-specific cell subsets ex vivo, polyantigenic ASIDs apparently did not induce 
cellular exhaustion and failed to attenuate EAE as a result. Together, these works emphasize the 
importance of characteristics such as antigen valency and context. The ongoing exploration of the 
ASID platform provides a foundation for assessing the utility of engineered local 






Above all, thanks be to God. He is my strong tower and the light to my path. 
I am forever indebted to the people who believed in me both leading up to and during my 
time as a Jayhawk; It is because of you that this dissertation was ever possible. It would be 
impossible to recount all of the ways that friends, peers, and mentors enabled this journey, but I 
will attempt to note a few here. 
 It is with tremendous gratitude that I thank my PhD advisor, Dr. Cory Berkland. Cory, you 
modeled for me what it means to be a man of intentionality, integrity, and tact in this field. You 
took me into your lab when I had little to offer, and I will never forget this outpouring of generosity 
you demonstrated to me. You taught me to internally define and strive for my own success in a 
world that longs for external laudations. Thank you for your guidance, investment, and friendship 
over the past four and a half years. I have immensely valued our conversations together.  
Thank you to my parents, Richard and Teresa Griffin. Dad, you spoke encouragement into 
me from a very young age and instilled in me an appreciation for the true value of exceptional 
effort. Mom, you constantly and selflessly demonstrated sacrificial love to my siblings and I, and 
because of it we are able to chase our dreams today.   
I am monumentally grateful to Madison ‘Al’ and Lila Self their gift that is the Self Graduate 
Fellowship. It is only because of their endless generosity and vision that I was able to complete 
this dissertation, both in the first place, but especially with the experiences and development that 
have prepared me to “make a real difference”. Thank you to the fellowship staff for your dedication 
and for giving me the opportunity to participate in this extraordinary program. Fellow fellows, it 
has been tremendous to grow with you over the past four years and I am forever grateful for the 
relationships we have built together. 
vi 
 
There is no lab quite like the Berkland lab - thank you to the lab mates who have made this 
such an enjoyable ride and have helped me so very much along the way. Jian Qian, Brad Sullivan, 
Brittany Hartwell, Lorena Napolitano, Chad Pickens, Shara Thati, Laura Northrup, Martin Leon, 
Matt Christopher, Jimmy Song, Melissa Mihalcin, Stephanie Johnson, Aric Huang, Sebastian 
Huayamares, Kyle Apley, Justin Ruffalo, Aparna Chakravarti, Mary Duncan, Bryce Stottlemire, 
Dakota Even, and Jon Whitlow, you have all enriched my graduate school experience beyond 
measure. Thank you as well to Michael Shao, Alex Sedlacek, and Deanna Diaz - the talented 
undergraduate students I had the privilege to work directly with. 
Wally Meyer, thank you for the mentorship and support you invested into me. I am 
indebted to you for the thoughtful questions and careful attention you gave me in encouraging the 
tangible realization of Exodus Biosciences. 
Thank you to Dr. Steve Jacobson. You took me in and showed me an entirely new world 
of research at the National Institutes of Health. 
The School of Engineering have been greatly supportive over my time as a graduate 
student. I am fortunate to have been able to work with Anna Paradis and Lynn Villafuerte as a 
graduate engineering ambassador, and special thanks go to Denise Bridwell for ensuring the 
success of me, along with all the other students of the Bioengineering Graduate Program. 
To my doctoral committee – Dr. Brandon DeKosky, Dr. Prajna Dhar, Dr. AJ Mellott, and 
Dr. Lisa Friis – thank you for your time, dedication, and feedback in edifying my development as 
a scientist and the dissertation herein. 





Table of Contents 
1. Introduction ............................................................................................................................. 1 
1.1 Autoantigen format directs the immune response: lessons from the clinic...................... 2 
1.2 Peripheral Autoimmunity is a Vicious Cycle ................................................................... 4 
1.3 Route and Size -Dependent Biotransport Dictates the Destination of Parenterally 
Delivered Compounds. ............................................................................................................... 7 
1.4 Allergy Immunotherapies as the Foundation for Antigen-Specific Approaches to 
Autoimmunity. .......................................................................................................................... 12 
1.5 Autoantigens Embody Physicochemical Profiles that Differ from Allergens ............... 16 
1.6 Immunological Fates for Delivered Autoantigen are Determined by Format ............... 20 
1.6.1 Systemic Drainage .................................................................................................. 22 
1.6.2 Lymphatic Transport ............................................................................................... 22 
1.6.3 Injection Site Retention........................................................................................... 23 
1.7 Strategies for Circumventing Delivery and Distribution Obstacles ............................... 24 
1.7.1 Intranodal delivery .................................................................................................. 24 
1.7.2 Transdermal delivery .............................................................................................. 25 
1.8 Next-Generation Approaches to Formatting Autoantigen for Optimizing ASIT .......... 25 
1.8.1 Soluble Delivery ..................................................................................................... 26 
1.8.2 Colloidal Delivery ................................................................................................... 26 
1.8.3 Depot Delivery ........................................................................................................ 27 
1.9 Conclusions .................................................................................................................... 27 
1.10 References .................................................................................................................. 28 
viii 
 
2. Acute B-Cell Inhibition by Soluble Antigen Arrays is Valency-Dependent and Predicts 
Immunomodulation in Splenocytes .............................................................................................. 35 
2.1 Introduction .................................................................................................................... 36 
2.2 Materials and Methods ................................................................................................... 38 
2.2.1 Materials ................................................................................................................. 38 
2.2.2 Synthesis and Characterization of Varied Valency Conjugates ............................. 39 
2.2.3 Raji B Cell Culture.................................................................................................. 39 
2.2.4 Induction of EAE .................................................................................................... 40 
2.2.5 Spleen Harvest and Splenocyte Isolation ................................................................ 40 
2.2.6 Fluorescent Staining and Flow Cytometry ............................................................. 41 
2.2.7 Measurement of Cytokines ..................................................................................... 41 
2.2.8 Measurement of Cellular Metabolism .................................................................... 42 
2.2.9 Statistical Analysis .................................................................................................. 42 
2.3 Results ............................................................................................................................ 42 
2.3.1 Synthesis of Varied-Valency Conjugates ............................................................... 42 
2.3.2 Inhibition of Short-Term B-cell Response is Valency-Dependent. ........................ 44 
2.3.3 Low-Valency Conjugates Induce Downstream Anergy in Mixed EAE Splenocytes .  
 ................................................................................................................................. 46 
2.4 Discussion ...................................................................................................................... 50 
2.5 Conclusions .................................................................................................................... 54 
2.6 Supporting Information .................................................................................................. 55 
2.7 Acknowledgments .......................................................................................................... 60 
2.8 References ...................................................................................................................... 60 
ix 
 
3. Tocopherol Emulsions as Functional Autoantigen Delivery Vehicles Evoke Therapeutic 
Efficacy in Experimental Autoimmune Encephalomyelitis ......................................................... 64 
3.1 Introduction .................................................................................................................... 65 
3.2 Materials and Methods ................................................................................................... 67 
3.2.1 Materials ................................................................................................................. 67 
3.2.2 Preparation of ETPGS Emulsions ........................................................................... 68 
3.2.3 Characterizing Size and Peptide Release from ETPGS Emulsions ........................ 69 
3.2.4 Measurement of ETPGS Antioxidant Power .......................................................... 70 
3.2.5 Acute Antioxidant Effect in a Model APC ............................................................. 70 
3.2.6 Induction of EAE and Therapeutic Study ............................................................... 71 
3.2.7 Tissue Harvest and Splenocyte Isolation ................................................................ 72 
3.2.8 Measurement of Cytokines ..................................................................................... 72 
3.2.9 Measurement of Cellular Metabolism .................................................................... 73 
3.2.10 Fluorescent Staining and Flow Cytometry ............................................................. 73 
3.2.11 Detection of Anti-PLP IgG ..................................................................................... 74 
3.2.12 Statistical Analysis .................................................................................................. 74 
3.3 Results ............................................................................................................................ 74 
3.3.1 Characterization of the ETPGS Formulation .......................................................... 75 
3.3.2 ETPGS influences oxidative stress in vitro ............................................................ 77 
3.3.3 ETPGS-facilitated autoantigen delivery delays and suppresses EAE in vivo ........ 79 
3.3.4 Ex vivo splenocyte cytokines and populations in ETPGS+PLP efficacy ............... 81 
3.3.5 Autoantibodies are largely restricted to the periphery in mice treated with 
ETPGS+PLP ......................................................................................................................... 85 
x 
 
3.4 Discussion ...................................................................................................................... 86 
3.5 Conclusions .................................................................................................................... 89 
3.6 Supporting Information .................................................................................................. 90 
3.7 Acknowledgments .......................................................................................................... 92 
3.8 References ...................................................................................................................... 93 
4. Antigen-Specific Immune Decoys Intercept and Exhaust Autoimmunity to Prevent Disease   
  ............................................................................................................................................... 98 
4.1 Introduction .................................................................................................................... 99 
4.2 Materials and Methods ................................................................................................. 101 
4.2.1 Materials ............................................................................................................... 101 
4.2.2 Synthesis of ASIDs ............................................................................................... 102 
4.2.3 Characterizing ASIDs ........................................................................................... 103 
4.2.4 Induction of EAE and Therapeutic Study ............................................................. 103 
4.2.5 Detection of Anti-PLP IgG ................................................................................... 104 
4.2.6 Spleen Harvest and Splenocyte Isolation .............................................................. 104 
4.2.7 Sponge Harvest and Spongeocyte Isolation .......................................................... 105 
4.2.8 Fluorescent Staining and Flow Cytometry ........................................................... 105 
4.2.9 Measurement of Cellular Metabolism .................................................................. 106 
4.2.10 Measurement of Cytokines ................................................................................... 106 
4.2.11 Histology ............................................................................................................... 106 
4.2.12 Statistical Analysis ................................................................................................ 106 
4.3 Results .......................................................................................................................... 107 
4.3.1 Synthesis and Functional Characterization of ASIDs ........................................... 107 
xi 
 
4.3.2 Subcutaneous Implantation of ASIDs prevents EAE in vivo ............................... 109 
4.3.3 ASID Infiltrates undergo Apoptosis upon PLP Rechallenge ................................ 112 
4.3.4 ASIDs Return Exhausted Immune Cells to Secondary Lymphoid Organs .......... 115 
4.3.5 Antigen-Specific Exhaustion Persists after PLP rechallenge ............................... 118 
4.3.6 Pro-inflammatory Cytokines are Elevated in ASID-Treated Splenocytes at Day 14 
and 25 ............................................................................................................................... 121 
4.4 Discussion .................................................................................................................... 124 
4.5 Conclusions .................................................................................................................. 127 
4.6 Supplementary Information.......................................................................................... 127 
4.7 Acknowledgements ...................................................................................................... 138 
4.8 References .................................................................................................................... 138 
5. Polyantigenic Immune Decoys Amplify Antigen-Specific Cell Populations but do not 
Suppress Experimental Autoimmune Encephalomyelitis ........................................................... 143 
5.1 Introduction .................................................................................................................. 144 
5.2 Materials and Methods ................................................................................................. 146 
5.2.1 Materials ............................................................................................................... 147 
5.2.2 Preparation of Gelatin Methacrylate ..................................................................... 148 
5.2.3 Fabrication of Homogenate-GelMA Scaffolds ..................................................... 148 
5.2.4 Synthesis of plpGelatin Materials ......................................................................... 148 
5.2.5 Characterizing Complex Decoys .......................................................................... 149 
5.2.6 Retained Antigen-Specificity Analysis ................................................................. 149 
5.2.7 Induction of EAE and Therapeutic Study ............................................................. 150 
5.2.8 Detection of Anti-PLP IgG ................................................................................... 150 
xii 
 
5.2.9 Spleen Harvest and Splenocyte Isolation .............................................................. 151 
5.2.10 Ex Vivo Screening with EAE Splenocytes ........................................................... 151 
5.2.11 Fluorescent Staining and Flow Cytometry ........................................................... 152 
5.2.12 Resazurin Cell Metabolism Assay ........................................................................ 152 
5.2.13 Statistical Analysis ................................................................................................ 152 
5.3 Results .......................................................................................................................... 152 
5.3.1 Fabrication of Complex Decoys ........................................................................... 152 
5.3.2 mbhGelatin Decoys are Persistent Depots that Incorporate Primary Tissue 
Homogenate and Retain Antigen-Specificity ..................................................................... 154 
5.3.3 mbhGelatin Decoys Elicit a Cellular Response and Amplify Antigen-Specific B 
cells ex vivo ........................................................................................................................ 157 
5.3.4 EAE splenocytes are largely unchanged by prophylactic mbhGelatin implantation ..  
  .............................................................................................................................. 161 
5.4 Discussion .................................................................................................................... 164 
5.5 Conclusions .................................................................................................................. 168 
5.6 Acknowledgments ........................................................................................................ 168 
5.7 References .................................................................................................................... 168 
6. Conclusions and Future Directions ..................................................................................... 172 
6.1 Conclusions .................................................................................................................. 173 







As prepared for peer-reviewed submission 
 
Griffin, J. Daniel, Jimmy Y. Song, Brandon J. DeKosky, and Cory J. Berkland. “Autoantigen 




















1.1 Autoantigen format directs the immune response: lessons from the clinic 
 Autoimmune disease has long persisted as a difficult and costly problem in modern 
medicine. Indeed, the American Autoimmune Related Diseases Association estimates that these 
diseases such as Multiple Sclerosis (MS), Type 1 Diabetes (T1D), and nearly one hundred others 
collectively affect over 50 million Americans and cost upwards of $100 billion to treat each year. 
A major criticism of this exorbitant treatment burden is that it does not adequately stifle disease 
presentations; contemporary therapeutics largely serve only to suppress symptoms without 
addressing the causative factors that drive autoimmunity1, 2. In this review, we will explore 
biotransport considerations for antigen-specific immunotherapies (ASIT) and glean insights for 
designing safe and potent autoimmune treatments. We will begin by analyzing the 
physicochemical properties of several predominant allergens, as desensitization therapies have 
provided the foundation for ASITs. We will highlight key differences between these properties 
and those of autoantigens to suggest design parameters for ASITs of the future to ultimately 
optimize clinical success. 
Prevailing treatment strategies across many autoimmune diseases involve the 
administration of immunosuppressive drugs. These compounds broadly compromise host 
immunity – healthy and aberrant alike3. While the virtue of these approaches is a slowing of disease 
progression, a steep tradeoff demanded by these routes is the ablation of protective immune 
function as well4. Glucocorticoids have been widely applied to suppress inflammatory function 
against a plethora of autoimmune diseases, though they are marked by increased patient 
susceptibility to infection5. In MS, natalizumab is proven to significantly reduce relapse rates, 
however this monoclonal antibody is also well known for imposing the risk of progressive 
multifocal leukoencephalopathy (PML) - a life-threatening result of the opportunistic JC virus 
3 
 
becoming activated6. Similarly severe risks exist with Rituxumab, a B-cell depleting 
immunotherapy that has been deployed for a plurality of autoimmune diseases such as Rheumatoid 
Arthritis (RA), T1D, and MS7.  
 The push for precision medicine is a major initiative that has built excitement and 
momentum especially in the arena of cancer, but it likewise captivates immense promise for 
autoimmunity8, 9. Breakthroughs of precision approaches to cancer have come by way of 
leveraging the genetic anomalies that are hallmark of specific kinds of tumors. Capitalizing on 
these discrepancies has enabled the design of delivery systems that can specifically target and 
eliminate malignancies with potent chemotherapeutics, and these approaches have radically 
transformed previously hopeless prognoses10, 11. Autoimmunity, however, has yet to see clinical 
success stories in the form of precision medicines. This setback is in part due to the fact that unlike 
cancers, the autoreactive cells that perpetuate disease can be phenotypically indistinguishable from 
healthy immune cells. The result has been an absence of targeted immunotherapies for 
autoimmune disease. Even Ocrelizumab, one recently approved drug for MS, works by broadly 
deleting B cells from patients12. Although more targeted, this approach has already been plagued 
by the same kinds of adversities as its predecessors from past decades13, 14. 
  Though autoimmune cells can appear similar to typical functional immune cell types, their 
detrimentality can be defined by a fundamental difference in the antigen receptor specificity15, 16. 
The immune system serves to exact homeostasis by maintaining recognition of “self” and “non-
self” antigens through highly specific T cell and B cell receptors (TCRs and BCRs, respectively)17. 
In the development of healthy immune cell progenitors, antigen receptors are selected by positive- 
and negative-filtering checkpoints18, 19. These tolerance mechanisms typically serve to remove or 
inactivate autoreactive T and B cells, though they are indelibly compromised when autoimmunity 
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ensues20, 21. Antigen-specific immunotherapy (ASIT) invokes a meaningful stride toward precision 
in treating autoimmunity through the promise of selectively targeting cells that escape tolerance22.  
 ASITs, in the context of autoimmunity, direct immunomodulation to the autoreactive cells 
that propagate disease23. This precision is accomplished by delivering formulations that 
incorporate the very same autoantigens responsible for the self-directed tissue destruction taking 
place. While the precision implications of ASITs are readily grasped from the cell-targeting that 
comes from delivering autoantigen, deeper mechanistic characteristics are critical to consider. 
Autoantigens and their constitutive epitopes widely vary in terms of physicochemical properties 
such as size, charge, and solubility, and these differences can vastly impact the way ASIT 
formulations are trafficked throughout the body and elicit effect24. In this review, we explore these 
physicochemical drivers of effect that hold great importance for the design of effective ASITs with 
potential for treating authentic human disease.  
 
1.2 Peripheral Autoimmunity is a Vicious Cycle 
 To understand antigen-specific approaches for the desensitization of aberrant 
autoimmunity, we must first review the underpinning mechanisms that propagate disease in the 
first place. In the cycle of autoimmunity, the faulty immune response is primed in secondary 
lymphoid organs and exacted in tissue compartments rich with cognate autoantigens (Fig. 1)25. In 
the origination of autoimmune destruction, an initial or ongoing insult disrupts tissue (Fig. 1.1)26. 
Damaged tissue both releases autoantigen and provokes innate arms of the immune system. 
Disrupted autoantigen is able to passively or actively drain to lymphoid organs (Fig. 1.2a) by 
following transport phenomena that will be covered in greater depth later on (Fig. 2). Also, 
however, innate arms of immunity are engaged through the tissue compartment becomes an 
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inflammatory microenvironment (Fig. 1.2b). Tissue damage generates a host of immune-boosting 
cues including reactive oxygen species and damage-associated molecular patterns that stimulate 
sentinel cells such as dendritic cells (DCs), macrophages (mφ), and monocytes to take up antigen 
and become activated27. With this activation comes a subsequent migration to regional lymph 
nodes; “active transport” implies antigen conveyed by this mechanism. (Fig. 3).  
 Once at the lymph node, autoantigen may undergo further processing to reach the T and B 
cell zones28. In these locales, follicular antigen presenting cells are capable to present autoantigen 
to cognate naïve CD4+ T helper cells (Fig. 1.4). Naïve T helper cells will become stimulated if 
antigen presentation occurs with the simultaneous ligation of B7 pathway surface proteins29. These 
proteins include CD80 and CD86 on the surface of antigen presenting B cells and DCs which can 
bind CD28 on T cells to propagate their activation30. Depending on T helper subtype and intranodal 
cues such as cytokines, these activated cells are compelled to proliferate and promote an effector-
driven immune response through receptor and cytokine signaling (Fig. 4.5)31. While a plethora of 
finely-tuned antigen-specific effector responses can ensue, they can broadly be categorized by 
cellular or humoral responses in nature. Cellular immune responses are characterized by T helper 
1 and 17 type responses which are recognizable by secreted inflammatory cytokines such as IL-2, 
IFN-γ, TNF-α, IL-23 and IL-1732, 33. Responses of this nature are most commonly indicated in 
autoimmune disease, as they stimulate phagocytic innate immune cells such as mφ to engulf target 
cells or debris34. Humoral immune responses recruit B cells into the effector response; these 
directive signals promoted through cytokines such as IL-4, IL-6, and IL-10 trigger antibody 
secretion by terminally differentiated plasma cells35. The ensuing antibody production is efficient 
to bind and label free antigen. Humoral immunity is recognized to play an increasingly important 
role in some autoimmune diseases such as Neuromyelitis Optica and MS36, 37.  
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Nevertheless, when effector responses are triggered, these activated cells home back to 
antigen-rich compartments to cause autoreactive damage and reinitiate the autoimmune cycle once 
more by renewing the production of immunogenic factors (Fig. 1.6)38. The cyclic nature of 
autoimmune potentiation may illustrate the relapsing-remitting pattern followed by many of these 
diseases. However, this thematic scheme likewise demonstrates the potential for ASIT to influence 
the immune system. Antigen processing, presentation, and signaling occurs in secondary lymphoid 
organs, and these tissues represent a priority target in modulating the aberrant response. It is critical 
to target ASIT to the lymphatics not just for their directive role in propagating immunity, but also 
for the inherent probability of interacting with T and B cells that possess cognate antigen receptors. 
The body has an estimated 1012-18 discrete theoretical T and B cell receptor specificities39-41 . In 
peripheral blood, only 2% of all lymphocytes are estimated to be circulating at any given time42. 
Since an overwhelming majority of clonalities are present in the lymphatics, the importance of 




Figure 1. Mechanisms of peripheral autoimmunity. Damaged tissue releases autoantigen (1) that 
either drains directly to lymphatics (2a) or is internalized by resident professional antigen 
presenting cells (pAPCs, 2b and 3). In the secondary lymphoid organs, follicular pAPCs process 
and present antigen to naïve T helper cells in the presence of costimulatory signals (4). Naïve T 
cells become stimulated to proliferate and differentiate a cellular or humoral effector response (5). 
These activated effectors egress from lymphatics and eventually home to antigen-rich tissue 
compartments once more, where more damage can be caused and the cycle of autoimmunity is 
renewed (6).  
 




 It is critical to understand the transport phenomena that that must be harnessed for delivery 
to immunologically directive tissues. Particularly with delivered allergy and antigen formulations, 
many administration routes have been investigated, but each presents its own unique delivery 
considerations. In this review, we will refine our analysis to focus on parental routes 
administration, as non-injected delivery introduces complex facets of mucosal immunity that have 
been well-reviewed in the past43-45. Our scope includes interstitial and intravenous (IV) strategies, 
which have been clinically investigated for both allergy and autoimmunity (Fig. 2). Interstitial 
administration indicates formulations delivered directly into tissue parenchyma and envelops 
common routes such as subcutaneous (SC), intramuscular (IM), and intradermal (ID) injection 
(Fig. 2a).  
Interstitial delivery is appealing for its ease of administration and proven successes over a 
century-long history in vaccines and allergy46, 47. This route can exploit extracellular matrix (ECM) 
properties and sentinel cell populations to deliver formulations to draining lymph nodes. The ECM 
largely consists of an interpenetrating network of collagen and glycosaminoglycan polymers and 
is able to hinder leakage from the injection site in a size-dependent manner. Both diffusion and 
convection can drive transport through the ECM. Albumin serves as an excellent reference 
(molecular weight 69 kDa, size 3.5 nm) in that compounds smaller than this protein can rapidly 
diffuse from the injection site and reach systemic circulation through the blood pool while the 
transport for larger entities is driven by convective flow48. A negative pressure gradient exists in 
the interstitium that drains to the lymphatics. When particles are larger than the size of albumin, 
this convective flow dominates over diffusive transport and enables accumulation at lymph nodes. 
Importantly, however, when administered moieties exceed 100 nm in size, transport is restricted 
by the ECM (in humans)48. Structures of this size persist at the injection site as depots and must 
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rely on active transport by innate immune cells to reach lymphoid organs. An important note is 
that actively transported antigen can be difficult to harness for immunosuppressive function, 
however, due to its particulate nature49. We will discuss this perspective later in the review.  
 Indeed, entities between the size of 4-100 nm are generally able to reach lymph nodes from 
the interstitium by convective flow, but reaching these organs alone is not sufficient for affecting 
immunity. Lymph nodes are contained by a capsule that excludes much of the extranodal content 
that would otherwise intrude from systemic circulation. The T and B cell zones where immunity 
is potentiated lie within nodal sinuses that are protected by the subcapsular space and its resident 
macrophages and dendritic cells28. Herein, a second barrier is embodied that must be considered 
for ultimately delivering ASITs via interstitial routes. Conduits at this interface largely determine 
the penetration of free antigen into the nodal cortex with a 70 kDa cutoff50. The size of these 
channels once again represents a reference point similar to albumin, though shape and flexibility 
can confer access to larger compounds51, 52. Entities between 10-100 nm reaching the subcapsular 
space are mostly excluded excepting transport by subcapsular innate immune cells53. Most of the 
active internalization by these macrophages and dendritic cells is Fc-mediated, meaning antigen 
bound with antibody can reach the cortex. However, these complexes are poised to be 
immunogenic as part of natural immunological cues.  
 A set of delivery principles can also be surmised for the IV administration of antigen 
formulations as well (Fig. 2b). Compounds injected directly to the blood stream can be deposed 
by the spleen, renal elimination, or liver processing. The spleen is poised as an immunologic filter 
from which systemic circulation is policed54. Delivery and penetration into this organ resembles 
the requirements for lymph nodes; moieties 4-200 nm in size are capable of reaching the spleen, 
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but only those between 4 to 10 nm can traverse conduits into the cortex. Small compounds (<4-6 
nm) are subject to renal excretion and do not persist to significantly influence immunity55.  
 Though antigens between 4-200 nm are able to reach the spleen, blood flow highly favors 
liver processing. Blood flow through the spleen is typically 5-10% of cardiac output while the liver 
draws up to 5-fold more blood56. Liver delivery has drawn interest for ASIT delivery due to its 
immunologically privileged nature that is conferred by unique cell subsets including Kupffer cells 
and liver sinusoidal endothelial cells57. For example, researchers have tuned properties such as size 
and charge to produce formulations that preferentially accumulate in the liver58. This design is 
important for ASIT, because autoantigen relegated to the liver has been applied to enact tolerance 
against autoimmune mouse models59, 60. Liver accumulation and retention is maximized with very 
large particles that exceed 200 nm in size, and persistence enables the longitudinal activation of 
tolerogenic mechanisms. In the case of 4-200 nm structures, exposure is less conducive to 




Figure 2. Parental routes of administration for influencing immunity. a. interstitial antigen 
transport is dictated by two major barriers. First, the ECM can serve to restrict the trafficking of 
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large entities greater than 100 nm in size. Small antigens less than 4 nm are subject to being lost 
to systemic circulation. Compounds between 4-100 nm can travel by convective transport to the 
lymph node, but only molecules between 4-10 nm are capable of traversing conduits into the 
directive T and B cell zones of lymph node parenchyma. b. IV administration poses the opportunity 
for antigen to reach the liver, spleen, or kidneys. Particles greater than 200 nm preferentially 
accumulate and are retained in the liver, but formulations 4-200 nm can also be processed via this 
route. The same 4-200 nm formulations can reach the spleen, and penetration into its cortex is 
dictated by the same principles as the lymph nodes. Finally, antigens less than 4 nm are subject to 
clearance by renal excretion.  
 
1.4 Allergy Immunotherapies as the Foundation for Antigen-Specific Approaches to 
Autoimmunity. 
With an understanding of the delivery parameters that influence the ability of formulations 
to access and influence the immune system, we can now look to practical examples for how 
aberrant immunity is modulated. ASIT as a strategy for addressing autoimmunity stems from 
historically successful applications in allergy desensitization therapies where hypersensitivity 
immune responses take place61. As such, we will assess historical underpinnings of allergy 
hyposensitization therapies and implications for ASIT applied to autoimmune disease. While 
recent ASIT strategies encompass a broad scope of approaches and delivery systems incorporating 
biomaterials, immunomodulatory drugs, and adjuvants, we have refined our focus here to the 
clinical delivery of allergen and autoantigen immunotherapies without co-delivery of drugs to 
enable the thorough analysis of physicochemical implications of these components. We aim to use 
this distilled approach to extrapolate a meaningful supposition about the clinical successes of 
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allergen-specific immunotherapies in contrast with the continued elusiveness of autoantigen ASIT 
implementation. Through understanding the role of autoantigen contextualization in directing the 
immune response, we propose that next-generation ASITs can be formatted for optimized action 
against autoimmune disease. 
 The first allergy immunotherapy was implemented with success in 1911 when Leonard 
Noon and John Freemen desensitized patients to grass allergy (known as hay fever at the time)62, 
63. In this seminal trial, the physicians subcutaneously administered grass pollen extract in regular 
intervals while increasing allergen dose over time to build resistance. This framework of repeated 
and escalating dose has overall remained essentially the same and informed allergy 
immunotherapies for the century since. Today there are 19 FDA-approved, standardized 
subcutaneous allergen desensitization regimens64.  
 With such broad and repeated demonstrations of effective allergen-specific 
immunotherapy regimens, it is important to explore the underlying characteristics driving these 
successes to enable rationalization against the comparative lack of breakthroughs within 
autoimmunity. Parameters such as size, charge and solubility each can play critical roles in 
directing the interaction between allergens and the immune system, and as such we have organized 
these data among three prominent allergens (Table 1).  
 Somewhat conserved physicochemical properties are evident across allergens. In terms of 
molecular weight (MW), extract fractions average 25.8, 21.4, and 21.0 kDa for timothy grass, 
peanut, and domestic cat, respectively. MW does not exceed 65.4 kDa (Ara h 1) across all 
allergens, though the minimum MW bottoms out at 2.6 kDa (Ara h 6). Isoelectric points (PI) are 
generally found at or below physiological pH between allergens. A PI of 10.5 was the maximum 
observed in the set (Ara h 11), while values did not go below 3.84 (Phl p 7). Finally, grand average 
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of hydropathicity (GRAVY) was used to roughly infer the water solubility of allergens through 
summing the hydropathy values of amino acids in the sequences. The GRAVY score describes the 
hydrophobicity of a given protein; larger, positive values generally mean the compound is 
insoluble while negative values imply hydrophilicity65. Interestingly, allergen extracts are mostly 















Phl p (avg) 25.8 5.90 -0.179 
Phl p 1 P43213 28.5 6.12 -0.433 
Phl p 2 P43214.1 13.4 4.28 -0.124 
Phl p 4 ABB78007.1 58.2 9.37 -0.127 
Phl p 5 CCD28287.1 31.1 7.5 0.195 
Phl p 6 CAA81608.1 13.9 5.08 0.041 
Phl p 7 CAA76887.1 8.7 3.84 -0.283 
Phl p 11 Q8H6L7.1 33.7 6.23 -0.562 
Phl p 12 CAA54686.1 19.1 4.78 -0.141 




Ara h (avg) 21.4 7.35 -0.316 
Ara h 1  AAB00861.1 65.4 6.91 -1.07 
Ara h 2 AAN77576.1 13.4 5.91 -1.22 
Ara h 3 AAD47382.1 54.1 5.29 -0.891 
Ara h 5 AAD55587.1 17.8 4.26 -0.078 
Ara h 6 ABQ96216.1 2.6 6.1 -0.821 
Ara h 7 AAD56719.1 19.6 5.8 -1.015 
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Ara h 8 AAQ91847.1 17 4.73 -0.365 
Ara h 9 ABX56711.1 11.6 9.15 0.572 
Ara h 10 AAU21499.2 9.5 10.07 0.153 
Ara h 11 AAZ20276.1 10.8 10.5 0.451 
Ara h 14 AAK13449.1 18.4 10.28 0.259 




Fel d (avg) 21.0 5.09 -0.170 
Fel d 1 
AAC37318.1, 
AAC41616.1 
17.8 4.5 0.265 
Fel d 2 CAA59279.1 38.3 5.27 -0.340 
Fel d 3 AAL49391.1 7.7 4.37 -0.584 
Fel d 4 AAS77253.1 15.9 4.62 -0.050 
Fel d 7 ADK56160.1 20.2 4.56 -0.521 
Fel d 8 ADM15668.1 25.9 7.24 0.209 
Table 1. Physicochemical properties of model allergens. Molecular Weight (MW), Isoelectric 
Point (PI), and Grand Average of Hydropathy (GRAVY) are reported for protein extract fractions 
where full amino acid sequences are available. Allergen extract fractions were identified by 
searching allergen.org for the major allergen (ex. Felis domesticus). MW and PI were calculated 
using the PepCalc.com online tool. GRAVY score was determined using the calculator at gravy-
calculator.de.  
 
Together, allergen extracts paint a cohesive picture about conserved properties that may 
point to their utility for desensitization. For the most part these extracts fall squarely in a size 
distribution between 10-70 kDa – precisely the range which facilitates lymphatic drainage and 
penetration while likely being excluded from the blood pool when administered as subcutaneous 
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or intramuscular injections (Fig. 2). Indeed, the desensitization regimens approved by the FDA 
enable the interstitial delivery of mixed extracts. Allergens are generally not extremely charged; 
these extracts possess PIs at or below physiological pH such that they carry a neutral or slightly 
negative charge. An absence of highly positively charged fractions means fibrillization and innate 
immunogenicity are generally circumvented. With these charge properties and net negative 
GRAVY scores, allergens avoid aggregation due to poor solubility and remain at a size that 
facilitates lymphatic transport and prevents the formation of large, immunogenic aggregates.  
 
1.5 Autoantigens Embody Physicochemical Profiles that Differ from Allergens 
While allergens appear to present with similar characteristics, autoimmune antigens come 
with many different size, charge, and solubility properties appreciable across several disease 
pathologies (Table 2). Myelin autoantigens including proteolipid protein (PLP), myelin 
oligodendrocyte glycoprotein (MOG), and myelin basic protein (MBP) are associated with MS. 
Their molecular weights are 30, 28.2 and 11.57 kDa, respectively, while each is positively charged 
at physiological pH. These autoantigens are found embedded within the fatty myelin sheath, and 
as such PLP and MOG display considerable hydrophobicity. Conversely, MBP presents with a 
highly water-soluble GRAVY score that is likely conveyed by its significantly positive 
physiological charge. T1D presents glutamate decarboxylase (GAD), preproinsulin, and 60 kDa 
heat shock protein (HSP60) as conserved autoantigens. Among these proteins, a negative charge 
is presented at physiological pHs. GAD and HSP60 are both somewhat soluble in water, while 
preproinsulin is slightly hydrophobic. RA autoreactivity includes specificity for 40 kDa heat shock 
protein (HSP40), which is negatively charged and slightly soluble. The thyrotropin receptor 
autoantigen in Grave’s disease is large (86.8 kDa), neutrally charged, and presents a positive 
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GRAVY score. In Hashimoto’s disease, a similar thyroid-directed autoimmunity, thyroglobulin is 
a colossal (304.8 kDa), but hydrophilic protein. Aquaporin 4 in neuromyelitis optica is moderately 
sized at 34.8 kDa, neutrally charged, and considerably hydrophobic.  
A number of clinical trials have been launched to investigate interstitial and IV delivery of 
autoantigenic epitopes within these proteins. Soluble antigen is reported as capable to skew 
immunity toward a regulatory phenotype and confer bystander immunosuppression effects. As 
such, a majority of injected autoantigen therapies within human MS patients has taken place using 
fragments of the soluble MBP protein. One phase III study investigated the immunodominant 
MBP82-98 epitope in 612 secondary-progressive MS patients possessing genetic dispositions for 
reactivity to the MBP protein in particular66. Over the two-year period, the epitope was safe and 
well tolerated during twice-yearly bolus administration, but no clinical benefit was observed. An 
alternate dose escalation study assessed the efficacy of a cocktail containing four MBP epitopes 
(30-44, 83-99, 130-144, and 140-154). While only 16 weeks long, a decrease in gadolinium-
enhancing lesions was evident67.  
In T1D, many insulin variants have been clinically evaluated. A 2002 study investigated 
the subcutaneous administration of insulin to first degree family members of T1D patients to assess 
its ability to prevent disease, though no success was realized68.  Likewise, an altered peptide ligand 
of the insulin B chain did not confer effect for newly-diagnosed patients69. Another study followed 
newly-diagnosed patients over 12 months as they were administered a proinsulin peptide70. Here, 
patients receiving the peptide did not exhibit significant adverse events and their glucoregulatory 
insulin requirements did not increase over the interval, suggesting some therapeutic benefit. 
Another T1D study administered a HSP460 peptide to patients71. While safe and well tolerated, 
the study was retracted due to biostatistical misconduct that distorted clinical differences between 
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the treatment and placebo groups. In patients with Grave’s disease, two peptides were 
intradermally injected for a Phase I study lasting 18 weeks72. While injection site swelling and 
pain were observed, the formulation was generally well tolerated and led to an improvement of 





















CAA52617.1 28.2 8.43 0.114   
Myelin Basic 
Protein 
AAC41944.1 17.8 11.57 -1.039   
82-98 66 2 6.75 -0.441 - 
30-44 67 1.7 9.94 -0.800 ++ 
83-99 67 2 8.85 -0.329 ++ 
130-144 67 1.7 10 -1.067 ++ 





AAB59427.1 67 7.11 -0.334   
Preproinsulin AAA59172.1 12 4.97 0.193   
Insulin 68 5.8 5.3 0.217 - 
Insulin B (9-23) 69 1.7 6.71 0.433 - 
Proinsulin peptide 70 1.9 8.75 0.133 ++ 
Heat Shock 
Protein 60 
P10809.2 61.1 5.46 -0.076   









AAA36783.1 86.8 6.58 0.066   
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  5D-K1 72 2.5 10.61 -1.314 + 
9B-N 72 1.3 6.71 -0.253 + 
Hashimoto's Thyroglobulin  CAA29104.1 304.8 5.25 -0.276   
Neuromyelitis 
Optica 
Aquaporin 4 AAH22286.1 34.8 7.41 0.420   
Table 2. Size, charge, and solubility properties for autoimmune antigens and interstitial/IV epitope 
treatments that have been clinical investigated. Property values were calculated using the same 
methodologies as in Table 1. Here, clinical responses are denoted with the following identifiers: 
(-) no therapeutic outcome, (+) biomarker improvement, and (++) clinical improvement. *The 
DiaPep277 study was retracted due to biostatistical misconduct.  
 
 In previously outlining allergen properties, a consistent trend of moderately sized (10-70 
kDa), slightly negatively charged (PI 5-7.4), hydrophilic (GRAVY < -0.15) fractions were 
observable. Such trends are not as evident in autoantigens. Many autoantigens are also moderately 
sized, but several including Thyroglobulin and Thyrotropin are well over the 70 kDa threshold. 
Charge properties are widely dispersed; unlike with allergens, autoantigens such as PLP, MOG, 
MBP, and HSP40 exhibit PIs greater than 8, conferring a positive charge at physiological pH, 
while others such as GAD and Preproinsulin resemble more neutral, allergen-like charges. 
GRAVY scores are also highly variable. Ranges across autoantigens are dispersed from -1.013 
(MBP) to 0.559 (PLP).  
 Further inference about allergen and autoantigen discrepancies can be gained by taking a 
perspective of MW, PI, and GRAVY scores holistically, rather than discretely. Very few 
autoantigenic proteins embody the full trifecta of size, charge, and solubility properties embodied 
by allergens. For example, while MBP is moderately sized (17.8 kDa) and theoretically water 
soluble (GRAVY -1.039), it carries an extreme positive charge which is known to be immunogenic 
20 
 
and disrupt cell membranes. Preproinsulin is likewise moderately sized (12 kDa) and it’s PI mirrors 
allergens (4.97), but it presents with hydrophobicity (GRAVY 0.193) that creates the possibility 
of aggregation in situ that would likewise be immunogenic73. Such unfavorable characteristics may 
pose safety and tolerability obstacles to the prospects of full-protein autoantigen administration. 
Clinical ASIT researchers have rather incorporated smaller peptide epitopes of immunodominant 
antigen regions to incorporate greater specificity to formulations. Peptide epitopes harnessed for 
parental interstitial and IV ASITs may neutralize safety concerns that may arise from whole-
protein autoantigen. MBP epitopes present charges that are slightly attenuated over full MBP. 
Thytotropin peptides cut down on the colossal size of the autoantigen. But is there a cost to electing 
these variants? What are the tradeoffs of size, charge, and solubility properties in the context of 
autoantigen delivery? 
 
1.6 Immunological Fates for Delivered Autoantigen are Determined by Format 
 The physical and chemical properties of delivered autoantigens are paramount in dictating 
distribution, kinetics, and immunological effect (Fig 2). These properties can together outweigh 
the primary intent of targeted interaction with autoreactive cells when they are not properly 
defined. The format of autoantigens can direct their distribution or retention in tissues, and these 




Figure 3. Autoantigen format dictates transport and can inform the resulting immune response. 
Small, hydrophilic entities that are interstitially delivered my replicate allergen regimens at low 
doses, but the peptide epitopes used are typically too small to be excluded from systemic exposure. 
As a result, low lymphatic loading and retention occurs, and efficacy becomes elusive. Conversely, 
anergizing lymphatic-draining formulations can be harnessed with intermediately-sized (10-70 
kDa), hydrophilic moieties that most closely resemble allergens. Antigens with this format are 
excluded from the blood and can achieve loading into lymph nodes in a low-density format that is 
most conducive for tolerance. Conversely, antigens that are net-hydrophobic or prone to fibril 
formation form immune complexes or are actively transported to the lymphatics, which entices an 
immunogenic response that introduces risks for autoimmune ASITs. Finally, large entities 
exceeding 100 nm are restricted by the ECM and retained near the site of injection. Likewise, 
entities with a strong positive charge can be retained through electrostatic interactions with the 
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negatively charged ECM. When formulations are retained, the innate immune system is recruited, 
and microenvironment (stimulatory or tolerogenic) directs the immune response.  
1.6.1 Systemic Drainage 
 Small, hydrophilic autoantigens and epitopes are destined for loss to the blood pool and 
systemic circulation. Low lymphatic loading results. For this reason, safety is maximized as 
antigen overstimulation and anaphylaxis are avoided, however potency in desensitization is also 
reduced. Many autoantigen epitopes that have been clinically investigated are classifiable under 
this fate. One of the major benefits of ASIT is the improved safety profile over global 
immunomodulatory drugs; as such, the development of a new class of immunotherapy mandates 
safety as a main priority. The epitope-alone strategies reviewed here consistently fall well below 
the 10 kDa cutoff for lymphatic drainage. Clinical results from these interventions are favorable 
in early-phase studies as they are safe and well tolerated, however efficacy has yet to be fully 
carried over to a full FDA approval for autoantigen epitopes.   
1.6.2 Lymphatic Transport 
 Lymph-draining formulations pose the opportunity to maximize autoantigen colocalization 
with directive immune populations. However, the resulting dose in lymphoid organs is extremely 
important to consider in directing immunity, as parameters such as valency and density can highly 
impact the nature of the resulting immune response. Indeed, the seminal allergy desensitization 
work that led to autoimmune ASITs was based on a low, but progressively escalating dose over 
time. This regimen is conducive to the physicochemical properties of allergens; intermediately-
sized (10-70 kDa), water-soluble allergen extract fractions are able to drain to and penetrate within 
lymph nodes for the retained delivery of controlled, low valency antigen. Autoantigen 
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physicochemical properties are not always conducive to the same routes. Immunogenic vaccines, 
in contrast, use adjuvants such as alum and MF59 to incorporate a high density of antigen in 
particulate formulations to trigger stimulatory processing and presentation by antigen-presenting 
cells74. The hydrophobic nature of some antigens such as PLP, MOG, and aquaporin 4 means these 
proteins are susceptible to aggregation after injection. Large aggregates of autoantigen complexes 
can confer the same immunogenic effects as adjuvant delivery systems, causing antigen-presenting 
cells to present high densities of antigen at lymph nodes via active transport73. Alternatively, in 
antibody-mediated autoimmunities, the aggregated autoantigen can invoke the formation of 
equally immunogenic immune complexes in the blood and interstitium75. Unduly concentrated 
autoantigen loads pose danger and could lead to anaphylactic or adverse events. While 
hydrophobic aggregation is one mechanism of these unintended effects, amphiphilic autoantigens 
or peptide epitopes can cause fibrils that embody similar nucleation events76. Even net hydrophiles 
are susceptible to the formation of particulates when regions of hydrophobicity are present77. 
1.6.3 Injection Site Retention 
 Some physicochemical properties may lead to the outright retention of formulations at the 
injection site. Human ECM restricts diffusion for entities that exceed 100 nm. While delivered 
autoantigens do not reach this threshold alone, significant aggregation or self-assembly can lead 
to macrostructures that are retained at the site of injection. Extreme positive charges can also retain 
autoantigen through electrostatic complexation with negatively-charged ECM components. 
Glatiramer acetate (Copaxone®) is a random chain of the four most prominent amino acids 
contained in MBP and is an FDA-approved injectable immunotherapy for MS patients78. While 
this formulation’s precise mechanism of action is unknown, we recently detailed that glatiramer 
acetate is highly retained at its site of injection through the electrostatic interaction of its many 
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lysine residues with negatively-charged glycosaminoglycans such as hyaluronic acid79. MBP, 
which is what glatiramer acetate was initially designed to mimic, expresses an even more polarized 
PI of 11.57 and shows that charge should be considered even though it confers a favorable 
calculated hydrophobicity.   
 Retained autoantigen can be a versatile tool for modulating immunity. With the formation 
of a depot at the injection site comes the recruitment of innate immune cells, and the accumulation 
of these actors can ultimately resemble tertiary lymphoid organs that form in disease states such 
as cancer and MS80, 81. The instructive immunity that results from the formation of these structures 
is highly determined by cues from the microenvironment. 
 
1.7 Strategies for Circumventing Delivery and Distribution Obstacles 
1.7.1 Intranodal delivery 
While the focus of our review is contained to the interstitial and IV administration of 
autoantigen-alone, several notable strategies exist to sidestep the inherent delivery constraints 
imposed by size, charge, and solubility. Interstitial injection may be favored over other routes for 
its ease and established history in allergy and vaccines, but intranodal injection directly administers 
antigen to target tissues. The principles governing the engineering of the lymphatic 
microenvironment have been well-reviewed in the past82 and may favor systemic immune 
tolerance83. It has been maintained that biomaterial delivery systems are necessary to increase 
lymphatic retention and sustained kinetics after intranodal delivery. In one study, researchers 
administered 165 patients with alum-adsorbed grass pollen allergen either subcutaneously for 54 
times over three years or just three intranodal injections over two months84. Striking results were 
obtained where tolerance in the intranodal group was attained in just four months compared to the 
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more intensive three-year plan. Further, these outcomes were achieved with just 1/1300 of the 
cumulative dose required for subcutaneous desensitization, and fewer adverse events were 
observed in the intranodal group. A study by the same group showed similar results for cat allergy. 
After just three intranodal injections over two months, nasal tolerance to cat allergen was increased 
74-fold85. These results highlight the importance of lymphoid organs as necessary target tissues in 
ASIT and illuminate the promise of direct intranodal administration. 
1.7.2 Transdermal delivery 
 Another notable strategy for overcoming ASIT delivery constraints is the controlled release 
of autoantigen through transdermal patches. As previously mentioned, autoantigen epitopes below 
10 kDa are likely to enter systemic circulation, thus bolus subcutaneous injections are not 
conducive to lymphatic loading and retention. Transdermal delivery offers a potential alternative 
to reformatting antigen for optimized trafficking. Here, the sustained depot release of epitopes can 
facilitate gradual lymphatic dosing. It is further hypothesized that transdermal administration can 
target resident Langerhans cells for active nodal transport86.  These interventions have already 
shown some successes in the realm of autoimmunity. For MS, a study was conducted where 
patients were administered three immunodominant epitopes (MBP85-99, MOG35-55, and PLP139-155) 
via the transdermal route87. Over one year, patch-treated patients exhibited significantly fewer 
clinical signs of disease progression than the placebo-treated cohort, and researchers observed a 
66.5% reduction in gadolinium-enhancing lesions over the interval.  
 
1.8 Next-Generation Approaches to Formatting Autoantigen for Optimizing ASIT 
 Clinical explorations of allergen and autoantigen immunotherapies shed light on delivery 
considerations, which should be harnessed in aiming to desensitize autoimmunity. Lymphatic 
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homing is paramount for evoking therapeutic effects. Interstitial and intranodal routes of 
administration appear to be most conducive for these effects, as splenic accumulation via the IV 
route is difficult to balance with hepatic accumulation. Physicochemical discrepancies between 
allergens and prominent autoantigens prompts the pursuit of next-generation ASITs that 
incorporate delivery systems and biomaterials to format the latter for optimal interfacing with 
tolerance mechanisms. 
1.8.1 Soluble Delivery 
 Immunogens that are below 100 kDa and hydrophilic are purported to be naturally 
tolerogenic88. Formatting autoantigens and their epitopes to more closely mirror these size and 
solubility properties should, therefore, enhance lymphatic delivery and amplify immune tolerance. 
Of course, inherent physicochemical autoantigen properties cannot be inherently changed, 
however net molecular properties can be modified using appropriate chemical modifications or 
carriers. Our group has employed polymers to solubilize antigen epitopes and control their valency 
properties to invoke immune tolerance pathways89-96. The size adjustment conferred to 
autoantigens enables exclusion from direct absorption into circulation while the solubility and 
spacing of antigen engages mechanisms of tolerance.  
1.8.2 Colloidal Delivery 
 A vast majority of autoimmune-targeted ASITs have recruited nanoparticulate delivery 
systems to deliver antigens and immunomodulatory drugs to lymph nodes. These systems 
incorporate polymers, metals, or emulsions to spatiotemporally restrict autoantigen and facilitate 
drainage to lymphoid organs as well as interaction with tissue-resident pAPCs. Notably, many 
vehicle materials are adapted from more mature fields such as cancer immunotherapy . Such 
delivery systems can invoke innate immunogenicity that is overlooked in applications where 
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inflammation is desirable97, 98. Some strategies for overcoming vehicle detriments for autoimmune 
ASITs involves developing functional vehicles that are formulated using immunologically 
instructive signals as constitutive building blocks99, 100. Others have utilized the ability of colloids 
to deliver drugs, such as immunosuppressants, to counteract any inherent immunogenicity and to 
direct downsteam response pathways.  
1.8.3 Depot Delivery 
 Immunologically-directive microenvironments are a powerful tool for evoking either 
inflammatory or regulatory responses101, 102. Another strategy for autoimmune ASITs is to 
intentionally retain autoantigen at the site of administration. Localization of autoantigens at the 
site of administration recruits pAPCs and cognate immune cells, encouraging processing at a locus 
that can be engineered with immunomodulatory signals. Though not delivering autoantigen, recent 
work by the Hubbell group showed the power of localized immunotherapies by homing anti-TNF-
α antibodies to collagen-rich inflammatory microenvironments and suppressing a mouse model of 
RA103. By skewing the inflammatory cues at the site of autoimmune destruction and autoantigen 
processing, disease was stifled. Depot-based autoantigen delivery systems may be further refined 
with the exploration of more immunological cues to control the inflammatory fates of autoantigen 
processing in situ.  
 
1.9 Conclusions 
 ASIT represents a compelling step toward precision medicine to treat autoimmune 
diseases. To date, many formulations have sought to interrupt the vicious cycle of autoimmunity 
by delivering the same autoantigens and epitopes implicated in disease. To date, however, no 
comparable ASITs are available for treating autoimmunity. ASIT underpinnings could learn from 
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historical successes in allergy, where a plethora of FDA-standardized allergen desensitization 
regimens are available. The physicochemical properties of allergen extracts differ substantially 
from those of autoantigens and their constitutive epitopes. Allergens are generally found between 
10-70 kDa in size with neutral or slightly negative charge and good water solubility. Autoantigens 
and their epitopes rarely express all three of these qualities, and these properties may confound 
their local transport in vivo. These discrepancies emphasize the role of molecular properties and 
delivery systems for developing ASITs to treat human autoimmune diseases.  
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Antigen presentation, especially with regards to valency (the number of antigens presented) 
can be a powerful therapeutic tool for either stimulating or suppressing immunity. More 
importantly, tuning ligand density on a macromolecule or colloid can vastly amplify or diminish 
immune signaling down either pathway 1-5. Targeting antigen-specific cell surface receptors may 
also provide a targeted approach to directing immune responses. Moving from monovalent antigen 
toward a multivalent antigen display can increase therapeutic potency by virtue of increasing 
receptor engagement through avidity 6-9. Investigation of both density and valency-dependent 
immunity matured in the late 1970s with seminal work by Howard Dintzis which illustrated starkly 
different immunological outcomes. By tuning properties including molecular size and ligand 
valency, Dintzis observed that large (>100 kD) polymers grafted with high ligand density (>20 
ligands/polymer, or 1 ligand per 5 kD) were immunogenic while smaller constructs (<100 kD) 
with similar or lower valency (<20 ligands/polymer) tended to be tolerogenic in nature 10-13. 
Central to this work was a focus on B-cells as potent directors of immunity. Nanoparticles 
target dendritic cells through nonspecific uptake that is mainly due to transport phenomena where 
depot formation at injection sites necessitates active transport by these sentinels to secondary 
lymphoid organs  14-17, but antigen-grafted polymers are uniquely able to target antigen-specific 
B-cell receptors by virtue of solubility (facilitating passive transport to B-cell rich lymph nodes), 
backbone flexibility, and retained ligand functionality 18. Much has been done to elucidate the 
signaling events triggered by occupation of B-cell receptors (BCR), especially in the area of 
valency-dependent receptor clustering 19, 20. Work by Kiessling and others has shown BCR 
clustering events as determinants of cell response, which has reflected many of Dintzis’ findings 
regarding the relationship between valency and immunogenicity 18, 21. For example, increased 
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avidity afforded by multivalent ligands was linked to the degree of BCR clustering as a driving 
factor dictating the B-cell response 22, 23. B-cells are known to be potent initiators of immunity 24, 
and the successful treatment of autoimmunity through depletion of these populations has 
reinforced their pathological role in directing the broader immune system 25-27.  
Soluble Antigen Arrays (SAgAs) exhibit size and valency characteristics of tolerogenic 
compounds espoused by Dintzis and others.  SAgAs are constructed using antigenic peptides 
conjugated to a linear, polymeric hyaluronic acid (HA) backbone as antigen-specific 
immunotherapy (ASIT) for combating autoimmunity 28, 29. Initially SAgAs were developed as a 
platform for displaying antigen alongside inhibitors of inflammatory immune responses 30-33, 
though recent mechanistic work has suggested the inhibitors may be somewhat dispensable. These 
studies have illustrated the integral role of antigen-specific binding and clustering of BCRs for 
effect 34-36. Past work has focused almost exclusively on SAgAs made using a 16-20 kD HA 
backbone displaying roughly 10 copies of antigenic peptide (PLP139-151) and 10 copies of a peptide 
(LABL) that inhibits binding of intracellular cell-adhesion molecule-1 (ICAM-1) 37. This work has 
gone far to expand our understanding of how multivalent polymers evoke immunological tolerance 
through the antigen-specific binding and clustering of BCRs 34-36. Past studies have shown these 
events anergize B cells by decreasing calcium flux, downregulating costimulatory molecule CD86 
and skewing cytokines toward a regulatory phenotype 35. Notably, valency has never been 
experimentally probed in this system where this avid engagement of B cells and clustering of BCRs 
has been identified as a central to the SAgA mechanism. 
Here, we hypothesized that titrating peptide valency could modulate initial B-cell behavior 
and ultimately tune downstream cellular immune responses in mixed splenocytes. To investigate 
this supposition, we modified a 16 kD hyaluronic acid backbone and employed click chemistry 38, 
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39 to synthesize a small library of SAgAs with discrete valencies for evaluation in both a B-cell in 
vitro model as well as an ex vivo experimental autoimmune encephalomyelitis (EAE) splenocyte 
assay. Furthermore, we tested the contribution of LABL as a secondary adhesion ligand by 
investigating the effects of SAgAs conjugated with only PLP139-151 antigen as well as those 
conjugated with both PLP139-151 and LABL. 
 
2.2 Materials and Methods 
2.2.1 Materials  
Hyaluronic acid (HA) sodium salt (MW 16 kDa) was purchased from Lifecore Biomedical 
(Chaska, MN). 11-azido-3,6,9-trioxaundecan-1-amine (NH2-PEG3-N3), N-hydroxysuccinimide, 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 2-(N-
morpholino)ethane-sulfonic acid sodium salt (MES), tris(3-hydroxypropyltriazolylmethyl)amine, 
and sodium ascorbate (NaAsc) were purchased from Sigma-Aldrich (St. Louis, MO). Copper(II) 
sulfate pentahydrate (CuSO4·5H2O) was purchased from Acros Organics (Geel, Belgium). 
Alkyne-functionalized peptides with an N-terminal 4-pentynoic acid (homopropargyl, hp) 
modification, hpPLP139-151 (hp-HSLGKWLGHPDKF-OH) and hpLABL (hp-ITDGEATDSG-
OH) were purchased from Biomatik (Cambridge, ON, Canada). Unmodified PLP139-151 (NH2-
HSLGKWLGHPDKF-OH) used for rechallenge was purchased from PolyPeptide Laboratories 
(San Diego, CA). Fluo-4 AM was purchased from Thermo Fisher Scientific (Waltham, MA). Raji 
B-cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). Affinity 
purified F(ab’)2 fragment goat anti-human IgM was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA). Incomplete Freund’s adjuvant (IFA) and killed Mycobacterium 
tuberculosis strain H37RA were purchased from Difco (Sparks, MD). Pertussis toxin was 
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purchased from List Biological Laboratories (Campbell, CA). R-phycoerythrin (PE)/Cy7-
conjugated anti-mouse CD3, PE-conjugated anti-mouse CD86, FITC-conjugated anti-mouse 
CD80, and respective isotype control antibodies were purchased from BioLegend (San Diego, 
CA). All other chemicals and reagents were analytical grade and used as received. 
2.2.2 Synthesis and Characterization of Varied Valency Conjugates 
  SAgAPLP and SAgAPLP:LABL were synthesized using click chemistry as previously reported 
35, where varied valency was attained by varying reactant hpPLP and hpLABL equivalents per 
HA-azide and assessing conjugation by RP-HPLC. Briefly, a two-step procedure was used to 
synthesize the conjugates used in this study. 16 kD sodium hyaluronate was reacted with 3-
(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine (EDC) and N-hydroxysuccinimide 
(NHS) before the addition of H2N-PEG3-N3. The product was dialyzed and lyophilized to yield 
hyaluronan-PEG3-N3 (HA). hpPLP139-151 and/or hpLABL were reacted with azide-modified HA in 
50 mM phosphate buffer at room temperature over 24h in the presence of tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), copper (II) sulfate pentahydrate (CuSO4·5H2O), 
and sodium ascorbate (NaAsc). SAgAs were analyzed quantitatively by RP-HPLC to assess target 
conjugation efficiencies (Supp. Fig. 1). 
2.2.3 Raji B Cell Culture 
 Raji B-cells were cultured in RPMI-1640 media with L-glutamine, 10% fetal bovine serum 
(FBS), and 1% penicillin/streptomycin (P/S) at 37 °C and 5% CO2. Calcium flux was performed 
only after cells reached confluency after 2 weeks of culture and before 8 passages were reached. 
Cells were split 1:10 once every 3 days, and calcium flux was performed on the second day after 
splitting (Raji B-cells in saturated culture at day 3 did not consistently respond to IgM stimulation). 
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Calcium Flux Experiments Calcium flux experiments were conducted as previously reported by 
our group 36. Briefly, Raji B-cells were loaded with 5 µM Fluo-4 for 30 minutes at room 
temperature. Cells were washed and resuspended in Hank Balanced Salt Solution (HBSS) before 
establishing a baseline fluorescence level on the flow cytometer for 60s. Raji B-cells were 
stimulated with 20 µg/mL goat anti-human IgM, and stimulated fluorescence was measured for 
another 60s. Stimulated cells were then treated with varied valency conjugates (dosed on a 353.18 
µM PLP basis), and fluorescence was read for an additional 180s. Data were analyzed by FlowJo, 
Kaluza, and GraphPad Prism. 
2.2.4 Induction of EAE 
 EAE was induced as previously described 40, 41 in 4-6 week-old, female SJL/J mice from 
Envigo Laboratories. Mice were housed under specified, pathogen-free conditions at the 
University of Kansas and under an approved protocol by the University's Institutional Animal Care 
and Use Committee. EAE was induced by subcutaneously administering mice with 200 µg of PLP 
in a 0.2 mL emulsion of Complete Freund’s Adjuvant (CFA). The CFA mixture was produced 
from equal volumes of PBS and IFA containing killed Mycobacterium tuberculosis strain H37RA 
at a final concentration of 4 mg/mL. The immunization was administered as four, 50 μL injections 
above the shoulders and the flanks. An additional 200 ng of pertussis toxin was given 
intraperitoneally on the same day of immunization (day 0) as well as day 2 post-immunization. 
Mice were weighed each day of the study and monitored with clinical scores starting on day 7.  
2.2.5 Spleen Harvest and Splenocyte Isolation 
 Splenocytes were harvested from EAE and healthy control mice at peak of disease (Day 
12 post-induction). Spleen harvest and splenocyte isolation was conducted as previously reported 
35. Briefly, spleens were passed through a wire mesh using the rubber stopper of a sterile 1 mL 
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syringe in RPMI-1640 media.  The strained cellular extracts were centrifuged, and the cell pellet 
was resuspended in red blood cell lysis buffer. The cells were incubated on ice for 3.5 minutes to 
lyse splenic red blood cells.  The lysis reaction was stopped by adding 10 mL RPMI 1640 media 
containing 10% FBS to the mixture before centrifuging.  The remaining splenocyte pellets were 
resuspended in fresh media (RPMI 1640 media containing 10% FBS and 1% Penicillin-
Streptomycin) and plated in 24-well cell culture plates at a cell density of 3x106 cells/well as well 
as a 96-well format at 1x106 cells/well. Varied valency conjugates were introduced in triplicate 
(both for EAE and healthy control splenocytes and in two sets per group for flow cytometry and 
cytokines, respectively) to each well at 141.3 µM to replicate dosing from past studies, as well as 
25 µM PLP. Each cell culture was incubated for 72 hours at 37 °C in a CO2 (5%) incubator.  
2.2.6 Fluorescent Staining and Flow Cytometry  
 Splenocytes were collected from 24-well plates after 72 hours and stained with fluorescent 
antibodies according to manufacturer recommendations. Cells were washed with 1 mL of RPMI-
1640 + 5% FBS before centrifuging and resuspending in 50 µL of 20 µg/mL TruStain fcX blocking 
antibody (anti-mouse CD16/32 antibody, Biolegend).  Cells were incubated on ice for 30 minutes 
before adding the fluorescent antibodies and isotype controls in 50 µL for 1 hour.  For flow 
cytometry data collection, 30,000 cells per sample were detected using a BD FACSFusion 
cytometer. Data were analyzed using Kaluza, FlowJo, and GraphPad Prism software. 
2.2.7 Measurement of Cytokines 
 Following the 72-hour incubation, splenocytes in a 96-well culture plate were centrifuged. 
Supernatants were collected for cytokine analysis (GM-CSF, IFN- γ, IL-2, IL-21, IL-6, IL-10, IL-
17, IL-23, TNF-α). Marker levels were detected using a U-Plex assay kit according to manufacturer 
instructions (Meso Scale Discovery). Briefly, each plate was coated with 50 μL of multiplex 
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coating solution consisting of linkers and biotinylated capture antibodies for each cytokine and 
incubated on a shaker at 700 rpm for 1 hour at room temperature. Following a 3X wash step with 
150 μL PBS containing 0.05% Tween 20, 25 μL of diluent and 25 μL of sample was added to each 
well and incubated again for 1 hour on a shaker at room temperature.  Detection antibody was then 
added at 50 µL/well and incubated for 1 hour.  Finally, each assay plate was read using the 
QuickPlex multiplex plate reader (Meso Scale Discovery). 
2.2.8 Measurement of Cellular Metabolism 
  Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) was incubated with centrifuged 
splenocytes leftover from cytokine supernatant collection to determine cellular metabolism. 75 
µM resazurin was introduced to splenocyte cultures and incubated for 3 hours. Metabolic reductive 
capacity was observed by viewing changes in fluorescence at excitation 560, emission 590 
(Spectramax M5, Molecular Devices). Background fluorescence were taken using RPMI media 
and subtracted out from splenocyte readings for analysis.  
2.2.9 Statistical Analysis 
 Statistical evaluation was performed using one- and two-way analysis of variance 
(ANOVA), followed by Tukey and Sidak multiple comparison tests. Statistical significance for all 
analyses was set at p<0.05. All statistical analyses were performed using GraphPad Software 
(GraphPad Software Inc.). 
 
2.3 Results 
2.3.1 Synthesis of Varied-Valency Conjugates 
 Soluble antigen arrays displaying antigen (SAgAPLP) or antigen plus inhibitor 




Reactant quantities of PLP and LABL peptides were titrated to yield constructs of varied valency, 
defined by percent ligand occupancy of the 42 azide-modified sites of a 16 kD HA backbone and 
calculated by RP-HPLC (Fig. 1, Supp. Fig. 1). SAgAPLP was synthesized in a single batch, where 
peptide conjugation deviated less than 5% from the desired conjugation efficiencies of 10%, 30%, 
50%, 70%, and 90% occupancy. For the SAgAPLP:LABL, the same efficiencies were targeted for 
overall valency, though backbone occupancy was equally divided between PLP and LABL. Single 
batch synthesis of these constructs maintained conjugation accuracy within 5%, excepting 90% 
SAgAPLP:LABL, where average peptide conjugation peaked at 82%.  
 
 
Figure. 1. Synthesis of varied valency conjugates. Antigen-only (SAgAPLP) and antigen plus 
inhibitor (SAgAPLP:LABL) conjugates were synthesized by click chemistry according to varied 
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target conjugation efficiencies for each 16 kD HA backbone.  RP-HPLC was used for 
characterization, and calculated peptide conjugations are reported.  
 
2.3.2 Inhibition of Short-Term B-cell Response is Valency-Dependent. 
 To investigate acute valency-dependent effects of SAgAPLP and SAgAPLP:LABL, an 
immortalized B-cell line (Raji B cells) were loaded with a calcium-indicating fluorochrome and 
stimulated with anti-IgM fragments 20. Influx of Ca2+ ions to B cells is critical for propagating 
immunity, and past SAgA studies have demonstrated the inhibition of this stimulatory signaling 
event 36. Here, Stimulated B-cells showed distinctly increased peak fluorescence over baseline 
(Fig 2A). Following SAgA treatment, a brief spike was consistently observed in Fluo-4 signal 
intensity and monitoring over the course of three minutes illustrated a net reduction that was 
normalized against untreated controls (Fig. 2B). The degree of reduction by SAgAPLP and 
SAgAPLP:LABL varied in a valency-dependent manner (Fig. 2C). In the one-signal SAgAPLP 
constructs, reduction trended inversely with valency, and the 10% construct elicited a significantly 
higher reduction in calcium signal than both 70% and 90% SAgAPLP. A similar trend was realized 
in the SAgAPLP:LABL cohort; 10% SAgAPLP:LABL reduced Fluo-4 signal significantly more than 70% 
and 90% SAgAPLP:LABL, while 30%, 50%, and 70% constructs each outperformed 90% 
SAgAPLP:LABL. Between SAgAPLP and SAgAPLP:LABL, dosing was maintained on a basis of PLP 
concentration (i.e. the total molar dose of SAgAPLP:LABL was roughly double SAgAPLP). For the 
HA alone control group, molar dose was selected to be equivalent to that of the lowest valency 
SAgA in this study such that this group would convey the highest relative number of molecules in 




Figure. 2. Calcium flux was used as a measure of acute B-cell response by varied valency 
conjugates. A) Raji B-cells were loaded with Fluo-4 as a fluorescent calcium indicator and 
stimulated with IgM. Fluo-4 signal was increased from baseline (left) after stimulation (right). B) 
Acute B-cell inhibition was measured by stimulating Raji B-cells for 60 s, followed by treatment 
with varied valency conjugates. After treatment, mean fluorescence intensity was monitored for 
180s and compared to the 60 second stimulation period. C) Reduced calcium signaling by one-
signal varied valency conjugates (SAgAPLP, blue), two-signal varied valency conjugates 
(SAgAPLP:LABL, red), monovalent PLP and azide-modified HA alone (white). (n > 3/group, *p < 




2.3.3 Low-Valency Conjugates Induce Downstream Anergy in Mixed EAE 
Splenocytes 
 Next, varied valency conjugates were tested against EAE splenocytes to investigate 
whether the findings of acute B-cell inhibition could predict outcomes in a more complex system. 
Splenocytes were harvested from healthy mice and from EAE mice at peak of disease. We 
incubated cells with a rechallenge of autoantigen epitope PLP139-151 to prompt stimulation of 
antigen-specific immunity in the presence of varied valency SAgAs. After a 72 hour incubation, 
samples were labeled for costimulatory markers CD86 and CD80 to assess the activation states of 
antigen-presenting cells (including B-cells). CD3 was also labeled in the panel to probe 
fluctuations in T cells (Fig. 3, Supp. Fig. 3). This study was conducted in two separate animal 
experiments, so population changes were reported as normalized to respective vehicle controls for 
comparison. For both SAgAPLP and SAgAPLP:LABL treatments, valency correlated with CD86 
expression at 72 hours. Only low valency conjugates (10% SAgAPLP, 10% SAgAPLP:LABL and 30% 
SAgAPLP:LABL) were statistically similar to healthy controls for each replicate, though all SAgAs 
tested elicited a decreased expression of this costimulatory marker (Fig. 3A). Interestingly, CD80 
expression showed the inverse; the same low valency conjugates exhibited the highest CD80 
expression, which may have indicated a regulatory phenotype when taken in conjunction with 
decreased CD86 and higher levels of T cells 42-45. The 10% SAgAPLP treatment doubled CD80 
expression compared to the healthy control, and 10% and 30% SAgAPLP:LABL remained 
comparable to the healthy control. When comparing the healthy control and all SAgAs, an increase 
in CD80 expression was consistently observed (Fig. 3B). SAgA treatment generally increased 
CD3+ populations with the exception of 70% and 90% SAgAPLP (Fig. 3C). Additional analysis of 
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CD86 dot plots for the historically reported, 50% conjugated SAgAPLP:LABL compared with low 





Figure. 3. Mixed splenocytes were harvested from EAE mice at peak of disease, treated with 
varied valency conjugates, and rechallenged with 25 µM PLP for 72h. Following the incubation, 
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cells were fluorescently labeled and analyzed by flow cytometry, where changes in A) CD86, B) 
CD80, and C) CD3 were compared to healthy control splenocytes (HC). All values are expressed 
in terms of fold-change as compared to vehicle treated EAE splenocytes. D) CD86 changes are 
shown by dot plot for PBS-treated EAE spenocytes, as well as those treated with low-valency 
SAgAPLP:LABL or SAgAPLP:LABL of typical valency from previous reports. (n = 3/group, *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001). 
 
Changes in cell metabolism were also investigated in splenocytes treated with varied 
valency conjugates (Fig. 4). Elevated metabolism is a hallmark of a stimulated immune response, 
so here we assessed decreases in metabolism to indicate inhibited immunity. The resazurin 
metabolic assay was employed toward this end, as this compound is reduced to fluorescent 
resorfurin in the presence of NADH, thus allowing quantification of cell respiration. In EAE 
splenocytes (Fig. 4A), SAgAPLP, but not SAgAPLP:LABL evoked significant decreases in resazurin 
metabolism. Notably, in healthy splenocytes (Fig. 4B), only low valency 10% SAgAPLP did not 
increase metabolism, while SAgAPLP:LABL treatment largely did not affect metabolic outcomes. 
Cytokine analysis was also performed for EAE splenocytes treated with SAgAPLP and 
SAgAPLP:LABL (Fig. 4C, Supp. Fig. 4). These biomarkers provide signals, which can indicate the 
stimulatory or tolerogenic nature of an immune response. Interestingly, two distinct signatures 
were apparent. SAgAPLP was characterized by non-valency discriminate increases in IL-6 and anti-
inflammatory Il-10, with a decrease in T cell proliferation suggested by reduced Il-2. However, 
low valency conjugates elicited smaller increases in Il-17 and Il-12, indicating less inflammation 
and costimulatory antigen-presentation. Inflammatory Il-17 production was markedly increased 
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by cells treated with SAgAPLP:LABL conjugates, and the cytokines Il-6 and TNF-α increased to a 
lesser extent. 
 
Figure. 4. A) EAE splenocytes treated with varied valency conjugates and 25 µM PLP rechallenge. 
Groups were incubated with resazurin after 72 hr to assess differences in cell metabolism. B) 
Likewise, healthy splenocytes were treated with varied valency conjugates and 25 µM PLP and 
subsequently incubated with resazurin after 72 hr. C) Supernatants were collected from conjugate-
treated EAE splenocytes and analyzed for GM-CSF, IFN- γ, Il-10, Il-12, Il-17, Il-2, Il-23, Il-6, and 
TNF-α. (n = 3/group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
 
2.4 Discussion 
While the number of antigens is an important characteristic for directing the type and 
magnitude of immune response 1-3, the valency at which antigens are presented along a polymeric 
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backbone requires further exploration. In recent work by Arthur et al., allogenic responses to blood 
transfusions were exacerbated by red blood cells containing high levels of alloantigen, but stifled 
by cells engineered to carry a low level of alloantigen 4. In 2018, the Jewell group showed that 
quantum dots displaying low antigen density were superior to those loaded with high levels of 
antigen in terms of evoking tolerance 5. Interestingly, this work focused on the modulation of 
dendritic cells as a mechanism, where nonspecific endocytosis drives effect. Certainly, nonspecific 
dendritic cell modulation was shown to be feasible in our system as well 35, but SAgAs are 
differentially capable of antigen-specific B-cell receptor engagement by virtue of a flexible, 
soluble polymeric backbone. In our present study, we evaluated the titration of antigen valency 
using this system, where distinct antigen-specific modulation of B-cells has been reported in 
autoimmune disease models 34-36.  
The work presented here built from the mechanistic foundations that have positioned B 
cells as key targets of the SAgA mechanism 34-36.  In past work elucidating these insights, we found 
SAgAs to be capable of specifically engaging B cells and inhibiting the acute (t = minutes) influx 
of Ca2+ ions necessary to propagate immunity 36. Later, we found these short-term changes 
observed ex vivo were correlated to in vivo efficacy 34. and Ex vivo costimulatory marker 
downregulation and a humoral skewing of immunity were also correlated to in vivo SAgA 
mechanisms of EAE prevention 35.  
Here, both acute-phase (Fig. 2) and downstream response (Fig. 3, Fig. 4) assays showed 
immunomodulatory outcomes were that were highly dependent on SAgA antigen valency (Fig. 5). 
For the short-term reduction of calcium signaling in Raji B-cells, both SAgAPLP and SAgAPLP:LABL 
showed an inverse relationship of similar magnitudes between calcium inhibition and PLP valency 
(Fig. 5A). Similar trending was observed when mixed EAE splenocytes were treated with SAgAs 
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for 72 hours. CD86+ cells decreased with valency, meaning SAgAPLP and SAgAPLP:LABL of low 
PLP conjugation translated to the highest reductions of this costimulatory marker (Fig. 5B). 
Together, these data suggest that low valency, but not monovalent, antigen display is able to evoke 
the most potent immunosuppressive effects in both the acute and downstream frames of immunity.  
 
Figure. 5. Inhibitory outcomes from treating EAE splenocytes with varied valency conjugates 
were assessed according to PLP valency, including A) acute inhibition of B-cells and B) CD86 
expression. Pearson correlation coefficients were calculated for each comparison. C) Correlation 
between acute B-cell inhibition and downstream CD86+ expression was also investigated. D) The 
relationship between PLP valency, calcium flux reduction, and CD86 expression changes was 
collectively analyzed to form a correlation matrix where Pearson correlation coefficients were 
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expressed. In Figures 5A and 5C, data points for 90% SAgAPLP:LABL are omitted for clarity, but 
readouts from this group are applied for the analysis in Figures 5D.  
  
Interestingly, SAgAPLP:LABL showed an apparent advantage over SAgAPLP in acute phase calcium 
inhibition that was not observed in the splenocyte experiments (Fig. 5A). While not statistically 
definitive, this discrepancy could be due to increased binding avidity afforded by the inclusion of 
LABL, which may allow SAgAPLP:LABL to engage and persist at the cell surface through binding 
ICAM-1 in addition to B-cell receptors. This marginal increase in short-term performance does 
not appear to critical to downstream effect, as CD86 downregulation of SAgAPLP:LABL mirrored 
SAgAPLP (Fig. 4B). The splenocyte experiment demonstrated a clear valency-dependent trend was 
maintained wherein the lowest valency SAgAPLP and SAgAPLP:LABL reduced CD86 expression to 
the greatest extent. Notably, this effect was found to inversely trend with CD80, another common 
marker of costimulation (Fig. 3B). While initially unexpected, reports have indicated CD80 in the 
absence of CD86, directs inhibition of T cells when regulatory T and B subsets are prevalent 42-45. 
The potential for this phenomenon to explain the data we observed is substantiated by an overall 
increase in T cell populations (possibly reflecting an increase in Tregs caused by SAgA treatment, 
Fig. 3C), though future studies are necessary to evaluate fully.  
Generally, incubation of EAE splenocytes with SAgAs led to a decreased metabolism after 
72 hours (Fig. 4A). In healthy splenocytes, 10% SAgAPLP and all SAgAPLP:LABL exhibited 
resazurin levels comparable to vehicle-treated control, but SAgAPLP of valency 30% and higher 
caused an elevated metabolism. This finding may be due to the higher antigen number of SAgAPLP 
over SAgAPLP:LABL triggering more immunogenicity, though this change did not translate to a 
stimulated immune response overall (Supp. Fig. 3). Cytokine responses between SAgAPLP and 
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SAgAPLP:LABL seemed distinct, possibly highlighting a difference in signaling pathways created by 
the inclusion of LABL (Fig. 4C). In SAgAPLP, a robust Il-10 response with the elevation of many 
other markers was consistent with past work, but the increased Il-17 response in SAgAPLP:LABL 
treated splenocytes was atypical. Differences in cytokines did not, however, translate to altered 
cell phenotypes (Fig. 3). 
Adding to the valency dependencies outlined in this work, acute B cell calcium flux 
inhibition was found to be highly correlative of CD86 expression in a mixed population of 
splenocytes (Fig. 5C). The implication of this observation further substantiates our past 
investigations of B cells as a key target of SAgAs for effect. While other mechanisms may aid in 
SAgA efficacy, fold change in calcium flux in this experiment proved informative for long-term 
(72 hours) outcomes in a more complex, mixed system of splenocytes. Ultimately, correlations 
between antigen valency, calcium flux reduction, and CD86 expression were all highly significant 
(Fig. 5D).  
 
2.5 Conclusions 
SAgAs were found to be capable of modulating B-cell calcium signaling and mixed 
splenocyte CD86 expression in a valency-dependent fashion. SAgAs were most effective when 
antigen valency was low, reflecting Dintzis’ “rules” with greater resolution than previously 
elucidated 46. SAgAs displaying 4-7 PLP were most effective, overshadowing the conventional, 
albeit effective SAgA constructs displaying 10 PLP, which have been the focal point of our prior 
studies. Furthermore, the level of acute B-cell inhibition studied in isolation correlated with 
downregulation of CD86 in splenocytes. Together, studies indicated SAgA valency was an 
55 
 
important driver of immune response, which casts light on the role of valency when designing 
antigen-specific immunotherapies.  
 
2.6 Supporting Information 
Supporting information is available. Figures include HPLC quantification of peptide conjugation, 





Supp. Fig. 1. All varied valency construct conjugation efficiencies were determined using a 20 
minute Reverse-Phase HPLC method employing a 95/5 to 30/70 aqueous:organic gradient scheme 
on a C4 RP column. A) Individual click reaction component peak retention times (HA-N3, 
CuSO4/THPTA, NaAsc, hpPLP, and hpLABL) are represented. B) Varied valency construct 
reaction mixtures were sampled before beginning reactions (Pre, green), after the reaction (Post, 
brown), and after dialysis (black), and C) conjugation efficiency was calculated by taking the 







Supp. Fig. 2. Cytometric population analysis for EAE splenocytes treated with varied valency 





Supp. Fig. 3. Changes in A) CD86, B) CD80, and C) CD3 expression were measured in healthy 
splenocytes treated with varied valency conjugates. (n = 3/group, *p < 0.05, **p < 0.01, ***p < 





 Supp. Fig. 4. Cytokines collected from EAE splenocytes treated with varied valency conjugates 
are reported in terms of concentration (pg/mL) with significance. (n = 3/group, *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001). 
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Current therapeutic approaches to autoimmune diseases such as multiple sclerosis (MS) 
are largely relegated to symptom management alone, and the most effective drugs evoke efficacy 
by imposing global immunosuppression 1-3. This immunosuppression leaves patients susceptible 
to life-threatening side effects such as opportunistic infections and malignancies 4-7. Indeed, there 
is a clear history of positive correlation between drug effectiveness and risk for adverse outcomes 
in the clinical treatment of MS 6, 8. Antigen-specific immunotherapy (ASIT) has proven itself 
compelling as a means to more selectively disarm autoimmunity without global 
immunosuppression. Recent trends suggest co-delivery of autoantigen with an immunomodulatory 
drug may target autoreactive cells to overcome the conventional efficacy/safety trade-off in 
autoimmune therapeutics 9-13.  
Co-delivering ASIT and an immune modulator requires spatiotemporal restriction of 
antigen and drug to ensure processing in the same immunological context for eliciting potent, 
antigen-specific outcomes 14, 15. To accomplish this necessity of space-time proximity, 
formulations have historically utilized vehicles from applications such as vaccines, cancer 
immunotherapy, and sustained-release drug delivery 16-20. While the polymers and metals that 
make up these vehicles are often touted as biocompatible and immunologically inert, co-delivery 
applications for autoimmunity have periodically shown negative outcomes for vehicle control 
groups in measures such as autoantibody titers and clinical disease severity 21, 22. These studies 
each reported overall promising therapeutic results, perhaps by overcoming deleterious vehicle 
effects on immunity via the immunosuppression imparted through the inclusion of drug. 
Ultimately, works such as these have resulted in a paradigm that inclusion of immunosuppressive 
drugs is required to overcome inherent immunogenicity of formulations.  
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 In recent work, co-delivery of autoantigen and dexamethasone in incomplete Freund’s 
adjuvant was shown to ameliorate experimental autoimmune encephalomyelitis (EAE), a murine 
model of relapsing-remitting multiple sclerosis 23. Nevertheless, incomplete Freund’s adjuvant is 
substantially toxic in humans and has even been used to induce EAE in primates 24, suggesting 
poor feasibility in terms of practical therapeutic application for autoimmune diseases such as MS. 
It seems an efficacious ASIT to combat autoimmunity should utilize components of a co-delivery 
system optimally tolerable to humans. Furthermore, ASIT delivery vehicles that also exhibit 
desirable immunological function may simplify formulation, yielding a more translatable approach 
to restore immune tolerance. 
Tocopherol emulsions (ETPGS) consisting of vitamin E oil and a PEGylated vitamin E 
surfactant (D-α-Tocopherol polyethylene glycol 1000 succinate, TPGS) in an aqueous continuous 
phase have been approved as safe pharmaceutical adjuvants since 2005 25, 26. The original 
application for ETPGS was the sustained delivery of paclitaxel as a chemotherapeutic agent, but 
since its emergence, the formulation has been pervasively modified and applied in other 
applications such as intestinal permeation enhancement and copolymerization 27, 28. Because it has 
already been approved in humans, tolerability is known when considering it as a potential vehicle. 
In addition, the wealth of various ETPGS formulations explored in many discrete biomedical 
applications indicate the physical properties of the suspension are highly tunable. For particulate 
ASIT delivery approaches in cancer, autoimmunity, and vaccines, the immunotherapeutic effect is 
most commonly evoked through nonspecific uptake of the formulation by antigen-presenting cells 
(APCs), leading to downstream inflammation or tolerance by processing of antigen in the context 
of immunostimulatory or suppressive compounds 29-31. Since ETPGS droplet size is versatile, 
suspensions can be created at mean diameters under 500 nm for optimal APC uptake 32. 
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Importantly, ETPGS can be tuned to have a mean diameter still greater than 100 nm to enable APC 
interaction to occur while increasing formulation persistence at the site of injection 33-35. The 
flexibility of ETPGS for ASIT delivery is augmented by the fact vitamin E is an effective 
antioxidant. The propagation of an immune response is driven by a cascade of inflammatory events 
36, 37. By staving off inflammation, antioxidant compounds can skew immune responses toward 
tolerance 27, 38.  
Herein, we report on the application of ETPGS to deliver autoantigen and ameliorate EAE 
in vivo. Efficacy was determined by comparing disease scores and weights of EAE mice. The 
immune response was characterized by quantifying cytokine responses in splenocytes and by shifts 
in autoantibody responses in blood and in tissues from the central nervous systems in mice. Finally, 
real-time measurement of oxidation in antigen presenting cells was conducted to more deeply 
understand the mechanism of ETPGS as an ASIT delivery vehicle.  
 
3.2 Materials and Methods 
3.2.1 Materials 
PLP139-151 (PLP), the antigenic peptide used, was purchased from Biomatik (Cambridge, 
ON, Canada). For the induction of EAE, incomplete Freund’s adjuvant (IFA) and killed 
Mycobacterium tuberculosis strain H37RA were purchased from Difco (Sparks, MD) as well as 
pertussis toxin, purchased from List Biological Laboratories (Campbell, CA). Murine RAW 264.7 
cells (ATCC® TIB71™) along with Dulbecco’s Modified Eagle’s Medium (DMEM), phenol red-
free DMEM, fetal bovine serum (FBS), and penicillin/streptomycin antibiotic solution were 
procured from American Type Culture Collection (ATCC, Manassas, VA, USA) and Atlanta 
Biologicals (Flowery Branch, GA, USA). Diethyldithiocarbamate (DDC), 2-methoxyestradiol (2-
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ME), phorbol 12-myristate 13- acetate (PMA), phosphate-buffered saline (PBS), 
lipopolysaccharide (LPS, from Escherichia coli 0111:B4), sodium dodecyl sulfate (SDS), and 
bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Interferon-γ (IFN-γ) was obtained from Calbiochem (Gibbstown, NJ, USA). 4-Amino-5-
methylamino-2',7'-difluorofluorescein diacetate (DAF-FM DA) and MitoSOX Red were supplied 
from Life Technologies (Carlsbad, CA, USA). For flow cytometry, Alexa Fluor® 488-conjugated 
anti-mouse CD3, Alexa Fluor® 647-conjugated anti-mouse CD19, and Pacific BlueTM-conjugated 
anti-mouse CD11c, and matched isotype controls were purchased from Biolegend (San Diego, 
CA). Goat HRP-conjugated anti-Mouse IgG for ELISAs was also purchased from Biolegend (San 
Diego, CA). Vitamin E and TPGS were received from Sigma Aldrich (St. Louis, MO). Other 
chemicals and reagents used for these studies were analytical grade and used as received.  
3.2.2 Preparation of ETPGS Emulsions 
ETPGS emulsions were prepared by adding TPGS to 1X phosphate-buffered saline (PBS), 
and agitating overnight at 42.5°C. If PLP was required, the peptide was then dissolved in the 
mixture before the aqueous phase was gently pipetted to a tube containing α-tocopherol mineral 
oil. Next, the tube containing α-tocopherol, TPGS and PBS (with or without PLP) was sonicated 
using a Fisher Scientific™ Sonic Dismembrator Model 500 with a 10 second on, 2 second off 
cadence (30% intensity) for 2 minutes, dipping the emulsion mixture in an ice bath during off 
periods to maintain temperature. After sonication, the emulsion was poured into a glass 
scintillation vial for storage, either on ice or at 4°C. For recipe development, amounts used of α-
tocopherol, TPGS and PBS were systematically varied, though final proportions used for the 
ETPGS emulsions in these studies were 2:1 α-tocopherol:TPGS ultimately constituting 10% of a 
10:90 oil-in-water emulsion. 
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3.2.3 Characterizing Size and Peptide Release from ETPGS Emulsions 
 Dynamic light scattering (DLS) was used to size ETPGS emulsions. Six ETPGS emulsions 
were fabricated (three with PLP, three without) and submitted to a NanoBrook Omni DLS to 
measure mean particle diameter and half-width for each formulation.  
 For imaging via transmission electron microscopy (TEM), 5 µl of ETPGS or ETPGS+PLP 
was placed onto 300 mesh copper grids with ultrathin carbon film. The wet grids were air-dried 
for several minutes prior to being examined under TEM. The emulsions were examined by bright-
field and dark-field transmission electron microscopy (TEM) using an FEI Tecnai F20 
transmission electron microscope at an electron acceleration voltage of 200 kV. High resolution 
images were captured using a standardized, normative electron dose and a constant defocus value 
from the carbon-coated surfaces. 
 To characterize peptide release, 4 mL of ETPGS emulsion containing PLP was inserted 
into regenerated cellulose dialysis tubing (6000-8,000 MWCO, 30 μm wall thickness, 
Fisherbrand Dialysis Tubing). This sealed tubing was submerged in 100 mL of PBS within a 
glass vessel and capped to prevent evaporation. Likewise, the same schematic was used for PBS 
containing PLP at the same concentration as a control. Release vessels were kept at 37°C with 
gentle shaking by an incubator (79 rpm, Excella E24 Incubator Shaker, New Brunswick 
Scientific). For sample collection, 1 mL was taken from the 100 mL bulk fluid of the release 
vessels and replaced with 1 mL of fresh PBS. Characterization of PLP concentration in samples 
was performed using reverse-phase HPLC (Waters 2796 Bioseparations Module, Waters Corp) 
on a C4 analytical column (Waters XBridge Protein BEH column, 300 Å, 3.5 μm, 4.6 mm x 150 
mm, 10-500 K).  Samples were eluted with mobile phases A (100% water with 0.05% 
trifluoroacetic acid (TFA)) and B (100% acetonitrile with 0.05% TFA) with a linear gradient of 
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95% A to 30% A over 20 minutes at a constant flow of 1 mL/min.  PLP was detected at 280 nm 
and DEX was detected at 240 nm with a dual wavelength absorbance detector (Waters 2487 
Dual λ Absorbance Detector, Waters Corp). Data was collected and processed using Empower 3 
Software (Waters Corp). Concentration losses of peptide from sampling and PBS re-addition 
were accounted for when data were analyzed.  
3.2.4 Measurement of ETPGS Antioxidant Power 
 For assessing antioxidant capabilities of ETPGS emulsions, the ferric-ion reducing 
antioxidant power (FRAP) assay was utilized as previously established 39. Briefly, ETPGS with 
and without PLP was prepared, diluted 1:1000 and titrated at various concentrations in duplicate 
into FRAP reagent containing Fe(III). Fe(III) conversion to Fe(II) was measured by reading 
samples at a wavelength of 593 nm (Spectramax M5, Molecular Devices) over various time points.  
3.2.5 Acute Antioxidant Effect in a Model APC 
 The acute effects of ETPGS on reactive nitrogen and oxygen species (RNOS) in RAW 
264.7 cells were measured using a previously established, highly sensitive microfluidic assay 40, 
41. Briefly, RAW 264.7 macrophages were cultured in 25 cm3 flasks and maintained at a density 
of 5x106 cells/flask. The cells were stimulated with IFN-γ (600 U/mL) and LPS (100ng/mL), and 
incubated for 20 hours. Cells were then treated with 0.1% (v/v) ETPGS and incubated for another 
60 minutes. Fluorescent probes DAF-FM DA and MitoSOX were loaded into cells at 
concentrations of 10 μM, each to indicate NO and superoxide species, respectively. Also included 
in the loading were superoxide dismutase inhibitors DDC (1 mM) and 2-ME (10 μM). After 
loading, cells were harvested, washed and lysed. The lysate was injected into a preconditioned 
PDMS/glass microfluidic device, and Labview software was used to collect and analyze data. 
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3.2.6 Induction of EAE and Therapeutic Study 
 Female SJL/J mice, 4-5 weeks of age were obtained from Envigo Laboratories and housed 
at the University of Kansas under specified, pathogen-free conditions. Female SJL/J mice are a 
well characterized and established strain known to exhibit a relapsing-remitting pattern of MS-like 
disease when immunized against the PLP139-151 epitope 
42-44. All live-mouse protocols were 
approved by the University of Kansas Institutional Animal Care and Use Committee. For the 
induction of EAE, mice were subcutaneously administered with 200 µg of PLP in a 0.2 mL 
emulsion of Complete Freund’s Adjuvant (CFA). The CFA mixture was comprised of equal 
volumes of PBS and IFA also containing killed Mycobacterium tuberculosis strain H37RA at a 
final concentration of 4 mg/mL. This immunization was given as four, 50 μL injections above the 
shoulders and the flanks. Additionally, 200 ng of pertussis toxin was given intraperitoneally on the 
same day of immunization (day 0) as well as day 2 post-immunization. The data presented are 
comprised of three independent in vivo studies; each group was comprised of 12-15 mice in total. 
Treatments were administered as 100 μL subcutaneous injections on days 4, 7 and 10 of the study. 
For the PLP and ETPGS+PLP groups, antigen was dosed at 200 nmol. ETPGS and ETPGS+PLP 
treatments were injected within 30 minutes of fabrication. One of the 15 PBS control mice was 
excluded from the study due to starting weight outside of the appropriate range. Two of 15 
ETPGS+PLP mice died within 24 hours of receiving the third treatment injection due to unclear 
circumstances and were excluded from the study as well. Disease progression was assessed on a 
five-point clinical scale including: 0, no clinical evidence of disease; 1, tail weakness or limp tail; 
2, paraparesis (weakness or incomplete paralysis of one or two hind limbs); 3, paraplegia 
(complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness or paralysis; and 5, 
moribund.  Body weight was taken each day as well. 
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3.2.7 Tissue Harvest and Splenocyte Isolation  
 Mouse spleens were harvested from EAE mice on day 25 post-immunization as previously 
described 23, 45, 46. Briefly, the spleens were first passed through a wire mesh using the rubber end 
of a sterile 1 mL syringe plunger and collected in 5 mL of RPMI 1640 media.  The cellular extracts 
were centrifuged, and the resulting cell pellet was resuspended in 3.5 mL of 1X Gey’s lysis 
solution. The cells were incubated on ice for 3.5 minutes to lyse splenic red blood cells.  The lysis 
reaction was stopped with the addition of 10 mL RPMI 1640 media containing 10% FBS and 
centrifuged at 1,100 x g for 5 minutes.  The remaining splenocyte pellets were resuspended in fresh 
media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and plated in 96-
well cell culture plates at a cell density of 1x106 cells/well in a final volume of 200 µL, and in 12-
well cell culture plates at a density of 5x106 cells/well and 1 mL volume. Plain media or 25 µM 
PLP was immediately introduced to cells. Stimulated cell cultures were incubated for 96 hours at 
37°C in a CO2 (5%) incubator. 
 Additionally, serum was taken from mice during sacrifice by accessing the caudal vena 
cava. Spinal cords were harvested, weighed, and homogenized with the Fisher Scientific™ Sonic 
Dismembrator Model 500 in PBS. The amount of PBS added was determined to create 50 mg 
homogenized central nervous tissue (hCNS) per 500 µL of PBS stocks. Serum and hCNS samples 
were stored at -20°C.   
3.2.8 Measurement of Cytokines 
 After 96 hours of incubation, splenocytes in a 96-well culture plate were centrifuged, and 
supernatants were collected for cytokine analysis (GM-CSF, IFN- γ, IL-2, IL-21, IL-4, IL-10, IL-
15, IL-17, IL-23, TNF-α). Marker levels were detected using a U-Plex assay kit according to 
manufacturer instructions (Meso Scale Discovery). Briefly, each plate was coated with 50 μL of 
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multiplex coating solution consisting of linkers and biotinylated capture antibodies for each 
cytokine and incubated on a shaker at 700 rpm for 1 hour at room temperature. Following a 3-time 
wash step with 150 μL PBS containing 0.05% Tween 20, 25 μL of diluent and 25 μL of sample 
was added to each well and incubated again for 1 hour on a shaker at room temperature.  Detection 
antibody was then added at 50 µL/well and incubated for 1 hour.  Finally, each assay plate was 
read using the QuickPlex multiplex plate reader (Meso Scale Discovery). 
3.2.9 Measurement of Cellular Metabolism 
 Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) was used to determine cellular 
metabolism. 75 µM resazurin was introduced to splenocyte cultures and incubated for 3 hours. 
Metabolic reductive capacity was observed by viewing changes in fluorescence at excitation 560, 
emission 590 (Spectramax M5, Molecular Devices). Background fluorescence were taken using 
RPMI media and subtracted out from splenocyte readings for analysis.  
3.2.10 Fluorescent Staining and Flow Cytometry 
 Splenocytes were collected from 12-well plates at 96 hours and stained with fluorescent 
antibodies. 1x106 cells were washed with 1 mL of wash buffer (RPMI 1640 media containing 5% 
FBS) before being centrifuged and resuspended in 50 µL of block buffer containing 20 µg/mL 
TruStain fcX (anti-mouse CD16/32 antibody, Biolegend) in wash buffer.  Cells were incubated on 
ice for 30 minutes before adding the fluorescent antibodies and isotype controls in 50 µL at 2x the 
manufacturer recommended concentration for 1 hour.  For flow cytometry data collection, 30,000 




3.2.11 Detection of Anti-PLP IgG   
 PLP-specific IgG titers were assessed in an ELISA format 47. 1µg/mL PLP was dissolved 
in an isoelectric (pH 9.5) solution of 50 mM NaHCO3. This coating buffer was seeded on Immulon 
2HB 96-well plates and incubated overnight at 4°C. Plates were then blocked at 37°C for 1 hour 
with 1% (w/v) bovine serum albumin (BSA) plus 0.5% Tween 20 after washing unbound 
component with the same procedure as used in the multiplex assays. Serum and hCNS samples 
were then introduced and serially diluted 1:1 across seven concentrations. After another 1 hour 
incubation (37°C), plates were again washed, and HRP-conjugated anti-mouse IgG (BioLegend) 
was added at 0.1 µg per 100 µL and incubated again for 1 hour at 37°C. Washing the plates once 
more, 100 µL of TrueBlue substrate was added and plates were covered and shaken at 75 rpm and 
room temperature for 15 minutes. Enzymatic conversion was stopped with 100 µL 2N H2SO4 and 
the plate was read at 450/540 nm (Spectramax M5, Molecular Devices). For analyzing titer, linear 
regions across sample titration readings were fitted with linear regressions and extrapolated to their 
1X concentration for comparison across samples.  
3.2.12 Statistical Analysis 
Statistical evaluation of data was performed using two-way analysis of variance 
(ANOVA), followed by Tukey and Sidak multiple comparison tests. The criteria for statistical 
significance for all analyses was set at p<0.05. All statistical analyses were performed using 





3.3.1 Characterization of the ETPGS Formulation 
 To develop ETPGS as a functional co-delivery vehicle, a formulation recipe was 
empirically derived by altering proportions of vitamin E, TPGS, and phosphate-buffered saline. 
By measuring fabricated particle diameters by DLS, outcomes were reconciled against the design 
criteria for an emulsion to contain droplets between 100-500 nm. Ultimately, a stable emulsion 
was obtained with 10% oil in PBS (w/w) and 2:1 E:TPGS (w/w, Fig. 1A,B). The selected 
formulation was evaluated by fabricating three replicate emulsions, both alone and when 
formulated with PLP (Fig. 1B). The ETPGS recipe alone yielded a mean diameter of 263.2 nm, 
and with the inclusion of PLP, the emulsion increased in mean size to 303.1 nm. Droplet half-
width decreased from 52.3 nm to 32.8 nm, suggesting that PLP may be surface active. The 
emulsions were sized again after one month at 4°C storage; negligible changes in droplet size were 
observed (data not shown). To image the association of PLP with ETPGS and confirm 
incorporation of the peptide into the formulation, transmission electron microscopy (TEM) was 
carried out, which suggested PLP accumulation at the oil-water interface (Fig. 1C). Peptide 
incorporation was further confirmed using elemental analysis to visualize nitrogen content within 
the oil phase of ETPGS with PLP, but not ETPGS alone (Supp. Fig. 1). A peptide release study 
was conducted to verify temporal restriction of peptide with the ETPGS formulation as well (Supp. 




Fig. 1. Formulation of a tocopherol-based vehicle for antigen delivery. A.) Emulsion fabrication 
using varied proportions of Vitamin E, TPGS and PBS enabled the construction of a ternary phase 
diagram, where scale denotes percent composition of each component. B.) Favorable component 
proportions were used to fabricate emulsions both with (ETPGS+PLP) and without (ETPGS) PLP 
for sizing via dynamic light scattering (n = 3/group) DLS sizes and half-widths are presented in 
terms of average size ± standard deviation. C.) formulations of ETPGS alone (left) and 
ETPGS+PLP (right) were also imaged with TEM to verify antigen incorporation into the emulsion. 




3.3.2 ETPGS influences oxidative stress in vitro 
To assess the antioxidant capacity of ETPGS emulsions, the ferric-ion reducing antioxidant 
power (FRAP) assay was selected as a colorimetric indicator of functionality. ETPGS with and 
without PLP was fabricated and titrated into FRAP reagent. After 10 minutes, a linear 
concentration dependence was recognized for all components (Fig. 2A). Over time, both ETPGS 
and ETPGS+PLP achieved similar reductions in ferric ions (Fig. 2B). Moving from these 
preliminary results in the simple FRAP system, acute antioxidant effects of ETPGS were measured 
in vitro in a model APC line. LPS-stimulated RAW 264.7 macrophages showed substantial levels 
of MitoSOX Red, but cells treated with ETPGS displayed markedly suppressed the analyte (Fig. 
2C). Notably, while ETPGS treatment resulted in an apparent overall decrease of reactive oxygen 
species, a slight increase of reactive nitrogen species was observed. A third, unknown product peak 




Fig. 2. In vitro antioxidant power analyses for ETPGS formulations. Ferric ion reducing 
antioxidant power results yielded A.) linear relationships between reduction and sample dilutions 
(reported for t = 10 minutes), and B.) reduction kinetics over time (reported at sample:FRAP ratio 
0.09). ETPGS alone is represented by green diamonds, ETPGS+PLP is represented by blue circles. 
C.) Acute measurement of reactive nitrogen and oxygen species in stimulated RAW 264.7 cells 
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alone (red), and ETPGS-treated cells (green) for three repeat runs, each. Superoxide peaks are 
identified with blue arrows, while reactive nitrogen peaks are denoted by orange arrows. 
 
3.3.3 ETPGS-facilitated autoantigen delivery delays and suppresses EAE in vivo 
Next, ETPGS formulated with autoantigen was tested for efficacy against EAE in vivo. 
This ETPGS+PLP group was evaluated against ETPGS alone, PLP alone, and PBS control groups 
with treatment administrations occurring on days 4, 7 and 10 post EAE induction. Clinical scoring 
and weight data were collected, and are reflected in Fig. 3A-C and 3D-F, respectively. PBS treated 
control mice exhibited disease onset at 9 days post-induction and reached peak severity (in both 
weight and clinical score) by day 14. Among PLP-treated mice, disease severity was largely 
suppressed as reflected by both scoring and weight, but disease onset occurred at a similar time to 
those in the PBS control group and was seemingly prolonged when compared to PBS control mice. 
ETPGS vehicle treatment alone substantially delayed the onset of EAE with clinical scores not 
occurring until day 13 and peak severity evident on day 16 as opposed to day 14 in the PBS control 
mice. Treatment consisting of ETPGS+PLP delayed disease presentation even further with 
symptoms not appearing until day 15 and a peak at day 19. Disease severity was also suppressed, 
evidenced by lower clinical scores and significantly higher weights even at the end of the 25-day 
study. In fact, ETPGS+PLP treatment resulted in greater than 50% of mice showing no signs of 
EAE at all (Fig. 4A). Cumulative scores were tallied for each treatment group and are presented 
in Fig. 4B. ETPGS+PLP treatment indeed significantly suppressed the accumulation of clinical 
scores when compared to PBS control and ETPGS alone, but significance was not realized between 




Fig. 3. Clinical disease scores (A-C) and weight changes (D-F) in EAE mice given treatment 
components. Disease score and weight change data for the PBS control treatment are compared to 
those of PLP treatment (A and D, respectively), ETPGS alone treatment (B and E), and 
ETPGS+PLP treatment (C and F). All treatments were administered on days 4, 7 and 10 post-
disease induction. Each group consisted of n = 12-15 mice combined from three independent trials 
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001 as compared to PBS). Error bars are reported 





Fig. 4. Clinical scoring data were analyzed by A.) disease onset by group, as determined by 
proportion of mice having exhibited any clinical score by the day of each time point, and B.) area 
under the scoring curve for each treatment group. (n = 12-15 mice/group, *p < 0.05, **p < 0.01, 
***p < 0.001). Error bars are reported as standard deviation among samples. 
 
3.3.4 Ex vivo splenocyte cytokines and populations in ETPGS+PLP efficacy 
On day 25 of the EAE study, all mice were sacrificed and splenocytes were isolated for ex 
vivo analysis. Isolated splenocytes were cultured for 96 hours either with or without a 25 µM 
autoantigen rechallenge. At the end of the incubation, cytokines were assessed by MSD multiplex 
and cell metabolism was measured via resazurin (Fig. 5). Cell populations were also probed using 
flow cytometry (Fig. 6).  
Surprisingly, a highly conserved trend was observed across many cytokines included in the 
study. ETPGS+PLP group splenocytes consistently exhibited elevated levels of cytokines when 
compared to PBS control cells, both in terms of tolerogenic and inflammatory cytokines. The most 
robust cytokine responses evoked in ETPGS+PLP splenocytes were in IL-21 and IL-10 (Fig. 5D 
and 5F), where significant elevation was recognized over all other groups. Responses in the PLP 
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group were statistically similar to those in PBS. ETPGS group splenocytes showed higher levels 
of IL-2 than those from PBS control mice (Fig. 5C). Interestingly, cell metabolism was 
significantly elevated in splenocytes from the ETPGS and ETPGS+PLP treatment groups (Fig. 
5K). This observation, combined with the conserved cytokine trend, mirrors the delayed disease 




Fig. 5. Splenocytes were harvested on day 25 from EAE mice treated in vivo with PBS, PLP, 
ETPGS alone, or ETPGS+PLP. Splenocytes were incubated for 96h with or without a 25 µM PLP 
rechallenge. Supernatant cytokine levels of A.) GM-CSF, B.) IFN-γ, C.) Il-2, D.) Il-21, E.) Il-6, 
F.) Il-10, G.) Il-15, H.) Il-17, I.) Il-23, and J.) TNF-α were determined and K.) cell metabolism 
was measured via resazurin. (n = 5-6 mice/group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 
0.0001). Error bars are reported as standard deviation among samples. 
 
From cell phenotyping metrics, unchallenged splenocyte populations showed some 
significant differences (Fig. 6A-C). Samples from the ETPGS treatment group had slightly 
decreased numbers of T cells (CD3+) compared to the PLP group, and a higher B cell (CD19+) 
count than PBS and PLP splenocytes. However, antigen-challenged cell population differences 
were not present among T, B, or dendritic cells (CD3+, CD19+, and CD11c+, respectively). A 
rhodamine-conjugated PLP was also used to probe cells capable of interacting with autoantigen, 
particularly by surface recognition of PLP-specific B cells (Fig. 6D). Again, resting cells displayed 
significant differences with PLP, ETPGS and ETPGS+PLP populations showing lower amounts 
of cells triggering events in the PLP channel. Upon antigen rechallenge, all groups showed similar 
levels of interaction with PLP. In previous ASIT studies investigating co-delivery systems, 
differences in a unique population of CD19+CD11c+ “autoimmune-associated B cells” have been 
observed and have been believed to contribute to tolerogenic outcomes. The same population was 
gated in this study (Fig. 6E), but no statistically relevant differences were found. Finally, T-to-B 
cell ratio was assessed for each group (Fig. 6F), and ETPGS was found to show a B cell-skewed 
proportionality compared to other groups in unchallenged populations, but not upon rechallenge. 
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ETPGS+PLP trended similarly to the ETPGS group, but was not significantly different than PBS 
or PLP splenocytes. 
 
Fig. 6. Splenocytes were harvested on day 25 from EAE mice treated in vivo with PBS, PLP, 
ETPGS alone, or ETPGS+PLP. Splenocytes were incubated for 96h with or without a 25 µM PLP 
rechallenge. The cells were stained with antibodies for CD3 (Alexa Fluor 488), CD19 (Alexa Fluor 
647), and CD11c (Brilliant Violet 421), as well as a Rhodamine-labeled PLP. Stained splenocytes 
were analyzed by flow cytometry. Cell populations were evaluated for A.) T-cells (CD3+), B.) B-
cells (CD19+), C.) Dendritic cells (CD11c+), D.) PLP-specific cells (PLP+), and E.) Autoimmune-
associated B-cells (CD19+CD11c+). Also analyzed was F.) ratio of T cells (CD3+) to B cells 
(CD19+) for each group. (n = 5-6 mice/group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p< 




3.3.5 Autoantibodies are largely restricted to the periphery in mice treated with 
ETPGS+PLP 
To compare evidence of immunity between the periphery and central nervous system, 
serum and hCNS were harvested and probed for anti-PLP IgG by ELISA (Fig. 7). In the serum 
(Fig. 7A) and hCNS (Fig. 7B) alone, no statistically significant differences existed between 
groups, though tissues from the PLP and ETPGS+PLP treated mice exhibited titers that trended 
higher than the PBS and ETPGS alone groups. However, when comparing the ratio of serum-to-
hCNS anti-PLP titer (Fig. 7C), a stark difference was realized; ETPGS+PLP group titer ratios 
were markedly higher than those in any other group. 
 
Fig. 7. On day 25 of the in vivo study, blood and spinal cords were collected from EAE mice 
treated with PBS, PLP, ETPGS alone, or ETPGS+PLP. Serum was isolated from blood, and spinal 
cords were homogenized and centrifuged to collect hCNS supernatants. Anti-PLP IgG titers were 
detected by ELISA for both A.) serum and B.) hCNS. C.) Ratio of serum to hCNS titers for each 
mouse was also determined. (n = 5-6 mice/group, *p < 0.05, **p < 0.01, ***p<0.001). Error bars 





 While autoantigen delivery as immunotherapy has shown tremendous capability to 
ameliorate autoimmunity across numerous disease models, past applications have pointed to the 
necessity for the inclusion of immunomodulatory molecules (i.e. immunosuppressant, adjuvant, 
etc.), such that the co-delivery of antigen and drug together can elicit maximal therapeutic 
effectiveness 21, 22. Delivery vehicles have been used to restrict these components to the same 
immunological context, but many of these vessels can evoke adverse inflammation, or are regarded 
as inert at best. In this work, we present ETPGS as a functional vehicle for autoantigen delivery, 
potentially dispensing the need for additional drugs or adjuvants. By comparing ETPGS+PLP 
treatment to ETPGS and PLP alone, we evaluated this formulation’s capacity to diminish EAE in 
vivo.  
 The development of an ETPGS formulation of appropriate size and stability was 
empirically derived by varying recipe components (Fig. 1A). TPGS content highly influenced 
emulsion droplet sizes, and oil-in-water content had a large bearing on stability. Formulations with 
greater than 25% oil were not stable over time or temperature. A 10% oil-in-water, 2:1 ETPGS 
recipe created stable emulsions that were in the ~250-300 nm range (Fig 1B) and advanced for 
further study.  PLP was found to be compatible for incorporation with ETPGS, as evidenced by 
TEM (Fig. 1C, Supp. Fig. 1) and peptide release (Supp. Fig. 2). ETPGS was confirmed to have 
antioxidant function in vitro by the FRAP assay (Fig. 2A), and the inclusion of PLP did not affect 
its reductive capacity (Fig. 2B). This antioxidant capability was further shown to definitively 
influence reactive nitrogen and oxygen species production by macrophages in vitro. 
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Moving to an in vivo murine model of multiple sclerosis, a synergistic effect was realized 
by treating EAE mice with ETPGS+PLP. PLP treatment alone led to a suppressed, but prolonged 
disease state (Fig. 3A, D), while ETPGS treatment resulted in a delayed, though fully severe 
presentation of EAE (Fig 3. B, E). Formulation of ETPGS with PLP as a treatment ultimately 
delayed disease even further compared to ETPGS alone, and the severity was dampened to a 
greater extent than in the PLP group, particularly evidenced by fewer days of clinical scores and 
statistical improvement in weight data at the end of the study (Fig. 3C, F). These effects were most 
pronounced in disease incidence, where markedly more ETPGS+PLP mice showed no clinical 
evidence of disease than any other group (Fig. 4A).  
Undoubtedly, there was therapeutic benefit to delivering PLP with ETPGS as a vehicle, 
and this effect suggested that these vitamin E emulsions are functionally contributive toward 
combating EAE. Despite this clinical success, ex vivo mechanistic measures proved somewhat 
confounding. ETPGS+PLP cytokine data showed robust production of markers such as IL-10 (Fig. 
5F) and IL-6 (Fig. 5E), which in combination have been shown to be productive toward 
ameliorating EAE 48-50. The conserved trend of increased ETPGS+PLP cytokine production of 
both IFN-γ (Fig. 5B) and TNF-α (Fig. 5J) was perplexing in that each of these are known to be 
inversely correlated with IL-10 and IL-6, respectively 51, 52. In this study, these cytokines among 
all others assessed were all elevated in the ETPGS+PLP splenocytes (Fig. 5A-J). Furthermore, 
cell population data were also inconclusive for discerning any induction of tolerance as a 
mechanism for ETPGS+PLP (Fig. 6). Significant differences between groups only existed in 
unchallenged splenocyte populations, and re-exposure to PLP consistently led to similar levels of 
T, B and dendritic cells as well as PLP-recognizing cells (Fig. 6A-D). In a previous study, 
therapeutic success was achieved when delivering PLP and dexamethasone with IFA, and 
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differences in a distinct population of CD19+CD11c+ were seen 23. These differences were 
believed to be mechanistically contributive, though in this work, no population differences in this 
subtype were observed (Fig. 6E).  
Though cytokine and phenotype readouts were largely inconclusive, it remains evident that 
ETPGS+PLP treatment enacted therapeutic efficacy, albeit perhaps not through the antioxidant 
mechanism first hypothesized. Extending from the universally elevated cytokine trends, it was 
apparent that ETPGS+PLP group splenocytes may have been more metabolically active than those 
from other groups. This assertion is substantiated by resazurin data (Fig. 6K), where cellular 
metabolism seems to correlate with temporal differences in disease presentation and resolution. 
While PBS and PLP groups began showing disease symptoms on the same day, the delays in both 
ETPGS and ETPGS+PLP onsets may translate to incompletely resolved, or “exhausted” 
splenocytes on day 25 at harvest. Since ETPGS+PLP mice got sick at the latest point in the study, 
it is reasonable to consider the splenocytes of this group may have been in a more stimulated state, 
affecting elevated cytokine levels and resazurin readouts.  
To reconcile observed delays in disease, we considered diversion of cells to the injection 
site as an explanation. One notable clinical observation of the ETPGS and ETPGS+PLP treatments 
was that they formed a depot at the injection site. The persistence of emulsion in the subcutaneous 
space was intended to draw immunological attention. This attraction of immune infiltrates could 
contribute to a prioritization of ETPGS and consequentially explain the slight delay in disease 
onset for ETPGS mice. Furthermore, the instance of encountering autoantigen in the periphery (as 
with the ETPGS+PLP treated mice) could trigger proliferation of PLP-specific cells before 
reaching the central nervous system (CNS). This off-site proliferation, preceding migration to the 
CNS, could result in therapeutic efficacy against the clinical onset of EAE. In fact, glatiramer 
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acetate, one of the most established MS treatments, is characterized by injection site inflammation 
occurring in up to 60% of patients receiving it 53, 54. The swollen nodules observed at the injection 
site of EAE mice may follow a similar mechanism.  
Anti-PLP IgG titers were probed in both the periphery (serum) and central compartment 
(hCNS) of the mice from the study (Fig. 7). Natural antibodies are unable to cross the blood brain 
barrier 55, so quantities were measured in both compartments as long-lasting evidence of 
autoimmunity between each location. While no statistical differences were definite in serum or 
hCNS autoantibodies discretely, the ratio of serum-to-hCNS titer yielded a distinct separation 
where ETPGS+PLP treated mice exhibited a markedly higher proportion of autoantibodies 
restricted to the periphery. These findings give credence to the possibility that ETPGS+PLP could 
create a lasting immunological decoy at the injection site. It is notable, however, that 
compartmental antibody titers trended higher compared to other groups for ETPGS+PLP as well. 
This information highlights the possibility that immunity could potentially also be shifted from a 
T helper type-1 (cellular) response to that of Th2 (humoral) response, which is known to be 
beneficial toward ameliorating EAE and MS 56, 57. Future investigation into the subclass of IgG 
response will be beneficial to discern skewed immunity by ETPGS+PLP, as IgG1/IgG2a ratio 
could provide information about the potentially protective nature of an IgG response in addition 
to its magnitude 58, 59. In all, the data collected in this study suggest that both a decoy effect and 
immunomodulation could be potential factors in the efficacy of ETPGS+PLP.  
 
3.5 Conclusions 
 The development of autoantigen delivery vehicles that also functionally direct the immune 
response would provide substantial benefit to ASIT for autoimmune diseases. In the past, 
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conventional vehicles such as Freund’s adjuvant have fallen short of clinical success 14, 23. In this 
work, the ability of tocopherol emulsions to act as functional vehicles for antigen delivery was 
investigated. PLP delivered by ETPGS was efficacious to ameliorate EAE in vivo as evidenced by 
a decrease in disease incidence as well as severity. While trends of skewed cytokine responses 
were not evident in splenocytes from ETPGS+PLP treated mice compared to controls, anti-PLP 
IgG was slightly elevated and significantly relegated to the periphery, potentially indicating a 
therapeutic shift to Th2-mediated immunity and restriction of autoimmune effectors from the CNS 
compartment. Overall, these data indicate that ETPGS can act as a functional delivery vehicle, 
making it a compelling candidate for further study. The pharmaceutical development of MF59 as 
an emulsion-based vaccine adjuvant has shown that large-scale manufacturing of pharmaceutical 
emulsions can be feasible in practice 60, 61, but it will be critical to further elucidate the mechanistic 
potential of ETPGS in general, as well as in the context of authentic autoimmune disorders.  
Moving forward, it is pertinent to further study the mechanistic drivers of therapeutic 
success in ETPGS as an antigen-delivery system. Evidence such as acute in vitro inhibition of 
RNOS production by macrophages and robust IL-10 generation in EAE splenocytes support an 
antioxidant mechanism, but cytokine and cell populations should be more carefully explored in 
secondary lymphoid organs, CNS tissues, and at the site of administration before drawing firm 
conclusions. The decoy effect is substantiated by delayed disease onsets and the restriction of anti-
PLP IgG to the periphery over the CNS, but more work is needed to assess the validity of this 
phenomenon as a mechanism to correct autoimmunity.  
 
3.6 Supporting Information 
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 Supporting information is available: Supp. Fig. 1 Scanning electron microscopy and 
elemental analysis of ETPGS formulations. Supp. Fig. 2 PLP Release from ETPGS formulation. 
Supp. Fig. 3 Overlaid clinical scoring and weight data from in vivo study. 
 
 
Supp. Fig. 1. Elemental Analysis of Scanning Electron Microscopy for ETPGS alone (Left) and 
ETPGS+PLP (Right). ETPGS+PLP, but not ETPGS alone, contains nitrogen in the dried oil phase, 





Supp. Fig. 2. Peptide release from dialysis tubing containing 4 mL of either PBS or ETPGS with 
PLP into 100 mL of bulk PBS. Peptide released into the bulk was sampled and analyzed by HPLC. 
PLP incorporation to ETPGS yielded a slightly impeded delivery over time as compared to PBS. 
  
 
Supp. Fig. 3. Overlaid clinical scoring and weight change data for EAE mice treated with either 
PBS, PLP, ETPGS, or ETPGS+PLP. Statistics are not represented.  
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 Central to the propagation of adaptive immunity is the maturation of antigen-specific 
responses in secondary lymphoid organs (SLOs) such as the spleen and lymph nodes 1-3. Following 
these initiatory events, antigen-specific populations are amplified, egress from SLOs, and traffic 
to antigen-rich locales 4, 5 for further stimulation and effector action 6-8. Acute adaptive immunity 
is robust, but short-lived for the rapid clearance of pathogens and abnormal cells. Following the 
steep deployment of a response, immune cells can become exhausted as a checkpoint mechanism. 
Under these conditions, functional capacity is diminished and apoptosis may ensue 9-11. Together, 
the migratory circuit between SLOs and diseased tissue coupled with the exhaustible nature of 
immunity is a hallmark of relapsing-remitting autoimmune diseases such as multiple sclerosis 
(MS) 12-15. In such diseases and their experimental models, a vicious cycle is entrenched where 
aberrant autoantigen-specific effectors are primed, trafficked to disease-specific sites, and further 
stimulated to cause damage before returning to SLOs and regaining functionality 16-18.  
 Some of the most clinically effective immunotherapies for MS work by blockading the 
migratory circuit between peripheral SLOs and the central nervous system 19, 20. Preventing egress 
from SLOs or blocking infiltration of myelin-specific immune populations can preserve host tissue 
integrity and stifle autoimmune destruction. These disease-modifying therapies are, however, 
nonspecific in their mechanism. The trafficking of entire populations of immune cells is broadly 
hindered, which severely handicaps both disease-relevant and healthy immune functions alike. 
Patients receiving such immunotherapies are subjected to risks of life-threatening infection that 
can far outweigh therapeutic benefits 21-23. Antigen-specific immunotherapies may offer an 
appealing improvement to the state of conventional treatments, promising to selectively disarm 
autoreactive cells while preserving healthy immune function. 
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Conventional migration-inhibiting immunotherapies broadly block cellular egress from 
lymph nodes 19 or extravasation across the blood brain barrier 20. Conversely, an antigen-specific 
approach may necessitate selectively attracting autoimmune cells or autoantibodies to a surrogate 
locale for sequestration. Engineered implantable biomaterials have emerged for evoking 
therapeutic, antigen-specific immune responses against cancer and autoimmunity alike 24-30. These 
materials create a unique niche 31-36 of antigen to recruit and tune antigen-presenting populations 
for activation or tolerance, often by including a stimulatory adjuvant or immunosuppressive drug 
37-45.  
We designed and tested a novel biomaterial, which mimics etiologic autoantigens via 
covalent surface conjugation of a peptide epitope to microporous collagen sponges. Collagen 
provided an appealing substrate for our application because of the immunologically benign nature 
and widespread use of collagen sponges 46. Antigen-Specific Immune Decoys (ASIDs) were 
designed to short-circuit the SLO-host tissue circuit by sequestering autoreactive effector cells 
from circulation, ultimately preserving host organs. Using murine experimental autoimmune 
encephalomyelitis (EAE) as a model, we set forth to evaluate the prophylactic, subcutaneous 
implantation of ASIDs for preventing paralysis in vivo. Analyzing cell isolates from both sponges 
and spleens, we explored the hypothesis that these constructs could work by intercepting T cell 
proliferation in the periphery. Ultimately, we discovered that ASIDs overstimulated immunity and 




Figure 4. Autoimmunity is primed in secondary lymphoid organs and travels to disease-implicated 
tissues. ASIDs were designed to intercept this response and exhaust it prematurely, leaving host 
tissue intact.  
 
4.2 Materials and Methods 
4.2.1 Materials 
Microporous collagen sponges (4 mm and 21 mm, columnar pore architecture) were 
purchased from Advanced Biomatrix (San Diego, CA). 2,5-dioxopyrrolidin-1-yl 1-azido-3,6,9,12-
tetraoxapentadecan-15-oate (azido-PEG4-NHS Ester) was purchased from Click Chemistry Tools 
(Scottsdale, AZ). Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), and sodium ascorbate 
(NaAsc) were purchased from Sigma-Aldrich (St. Louis, MO). Copper (II) sulfate pentahydrate 
(CuSO4·5H2O) was purchased from Acros Organics (Geel, Belgium). Alkyne-functionalized PLP 
with an N-terminal 4-pentynoic acid (homopropargyl, hp) modification, hpPLP139-151 (hp-
HSLGKWLGHPDKF-OH) was purchased from Biomatik (Cambridge, ON, Canada). Unmodified 
PLP139-151 (NH2-HSLGKWLGHPDKF-OH) used for EAE induction, rechallenge assays, and anti-
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PLP IgG ELISA was purchased from PolyPeptide Laboratories (San Diego, CA). Incomplete 
Freund’s adjuvant (IFA) and killed Mycobacterium tuberculosis strain H37RA were purchased 
from Difco (Sparks, MD). Pertussis toxin was purchased from List Biological Laboratories 
(Campbell, CA). R-phycoerythrin (PE)/Cy7-conjugated anti-mouse CD3, PE-conjugated anti-
mouse CD86, FITC-conjugated anti-mouse CD80, and respective isotype control antibodies were 
purchased from BioLegend (San Diego, CA). All other chemicals and reagents were analytical 
grade and used as received. 
4.2.2 Synthesis of ASIDs 
  Collagen sponges (4 mm or ¼ sections of 21 mm diameters) were modified by reacting in 
a 2 mg/ml solution of 2,5-dioxopyrrolidin-1-yl 1-azido-3,6,9,12-tetraoxapentadecan-15-oate 
(azido-PEG4-NHS ester) in 50 mM HEPES buffer at pH 8.3 for 4 hours at room temperature. 
Subsequently, the sponges were washed five times with deionized water. The washed sponges 
were then placed in an solution of N-(6-(diethylamino)-9-(2-(prop-2-yn-1-ylcarbamoyl)phenyl)-
3H-xanthen-3-ylidene)-N-ethylethanaminium (Rhodamine-alkyne, 1.22 mM) or hpPLP139-151 
(1.22 mM, 2 mg/mL) in pH 8.3 HEPES, followed by the addition of a premixed solution of tris-
hydroxypropyltriazolylmethylamine (THPTA, 4.5 mM) and copper (II) sulfate pentahydrate (0.8 
mM). Finally, sodium ascorbate (16 mM) was added to begin the reaction. The reaction was carried 
out overnight at room temperature. The sponges were then washed 5 times with deionized water 
and stored in 100% ethanol. The unmodified sponges were treated with the same procedure 
outlined above, with the omission of azido-PEG4-NHS ester. For in vivo studies, sponges were 
washed five times over the course of a day in 1X PBS and stored overnight at 4C in a solution of 
1200 ng/mL of mouse GM-CSF.  
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4.2.3 Characterizing ASIDs 
 Scanning Electron Microscopy (SEM) was employed at 150X magnification to 
approximate collagen pore size. SEM images were taken on an FEI Technai F20 XT Field 
Emission Transmission Electron Microscope with dehydrated collagen sponges. PLP conjugation 
to collagen sponges was determined using a 20 minute Reverse-Phase HPLC method employing a 
95/5 to 30/70 aqueous:organic gradient scheme on a C4 RP column. PLP conjugation was assessed 
by sampling “pre” and “post” reaction mixtures from before and after the addition of sodium 
ascorbate, respectively. Peptide conjugated was indirectly determined by comparing the 
percentage loss of the PLP peak area (8.9 minutes) from “pre” to “post” reaction.  H2O + 0.05% 
trifluoroacetic acid was used as the aqueous phase, and acetonitrile + 0.05% trifluoroacetic acid 
was used for the organic. Functional characterization of ASIDs was completed by incubating PLP-
conjugated and unconjugated sponges with 1:100 anti-PLP139-151 IgG positive mouse serum for 1 
hour at room temperature. Sponges were washed, and bound anti-PLP139-151 IgG was detected with 
HRP-conjugated anti-mouse IgG.  
4.2.4 Induction of EAE and Therapeutic Study 
 EAE was induced as previously described 47, 48 in 4-6 week-old, female SJL/J mice from 
Envigo Laboratories. Mice were housed under specified, pathogen-free conditions at the 
University of Kansas with authorization approved under a protocol passed by the University's 
Institutional Animal Care and Use Committee. EAE was induced by subcutaneous administration 
of 200 µg of unmodified PLP139-151 in 200 µL of Complete Freund’s Adjuvant (CFA) emulsion. 
The CFA mixture was produced from equal volumes of PBS and IFA containing killed 
Mycobacterium tuberculosis strain H37RA at a final concentration of 4 mg/mL. The immunization 
was administered as four, 50 μL injections above the shoulders and the flanks. Additionally, 200 
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ng of pertussis toxin was administered as an intraperitoneal injection on the same day of 
immunization (day 0) as well as day 2 post-induction. For therapeutic study, mice received a 
subcutaneous implantation surgery between the shoulder blades on Day 7. Mice were weighed 
each day of the study and monitored with clinical scores starting on day 7. Disease progression 
was assessed on a five-point clinical scale including: 0, no clinical evidence of disease; 1, tail 
weakness or limp tail; 2, paraparesis (weakness or incomplete paralysis of one or two hind limbs); 
3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia with forelimb weakness or 
paralysis; and 5, moribund.  
4.2.5 Detection of Anti-PLP IgG 
 PLP-specific IgG titers were assessed in an ELISA format as previously described 48, 49. 
Briefly, 1µg/mL PLP was dissolved in a pH 9.5 solution of 50 mM NaHCO3. This coating buffer 
was seeded on Immulon 2HB 96-well plates and incubated overnight at 4°C. Plates were then 
blocked with 1% (w/v) bovine serum albumin (BSA). Serum and homogenized central nervous 
system tissue (hCNS) were then introduced and serially diluted 1:1 across seven concentrations 
starting at 1:100. After washing, HRP-conjugated anti-mouse IgG (BioLegend) was added at 0.1 
µg per 100 µL. After a final washing regimen, 100 µL of TrueBlue substrate was added, and plates 
were covered and shaken at 250 rpm and room temperature for 15 minutes. Enzymatic conversion 
was stopped with 100 µL 2N H2SO4 and the plate was read at 450/540 nm (Spectramax M5, 
Molecular Devices). For analyzing titer, linear regions across sample titration readings were fitted 
with linear regressions and extrapolated to their 1X concentration for comparison across samples.  
4.2.6 Spleen Harvest and Splenocyte Isolation 
 Spleen harvest and splenocyte isolation was conducted as previously reported 50. Briefly, 
spleens were passed through a wire mesh using the rubber stopper of a sterile 1 mL syringe in 1X 
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PBS.  The strained cellular extracts were centrifuged, and the cell pellet was resuspended in red 
blood cell lysis buffer. The cells were incubated on ice for 3.5 minutes to lyse splenic red blood 
cells.  The lysis reaction was stopped by adding 10 mL RPMI 1640 media containing 10% FBS to 
the mixture before centrifuging.  The remaining splenocyte pellets were resuspended in fresh 
media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and counted for 
further analysis and experimentation.   
4.2.7 Sponge Harvest and Spongeocyte Isolation 
 Cellular infiltrates to ASIDs and Blank Sponges were isolated by retrieving sponges from 
the subcutaneous space. In an Eppendorf tube, sponges were either chemically digested using 0.5 
mg/mL Liberase TL (Sigma Aldrich, St. Louis, MO) in HBSS or mechanically disrupted with 
microscissors. The resulting freed cell suspension was then passed through a 70 µm strainer. The 
suspension was pelleted, replenished with 1 mL of RPMI 1640 media containing 10% FBS and 
1% Penicillin-Streptomycin, and cells were counted for further processing and plating. 
4.2.8 Fluorescent Staining and Flow Cytometry 
  Splenocytes were collected from 24-well plates after 96 hours and stained with fluorescent 
antibodies according to manufacturer recommendations. Cells were washed with 1X PBS + 5% 
FBS + 0.1% sodium azide before being incubated for 20 minutes with Zombie Aqua viability stain 
(Biolegend) at room temperature. Following the incubation, fluorescent antibodies and isotype 
controls were added for 30 minutes on ice.  For flow cytometry data collection, 100,000 cells per 
sample were targeted using a BD FACSFusion cytometer. Data were analyzed using FlowJo and 
GraphPad Prism software. 
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4.2.9 Measurement of Cellular Metabolism 
 75 µM Resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) was incubated with 
splenocytes in a 96 well plate for 3 hours. Metabolic reductive capacity was observed by viewing 
changes in fluorescence at excitation 560, emission 590 (Spectramax M5, Molecular Devices). 
Background fluorescence was taken using RPMI media and subtracted out from splenocyte 
readings for analysis.  
4.2.10 Measurement of Cytokines 
 Following a 96-hour incubation, splenocytes in a 96-well culture plate were centrifuged. 
Supernatants were collected for cytokine analysis (GM-CSF, IFN- γ, IL-2, IL-21, IL-6, IL-10, IL-
17, IL-23, TNF-α). Marker levels were detected using a U-Plex assay kit according to manufacturer 
instructions (Meso Scale Discovery). Each assay plate was read using the QuickPlex multiplex 
plate reader (Meso Scale Discovery). 
4.2.11 Histology 
 Resected sponges and tissues were cryoembedded with Tissue-Plus O.C.T. Compound 
(FisherSci) and sectioned into 20 µm on microscope slides in triplicate. Slides were fixed in 10% 
neutral buffered formalin for 10 minutes, and Masson’s trichrome stain (Sigma Aldrich) was 
conducted.  
4.2.12 Statistical Analysis 
 Statistical evaluation was performed using one-way analysis of variance (ANOVA), 
followed by Tukey and Sidak multiple comparison tests. Statistical significance for all analyses 






4.3.1 Synthesis and Functional Characterization of ASIDs 
 We designed ASIDs as an implantable depot displaying covalently-coupled autoantigen. 
Microporous collagen sponges were selected as a scaffolding material due to their 
immunologically inert nature, widespread clinical utility since the 1970s 46, and commercial 
availability. The sponges we obtained for this work consisted of type I collagen with a columnar 
pore architecture (Supp. Fig. 1a). We hypothesized primary amine moieties would be chemically 
accessible on the surface of these collagenous materials (Fig. 2a) and pore diameters of ~200 µm 
would facilitate unhindered cell infiltration and nutrient transfer (Fig. 2b). To qualitatively assess 
surface accessibility of primary amines, a bifunctional NHS-PEG4-Azide linker was installed to 
collagen sponges, and rhodamine-alkyne was successfully conjugated using copper (I)-catalyzed 
azide-alkyne cycloaddition (Fig. 2c). Likewise using the same chemistry, a homopropargyl version 
of model autoantigen PLP139-151 (hpPLP) was coupled to the collagen sponges to synthesize 
ASIDs. We indirectly quantified peptide conjugation efficiency by HPLC and determined 1.5 mgs 
of PLP was conjugated per 175 mm3 collagen sponge (Supp. Fig. 1b). Accounting for the surface 
area of the microporous collagen sponges (2,000 mm2), we estimate that antigen density was 0.468 
nmol/mm2 on the implant. 
The functionality of conjugated autoantigen was then validated. ASID and Blank collagen 
sponges were each incubated in anti-PLP IgG-positive mouse serum. HRP-conjugated anti-mouse 
IgG was used to detect bound autoantibody (Fig. 2d), and the ASID, but not Blank sponge, showed 
successful capture. Additionally, EAE splenocytes were harvested at peak of disease and cultured 
ex vivo with ASIDs. Functional outcomes were compared with cells stimulated with 25 µM soluble 
PLP139-151 as well as vehicle control (Fig. 2e-g). After 96 hours, splenocytes cultured with ASID 
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exhibited a significantly elevated metabolism over vehicle control (Fig. 2e), and CD86 expression 
levels were analogous to cells stimulated with soluble antigen (Fig. 2f). Likewise, soluble PLP and 
ASIDs generated robust IL-17 secretion, though only ASID culturing enabled high IL-12 after the 
incubation, indicating sustained APC activity (Fig. 2g).  
 
Figure 5. Synthesis and characterization of immunologically active PLP-conjugated ASIDs. a) 
The synthesis reaction scheme modified surface primary amines on collagen sponges with an 
azide-functional PEG linker subsequently clicked to homopropargyl PLP139-151. b) Microporous 
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collagen sponges were used, and 150X SEM imaging showed an average pore size of 
approximately 200 µm. c) To visualize surface accessibility of primary amine moieties, 
rhodamine-alkyne was installed (left) and imaged compared to a Blank sponge (right), where dye 
conjugation could be confirmed. d) ASID with surface-conjugated PLP (left) captured anti-PLP 
IgG (note blue color) from mouse serum and a Blank collagen sponge (right) did not. e) Day 12 
EAE Splenocyte metabolism was measured after incubation with vehicle (-PLP), soluble antigen 
(+PLP), or ASID. ASIDs significantly elevated metabolism over vehicle-treated splenocytes after 
96 hours. f) Under the same conditions, CD86 expression was measured by flow cytometry, where 
ASIDs likewise upregulated costimulation in a manner similar to that of soluble antigen. g) In the 
same experiment, quantification of cytokine production showed that inflammatory IL-17 (left) was 
elevated by both +PLP and ASID treatment, however APC-indicating IL-12 (right) was only 
stimulated by incubation with ASIDs. (Statistical analysis was performed against –PLP as a 
control. n = 3/group, *p < 0.05, **p < 0.01, ***p < 0.001). 
 
4.3.2 Subcutaneous Implantation of ASIDs prevents EAE in vivo 
 To investigate ASID therapeutic capacity, we subcutaneously implanted EAE mice with 
these constructs between the shoulder blades on day 7 post-induction, prior to the onset of 
symptoms (Fig. 3a). Healthy mice were also implanted with ASID to assess whether decoys 
themselves would stimulate an immune response. All implanted sponge constructs were sterilized 
and soaked overnight in a solution of 1200 ng/mL mouse GM-CSF prior to implantation to create 
impetus for cell infiltration and to normalize for inflammatory discrepancies that may have arisen 
from variability in surgery. This GM-CSF soaking concentration was informed by past work 51 
and designed to be subtherapeutic in dose (roughly 200 ng per sponge). ASIDs highly suppressed 
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EAE in vivo, both in terms of significant scoring reduction as well as weight loss (Fig. 3b-d). Only 
two of four ASID mice showed any EAE symptoms at all, and none exhibited substantial paralysis 
which is defined as a clinical score of 2 or greater (Fig. 3e). Blank sponge implantation and Mock 
Surgery had no significant clinical effect on disease course, as these mice did not vary as compared 
to EAE alone with no surgical procedure or treatment. Control disease in this study was severe, as 
one mouse from the Blank group and one mouse from the Mock Surgery group each succumbed 
to disease at its peak. Strikingly, weight gain in EAE mice treated with ASID mirrored that of the 
healthy mice that were completely unhindered by disease (Fig. 3c).  
 At the conclusion of the study, serum and whole brain homogenates were collected. Anti-
PLP139-151 IgG ELISA was used as previously described 
48, 49, 52 to detect relative autoantibody 
titers between the periphery (serum) and CNS (homogenized whole brain, Fig. 3f, Supp. Fig. 2). 
EAE mice implanted with an ASID presented with an elevated serum anti-PLP titer that did not 







Figure 6. Therapeutic Evaluation of ASIDs against EAE in vivo. a) Mice were induced with EAE 
(excluding the HC, healthy controls group). On day 7, before symptoms began, mice were 
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subcutaneously implanted with either an ASID or Blank Collagen Sponge, given Mock Surgery, 
or no treatment (EAE alone). b) Clinical Scoring and c) Weight change data were collected over 
the course of 25 days and demonstrated that ASID implantation significantly suppressed disease 
and did not induce autoimmunity in healthy mice. d) Cumulative clinical score was calculated and 
compared between groups, reinforcing the significance of ASID effect. e) Additionally, disease 
incidence was stratified by presence of disease at or above a clinical score of 2, where ASID 
implantation completely prevented incidence of severe symptoms. f) After the study, serum and 
hCNS were collected from mice, and anti-PLP IgG titer was compared. ASID-implanted EAE 
mice exhibited a significantly elevated serum titer of anti-PLP IgG, but there was no change in 
hCNS titer (n  = 3-4/group, *p < 0.05, **p < 0.01, ***p < 0.001). 
 
4.3.3 ASID Infiltrates undergo Apoptosis upon PLP Rechallenge 
 We hypothesized the persistent, antigen-specific depot in ASIDs could selectively 
sequester autoreactive cell populations responsible for propagating autoimmunity to prevent 
disease. To evaluate this proposed decoy mechanism, we implanted EAE mice with both a Blank 
collagen sponge as well as an ASID on day 7 post-induction (Fig. 4a). Sponges and spleens were 
harvested at typical disease onset (day 10) or peak of disease (day 14). Cells were isolated and 
rechallenged with 25 µM PLP for 96 hours. At day 10, there were no significant differences in 
resazurin cell metabolism across splenocytes and sponge isolates (Fig. 4b), though ASIDs were 
considerably more degraded than Blank sponges (Fig. 4c). At day 14, metabolism in ASID 
infiltrates was roughly halved as compared to the Blank sponge and spleen (Fig. 4b). These results 
were initially surprising as we expected PLP-specific cells isolated from ASIDs to elicit a greater 
metabolic response upon rechallenge. To further investigate, harvested sponges were 
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cryosectioned and Masson’s trichrome staining was used to assess morphological differences (Fig. 
4c). Reflecting resazurin metabolism data, few differences were observable at day 10 (though 
ASID sections showed relatively more cell infiltrates). In contrast, ASID infiltrates appeared 
disjointed and unhealthy at the day 14 timepoint, while Blank sponge sections showed apparently 
healthy, ordered cell structures. Bright field microscopy of isolated splenocytes and spongeocytes 
after 96-hour PLP rechallenge corroborated apoptotic allusions. ASID isolates at the day 14 






Figure 7. Same-animal sponge infiltrate analysis. a) On day 7 post-induction, EAE mice received 
both an ASID and Blank Sponge separately placed in the subcutaneous space. b) At both onset 
(day 10) and peak (day 14) of disease, sponges and spleens were retrieved and challenged with 25 
µM PLP. After 96 hours, metabolism was measured, and showed that while few differences were 
appreciable at day 10, the day 14 timepoint demonstrated that metabolism was significantly 
decreased in ASID cell infiltrates. c) Resected sponges were imaged upon retrieval and 
cryosectioned for trichrome histology on day 10 (top) and day 14 (bottom). Here, healthy and 
ordered cell structures were observed in the Blank construct by day 14, but ASID infiltrates were 
disordered and misshapen.  d) These observations were conserved in splenocytes (left) and 
spongeocytes (Blank, middle, and ASID, right) after being isolated from the same mouse and 
rechallenged with 25 µM PLP. After 96 hours, splenocytes and Blank sponge infiltrates appeared 
largely healthy, however death was abundantly prevalent in ASID isolates (n = 3 biological 
replicates per group, *p < 0.05). 
 
4.3.4 ASIDs Return Exhausted Immune Cells to Secondary Lymphoid Organs 
 In the same-animal implant experiment (Fig. 4), we noticed that secondary lymphoid organs 
appeared substantially engorged at times in disease course when splenopenia is typical, due to 
autoimmune cell egress to the CNS (Supp. Fig. 3). To further probe this phenomenon as a potential 
mechanistic underpinning of ASID efficacy, we implanted EAE mice with either an ASID, Blank 
sponge, or Mock Surgery on day 7 post-induction and harvested at peak of disease on day 14 (Fig. 
5a). ASID-implanted mouse spleens were larger than those of the other groups by a factor of 4, 
and a similar size discrepancy in lymph nodes was evident (Fig. 5b, Supp. Fig. 4). The largest 
numbers of splenocytes were also harvested from these spleens, where yields averaged a multiple 
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of two and four times those from Mock and Blank controls, respectively. Cells were also isolated 
from sponges, and ASID isolates numbered roughly 5 million cells per construct while Blank 
infiltrates were on the order of 10,000 cells per sponge (Fig. 5b). 
Isolated splenocytes and spongeocytes were rechallenged with media alone, 25 µM PLP, or 
2.5 µg/mL of mitogenic Concanavalin A (ConA) for 96 hours (Fig. 5c). Unchallenged ASID 
splenocytes showed a significantly higher level of metabolism after the incubation (compared to 
controls), but the inclusion of PLP or ConA abrogated this increase. In the sponges, ASID isolates 
exhibited metabolism that was not exhaustive in response to PLP or ConA, and was significantly 
elevated over Blank sponge isolates, but these cells were much lower in number as mentioned 
above (Fig. 5b). 
Flow cytometry was used to phenotype splenocytes immediately after harvest (Fig. 5d, e). 
Moving from our previous same-animal experiment and observations of enlarged spleens, we 
hypothesized that ASIDs may have worked to evoke antigen overstimulation to exhaust the EAE 
autoimmune response and prematurely return perpetrating cells to secondary lymphoid organs. In 
accordance with our hypothesis, we found T (CD3+) and B (CD19+) cell populations to be 
significantly depleted in ASID spleens compared to those of Mock Surgery (Fig. 5d). Seemingly 
conflicting with these decreased levels of effector subsets, though, was an increase in CD11c+ 






Figure 8. Differences in composition at peak of disease. a) EAE mice were implanted with ASID, 
Blank Sponge, or Mock Surgery. On day 14, spleens were harvested. b) Spleen weights were 
compared at harvest (left) in addition to isolated splenocyte (middle) and spongeocyte (right) 
counts. ASIDs both recruited the most spongeocytes and induced significant spleen engorgement.  
c) Cell isolates from spleens (left) and sponges (right) were incubated with vehicle (-PLP), 25 µM 
PLP (+PLP), or 2.5 µg/mL Concanavalin A (ConA) for 96 hours and cell metabolism was 
measured. ASID splenocytes exhibited high metabolism when incubated with vehicle, but PLP 
rechallenge diminished this elevation. In spongeocytes, metabolism was largely conserved across 
all three treatments. d) Flow cytometry was used to phenotype splenocytes for CD3 (left), CD19 
(middle), and CD11c (right), and splenocytes from ASID implanted mice were found to be 
relatively depleted of T and B cell subsets. Additionally, CD11c+ populations were increased in 
ASID spleens as compared to controls. e) CD80 and CD86 were also observed between groups, 
where CD86+CD80+ costimulation was slightly elevated by Blank sponges and ASIDs. 
(Statistical analysis was performed against the Mock group as a control. n = 4 biological replicates 
group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001).  
 
4.3.5 Antigen-Specific Exhaustion Persists after PLP rechallenge 
 Moving from baseline phenotyping, day 14 splenocytes were also rechallenged with 25 
µM PLP for 96 hours. After the incubation, many baseline trends persisted (Fig. 6a). ASID 
splenocyte CD3+ T cells remained lower in proportion to controls both with and without 
rechallenge, though CD19+ B cells were relatively similar at this time point. CD11c+ APCs were 
significantly elevated when incubated with vehicle media, but not significantly different when 
challenged with antigen. However, an inverted antigen rechallenge trend was appreciable; the 
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inclusion of PLP led to expanded CD11c+ populations in Mock and Blank controls, but led to a 
decrease when included with ASID splenocytes (Fig. 6a). Despite this decrease, the CD11c+ 
proportion of rechallenged ASID splenocytes was slightly higher than those of the controls. 
Costimulation was promoted upon rechallenge without exception across groups, but PLP 
rechallenge in ASID splenocytes promoted exorbitantly higher levels of CD80+ as well as 
CD86+CD80+ double positive cells (Fig. 6a).  
 One major limitation of the EAE model is a lack of tools for probing antigen-specificity. 
In recent years, our group has published a multivalent nanomaterial known as the soluble antigen 
array (SAgA), which has been developed as an antigen-specific immunotherapy 53-56. SAgAs 
evoke efficacy by specifically engaging surface-bound B cell receptors 50, 57-59. In this study, we 
hypothesized that fluorescently labeled SAgAs could identify antigen-specific B cells much in the 
same way that MHC-tetramers are employed for T cells. By including SAgAs with other 
fluorescent antibodies, we developed a method in which antigen-specific cells could be identified 
by gating on CD19 (Fig. 6b, Supp. Fig 4). Extrapolating this protocol allowed identification of 
antigen-specific subsets of B cells in EAE splenocytes (Fig. 6c). CD19+CD11c+ autoimmune-
associated B cells (ABCs) have been reported as potent, antigen-specific instigators of immunity 
in EAE and autoimmune disease alike 47, 50, 60. Interestingly, ASID splenocytes showed 
significantly elevated proportions of this population when incubated with vehicle (Fig. 6c), though 
much like resazurin (Fig. 4b, Fig. 5c), these cells were diminished by PLP rechallenge. The SAgA 
probe verified this trend was conserved within the antigen-specific CD19+CD11c+ ABC subset, 




Figure 9. PLP rechallenge response among harvested splenocytes. a) From the previous 
experiment, excess splenocytes were phenotyped after 96 hours of vehicle (-PLP, open bars) or 25  
µM PLP treatment (+PLP, solid bars) for CD3, CD19, and CD11c (top row, left to right) as well 
as costimulatory markers CD86, CD80 and double positive CD86+CD80+ populations (bottom 
row, left to right). Similar trends to the baseline analysis were appreciable; CD3+ T cell 
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proportions were suppressed in ASID spleens, but CD11c+ populations were slightly more 
prevalent.  b) SAgAs were used to reliably tag antigen-specific B-cells and ultimately c) probe 
disease-relevant ABCs (left), SAgA+ B cells (middle), and SAgA+ ABCs (right). Within ASID 
splenocytes, the ABC subset showed a considerable decrease in prevalence in response to antigen 
rechallenge.  (Statistical analysis was performed against the Mock group as a control. n = 4 
biological replicates per group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001). 
 
4.3.6 Pro-inflammatory Cytokines are Elevated in ASID-Treated Splenocytes at Day 
14 and 25 
 In addition to phenotypic changes in response to antigen rechallenge, we assessed cytokine 
responses in splenocytes harvested on day 14 or 25 and cultured with 25 µM PLP or vehicle for 
96 hours (+PLP reported in Fig. 7a, -PLP and absolute concentrations in Supp. Fig. 8). At day 14, 
ASID mice showed increased in pro-inflammatory cytokines GM-CSF, IFN-γ, and IL-6 as 
compared to the Mock Surgery group, while splenocytes from mice implanted with a Blank sponge 
largely secreted less of each analyte screened. At day 25, ASID-treated splenocytes still exhibited 
elevated levels of pro-inflammatory cytokines IFN-γ, IL-15, IL-17, and IL-6, though at this point, 
anti-inflammatory IL-10 was most profoundly upregulated.  
We contextualized cytokine trends across a number of mechanistically indicative ratios 
(Fig. 7b). IL-2/IL-17 was used as a measure of T cell proliferation proportional to overall EAE 
inflammation. Mock Surgery and Blank-treated mice showed increases in T cell proliferation at 
day 14 which was resolved by day 25, but ASID treatment appears to have restricted IL-2 at peak 
of disease. This trend is in concordance the exhaustive mechanism suggested by our other 
experiments. IL-12/IL-2 was used to interrogate the balance between APCs and T cells. Consistent 
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with our earlier observations, ASID-treatment seems to cause an upward skew in this ratio, where 
APC levels are sustained while IL-2 is diminished. Finally, to investigate the observed increase of 
IL-10 from ASID splenocytes at day 25, IL-10/IFN-γ was employed to probe a potential 
tolerogenesis where anti-inflammatory IL-10 precludes pro-inflammatory IFN-γ production. 
Interestingly, despite these observed increases in IL-10, IFN-γ remains proportionally abundant 
such that this ratio fell well within the bounds of the controls.  
 Finally, we sought to discern whether ASID implantation would protect mice from the 
recurring paralysis that is characteristic of the PLP139-151-EAE model. In our early studies, ASIDs 
and Blank sponges alike were found to be completely resorbed by day 25. We wondered if a 
durable therapeutic effect could be realized as a result of ASID-induced cell exhaustion (Fig. 7c). 
During the initial phase of disease, only one of three ASID recipients displayed any EAE 
symptoms, and each of the Mock Surgery cohort exhibited a fully severe initial presentation. 
Remarkably, all ASID-implanted mice were protected from recurrent disease through day 60 while 
two of three Mock Surgery mice displayed robust relapses on days 37 and 38 post-induction. Ex 
vivo analyses revealed few differences between splenocytes in response to PLP rechallenge (Supp. 




Figure 10. Cytokine changes in PLP challenged splenocytes. a) Day 14 (left) and day 25 
splenocytes (right) were challenged for 96 hours with 25 µM PLP, and changes are expressed in 
terms of median fold-change with respect to Mock as a control. At day 14, inflammatory cytokines 
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GM-CSF, IFN-γ, and IL-6 abounded in ASID splenocytes, though IL-2 was suppressed. At day 
25, both inflammatory and anti-inflammatory cytokines were elevated in the ASID cohort. b) 
Cytokine ratio analysis of IL-2/IL-17, IL-12/IL-2, and IL-10/IFN-γ (left to right) at both time 
points was used to provide greater resolution of inflammatory trends. Decreased ASID IL-17/IL-
12 showed that despite increases in general inflammation, T cell proliferation did not occur. 
Additionally, IL-12/IL-2 was employed to investigate exhaustion, where increased antigen 
presentation (IL-12) did not stimulate T cell proliferation either. To rule out tolerogensis, IL-
10/IFN-γ was employed, showing that ASID implantation did not evoke a response of that nature.  
c) Mice were implanted with either ASID (blue) or Mock Surgery (Black) on day 7 post-induction. 
By day 60 (after ASIDs had been completely resorbed), no ASID mice had relapsed, while two of 
three Mock Surgery mice displayed a fully severe recurrence of disease. (Statistical analysis was 
performed against the Mock group as a control. n = 3-4 biological replicates per group). 
 
4.4 Discussion 
 Previous works exploring antigen-specific immunotherapies for autoimmunity delivered 
autoantigen in vastly differing ways, including soluble, insoluble, and biomaterial compositions. 
ASIDs utilize covalent attachment of autoantigen onto a microporous scaffold to inhibit EAE in 
vivo when implanted subcutaneously after disease induction, but before the appearance of 
symptoms. Past work exploring immunologically-active therapeutic biomaterials has mostly 
explored co-delivery formulations 27. To our knowledge, ASIDs represent a first demonstration of 
antigen-specific immune cell sequestration for therapeutic effect. Recently, the Serwold group 
disseminated an implantable biomaterial soaked in autoantigen for the purpose of homing and 
enriching antigen-specific populations in models of Type 1 Diabetes, but interestingly, no 
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therapeutic effect was realized 35. Our data also indicated antigen-specific cell infiltration into 
ASIDs (Fig. 4, Fig. 5b), but the therapeutic capacity we observed likely resulted from the 
specification of irreversible epitope conjugation to our constructs, which has been well described 
to enable antigen persistence and boost T cell stimulation 61. In our example, such overstimulation 
proved itself a driver of effect through exhaustion and may explain our differential therapeutic 
success. 
 ASIDs elicited robust DC activation ex vivo (Fig. 1e-g). We initially hypothesized that this 
mechanism would solely facilitate the recruitment and sequestration of T and B effectors in vivo. 
When implanted, however, ASIDs spurred exhaustion and apoptosis within the constructs (Fig. 
3). Evidence has emerged regarding the potential for “therapeutic exhaustion” by extrapolating a 
liability observed during chronic infection for possible benefit in autoimmunity 62.  In our studies, 
exhaustion was implicated in the prevention of disease. Spleen weights correlated highly with 
suppression of EAE, where engorgement was likely a consequence of ASID-induced exhaustion 
and return to SLOs (Fig. 5b, Supp. Fig. 4 14, 63. The exhausted state of splenocytes in ASID-treated 
mice was corroborated by effector non-responsiveness to antigen rechallenge. Despite the presence 
of CD86+CD80+ active DCs (Fig. 5d, e, and Fig. 6), we observed an absence of IL-2 despite 
upregulation of other inflammatory markers such as IFN-γ (Fig. 7a, b). Interestingly, proliferation 
of resting (unchallenged) ABCs was diminished in the presence of PLP rechallenge (Fig. 7c). 
Abrogated proliferation was most severe in the antigen-specific population of this subset, 
suggesting that population changes may be driven by PLP-specific mechanisms. Autoimmunity 
was restricted to the periphery, exclusive of the CNS, as evident in the elevation of serum anti-
PLP IgG, which was not observed in homogenized brain (Fig. 3f). In effect, the PLP-specific 
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response was short-circuited and exhausted in ASID-treated mice, which translated to therapeutic 
success. 
Remarkably, no ASID-implanted EAE mice developed significant disease (score >1) over 
60 days. All three Mock Surgery-receiving counterparts exhibited severe primary EAE, and two 
of these mice exhibited robust flare-ups over this interval after day 25 (Fig. 7c). After the initial 
25-day efficacy study, ASID and Blank constructs had been completely degraded, so this 
experiment was conducted to observe relapsed autoimmunity that is typical of the PLP139-151-EAE 
model. We originally expected ASID-treated mice to develop paralysis similarly to those given 
Mock Surgery by virtue of regained functionality after exhaustion, perhaps even at a higher rate 
or intensity of disease due to a delayed hypersensitivity reaction. In retrospect, initial disease 
prevention in ASID mice may have limited primary tissue inflammation and abrogated subsequent 
migration to the CNS. Alternatively, past work has shown that antigen, once trafficked to lymphoid 
organs, can persist for several months after exposure 64, 65. Future studies in the ASID model should 
investigate the presence of autoantigen in engorged lymphoid organs, as persistence may enable 
the continued modulation of immunity even after the biomaterial has degraded. 
Alternatively, ASID implantation could have induced differentially robust exhaustion 
similar to what is observed in chronic infection where clonal deletion or permanent anergy can 
ensue 18, 66-68. In the EAE model employed here, immunity is generated against the PLP139-151 
epitope, a small fraction of the larger PLP antigen, which is ultimately one of many constitutive 
building blocks of the myelin sheath. As a result, PLP139-151 density in the CNS is low and 
inaccessible relative to an ASID 69. Conversely, PLP139-151 density in ASIDs is high and by design, 
easily accessible to extravasating immune cells. Antigen density is known to highly dictate 
costimulation and downstream immunity 69-72, where excessively high density can drive 
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overstimulation and cell death 73-75. Differences in these outcomes were evident between ASID-
implanted mice and controls, especially in histological studies and bioassays of spongeocytes (Fig. 
4). Future studies titrating the antigen density in ASIDs could provide an interesting design 
characteristic directing cell exhaustion for therapeutic benefit.   
 
4.5 Conclusions 
In clinical practice, some of the most effective MS therapeutics such as natalizumab and 
fingolimod work by inhibiting immune cell migration and trafficking to the CNS 19, 20. Such drugs 
have a steep trade-off, risking life-threatening consequences of nonspecific immunosuppression 
for therapeutic efficacy 21-23. By demonstrating the potential to affect immune cell migration in an 
antigen-specific fashion, our work suggests autoimmunity may be short-circuited in potent, yet 
safer ways. Additional studies will determine if ASID performance can be extrapolated to a 
broader palette of autoantigens and if therapeutic efficacy can be achieved when intervening at 
different points in the disease. The immunological mechanism of ASID capture, deactivation, and 
release of exhausted autoimmune cells offers a new paradigm to short circuit immune cell 
migration to prevent relapsing autoimmune diseases.  
 




Supplementary Figure 1. Collagen sponges possess appealing porosity and are immunologically 
inert, making them suitable for the present application. a. 40X (left) and 80X (right) SEM images 
were provided with permission from Advanced Biomatrix to show columnar architecture and 
porosity such that surface area could be calculated (2,000 mm2 per implant). b. RP-HPLC results 
for quantifying PLP139-151 conjugation to collagen sponges. Pre and post reaction mixtures were 
sampled and PLP peak areas were determined (t =8.9 minutes. 73.8% of the 2 mgs (excess) of 
peptide in the reaction mixture was consumed from pre to post reaction, indicating that 1.5 mgs of 
peptide was conjugated to the material. c. Sponges used in the animal studies for this work were 





Supplementary Figure 2. Serum and hCNS autoantibody titers were detected by anti-PLP IgG 
ELISA. To compare relative titers, absorbance values were collected across seven dilutions, and 






Supplementary Figure 3. In the same animal implant experiment, we observed engorged spleens 
at a time when secondary lymphoid organs are typically small. a) Day 10 and b) Day 14 sponges 









Supplementary Figure 4. EAE mice were implanted with either ASID, Blank Sponge, or Mock 
Surgery on Day 7 post induction. At day 14 (peak of disease), a) ASID popliteal lymph nodes were 
visibly swollen over Blank and Mock lymph nodes. b) Trichrome staining revealed a higher cell 




Supplementary Figure 5. Soluble Antigen Arrays (SAgAs) consist of autoantigen epitopes 
conjugated to a 16 kDa hyaluronic acid backbone. a) By incubating FITC-labeled SAgAs with 
EAE splenocytes, antigen-specific B cells were tagged through avid binding of the BCR. b) To 
determine a labeling method for fluorescent SAgAs, we titrated the amount of SAgA incubated 
per million splenocytes. Via flow cytometry, we measured antigen specific populations (ABCs, 
CD19+CD11c+) and nonspecific populations (CD19-CD11c-).  10 µg of SAgA per million 
splenocytes was selected as an appropriate labeling concentration, as it maximized specific binding 














Supplementary Figure 7. Gating for phenotypical populations. Shown are single stain controls 






Supplementary Figure 8. Cytokine analyses are presented as absolute pg/mL values to supplement 
heatmap results presented in Figure 7. Samples incubated with 25 µM PLP (+PLP) are indicated 
by black bars, while samples incubated with vehicle alone (-PLP) are represented in gray.  
 
 
Supplementary Figure 9. PLP rechallenge response among harvested D60 splenocytes. A) Spleen 
weights were taken upon harvest and compared to D14 observations. B) Resazurin cell metabolism 
was measured after 96 hours of incubation with –PLP, +PLP, or ConA. C) Splenocytes were 
phenotyped after 96 hours of vehicle (-PLP, open bars) or 25  µM PLP rechallenged (+PLP, solid 
bars) for CD3, CD19, and CD11c (top row, left to right) as well as antigen-specific B cell 
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populations (middle row), and costimulation (CD86, bottom row). n = 3 biological replicates per 
group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001). 
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 Antigen-specific immunotherapies (ASIT) are an appealing supposition for treating 
autoimmune disease1, 2. Classically, autoimmunity has been treated through the nonspecific 
suppression of host immunity, which certainly dampens deleterious autoreactivity but also 
compromises protective functions of the immune system as well3. ASIT posits that the selective 
targeting of immunosuppression to the cell subsets responsible for disease could drastically 
improve safety and efficacy. Recent strategies have co-delivered autoantigen with drug to 
preferentially engage and deactivate cells with cognate receptors specific for self-tissue4. Despite 
many manifestations of these approaches, to date no autoimmune ASITs have advanced to clinical 
approval5.  
 One obstacle to ASIT implementation could be the complexity of authentic human 
autoimmune disease that far exceeds what is capitulated by mouse models6, 7. Particularly, 
authentic autoimmunities are typically polyclonal and progression is accompanied by epitope 
spreading over years of disease8, 9. In Multiple Sclerosis (MS) where autoreactive cells attack 
myelin autoantigens in the CNS, over 100 potential autoantigens have been implicated to date and 
autoreactive specificities can vary greatly between patients9, 10. It is impractical to fabricate ASITs 
that discretely co-deliver all epitopes and it may be infeasible to tailor the formulations for 
personalized treatments. ASIT proponents have suggested bystander tolerance as a potential 
mechanism of therapeutic prowess11-14, but formulations with single or several autoantigen 
epitopes have not exhibited definitive clinical successes. A format to introduce specificity to 




 In a recent report, we detailed antigen-specific immune decoys (ASIDs) as a biomaterial 
therapeutic with remarkable efficacy against experimental autoimmune encephalomyelitis (EAE), 
a mouse model of MS15. These peptide epitope-conjugated microporous collagen sponges were 
designed to recruit and sequester autoreactive cell populations to prevent disease. Evidence 
supported that these biomaterials were able to exhaust migrating effector cells after their egress 
from lymphatic organs but before reaching the central nervous system (CNS). This cellular 
exhaustion resulted in the premature return of immune cells to lymphoid organs and the 
hypersensitivity of these cell types that led to their deletion upon re-exposure to autoantigen. While 
ASIDs were designed as monoantigenic biomaterials in the first iteration, the format readily 
supports the inclusion of polyantigenic compositions. In the present work, we hypothesized that 
the integration of primary tissue into porous collagenous materials could represent a 
comprehensive palette for autoantigens while retaining discrete epitope antigenicity. We 
envisioned that such a material might elicit broad antigen-specific effects against heterogeneous, 
polyclonal autoimmune diseases.  
 In seeking to fabricate a polyantigenic, “complex” decoy that extends beyond the findings 
of our previous proteolipid protein (PLP)-conjugated “simple” system, several design parameters 
must be conserved. In building a decoy it is critical to create a persistent depot with a microporous 
architecture to ensure adequate cell and nutrient transfer both in vivo an ex vivo. To isolate the 
“decoy effect” as a therapeutic mechanism, an immunologically inert material is ideal. Further, 
antigen immobilization into the microstructure must be irreversible, such that sustained antigen 
release is not a driving mechanism of effect. Most important of all, however, is that incorporated 
antigen is functional and retains its ability to bind cognate receptors.  
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 Gelatin was selected as a suitable substrate for the present application. Particularly, 
methacrylated gelatin polymers (gelatin methacrylate, GelMA) have been extensively applied in 
the literature for tissue engineering and drug delivery for their biocompatible and tissue-like 
characteristics16, 17. Some gelatin material variants have even been FDA-approved for wound-
treatment18. Photocrosslinkability is particularly appealing for our application, because the sol-gel 
transformation enables mixing of polyantigenic primary tissues prior to microstructure formation 
to enable integration, as chemical conjugation is not feasible for a non-discrete, heterogeneous 
autoantigen composition. We hypothesized that introducing mouse brain homogenate (MBH) to a 
precursor solution of GelMA may enable the chemical integration of primary tissue into the 
resulting gel, as nondiscriminate free radicals generated during UV exposure may facilitate 
crosslinkage with gelatin polymers.  
 In the present work, we set forth to incorporate MBH into GelMA scaffolds to create 
complex immune decoys theoretically encompassing a full palette of the autoimmune epitopes in 
MS. We endeavored to build such a material, but pertinent questions would loom. Could a 
complex, homogenate containing antigen slurry biomaterial maintain discrete epitope 
functionality? Using EAE as a model disease of discrete antigen-specificity, we assessed cell ex 
vivo activation and amplification to evaluate this functionality. However, it would remain to be 
seen if discrete antigenicity would ultimately translate to clinical efficacy in vivo. Would complex 
decoys be able to instill the same immune exhaustion that was harnessed for therapeutic efficacy 
in the prior single-epitope iteration? 
 




Gelatin type A from porcine skin, methacrylic anhydride, and Irgacure 2959 were 
purchased Sigma Aldrich (St. Charles, MO). Mouse brain material was obtained from SJL/J mice 
(Envigo, Cambridgeshire, UK) housed in specified, pathogen free conditions at the University of 
Kansas. Mouse brain homogenate was prepared adding 1X PBS to obtain a concentration of 1 
g/mL. Using a sonicator probe, the mixture was homogenized for 2 minutes using 10 seconds on, 
2 seconds off regimen. The resulting mouse brain homogenate was stored at -20°C.  2,5-
dioxopyrrolidin-1-yl 1-azido-3,6,9,12-tetraoxapentadecan-15-oate (azido-PEG4-NHS Ester) was 
purchased from Click Chemistry Tools (Scottsdale, AZ). Tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), and sodium ascorbate (NaAsc) were purchased 
from Sigma-Aldrich (St. Louis, MO). Copper (II) sulfate pentahydrate (CuSO4·5H2O) was 
purchased from Acros Organics (Geel, Belgium). Alkyne-functionalized PLP with an N-terminal 
4-pentynoic acid (homopropargyl, hp) modification, hpPLP139-151 (hp-HSLGKWLGHPDKF-OH) 
was purchased from Biomatik (Cambridge, ON, Canada). Unmodified PLP139-151 (NH2-
HSLGKWLGHPDKF-OH) used for EAE induction, rechallenge assays, and anti-PLP IgG ELISA 
was purchased from PolyPeptide Laboratories (San Diego, CA). Incomplete Freund’s adjuvant 
(IFA) and killed Mycobacterium tuberculosis strain H37RA were purchased from Difco (Sparks, 
MD). Pertussis toxin was purchased from List Biological Laboratories (Campbell, CA). PE/Cy7-
conjugated anti-mouse CD3, PE-conjugated anti-mouse CD86, Alexa Fluor 647-conjugated anti-
mouse CD19, and Brilliant Violet 421-conjugated anti-mouse CD11c were purchased from 




5.2.2 Preparation of Gelatin Methacrylate 
A 10% (w/v) solution of porcine gelatin was prepared in PBS. The solution was warmed 
to 60°C and stirred vigorously as methacrylic anhydride was added dropwise (up to 8% of total 
gelatin content) to methacrylate the amine groups on gelatin polymers. After two hours of 
continued mixing, the solution was diluted with PBS and dialyzed (12-14 kDa cutoff) with 
deionized water for one week with twice daily water changes. The dialyzed GelMA was frozen at 
-80°C before being lyophilized to yield a purified solid product. 
5.2.3 Fabrication of Homogenate-GelMA Scaffolds 
The mbhGelatin scaffolds were produced by creating a 2X (14%) solution of GelMA 
containing an excess of Irgacure 2959 photocrosslinker and a 2X solution of mouse brain 
homogenate in 1X PBS that was proportional to GelMA content by weight. GelMA and 
homogenate-containing solutions were mixed in equal parts and added to wells of a 24-well plate. 
Using a UV light source, the mixtures were photocrosslinked for 7 minutes. Gelatin constructs 
were then frozen overnight at -80°C and lyophilized for storage. 
5.2.4 Synthesis of plpGelatin Materials 
 PLP-conjugated materials were prepared as previously described15. Briefly, blank gelatin 
scaffolds were hydrated in pH 8.3, 50 mM HEPES buffer. 2 mg/mL azido-PEG4-NHS was added 
and the mixture was reacted for 4 hours at room temperature. The materials were washed 5 times 
in deionoized water before being placed in a solution of 2 mg/mL hpPLP139-151 prior to the addition 
of a premixed solution of 4.5 mM THPTA and 0.8 mM copper (II) sulfate pentahydrate. Sodium 
ascorbate (16 mM) was added to commence the reaction, which was run overnight at room 
temperature. The resulting plpGelatin materials were washed 5 times in deionized water and stored 
in 100% ethanol. PLP conjugation to collagen sponges was determined using a 20 minute Reverse-
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Phase HPLC method employing a 95/5 to 30/70 aqueous:organic gradient scheme on a C4 RP 
column.  
5.2.5 Characterizing Complex Decoys 
Scanning electron microscopy (SEM) was carried out at 150X, 500X, and 1000X 
magnifications to approximate gelatin pore size. SEM images were taken on an FEI Technai F20 
XT Field Emission Transmission Electron Microscope with dehydrated gelatin hydrogels. 
mbhGelatin constructs of varying homogenate contents were subjected to rheological and 
mechanical testing to characterize homogenate effects on these properties. Rheological testing was 
carried out across oscillatory frequency and strain sweeps using an AR2000 rheometer. Elastic 
modulus, G’, and loss modulus, G”, were recorded. Frequency sweeps consisted of oscillatory 
measurements at a low fixed strain (1%) with increasing frequency amplitudes to determine the 
G’ and G’’ of the constructs as a function of frequency. The strain sweeps consisted of oscillatory 
measurements at a fixed frequency (1 Hz) with increasing strain amplitudes. Tanδ is the ratio of 
G’’ to G’ and is used in strain sweeps to help recognize the strain at which the gel’s structure 
breaks mechanically. A release study was conducted by procuring 20mg sections of mbhGelatin 
at varied G:H ratios and adding to scintillation vials containing 20 mL of PBS. Across time points, 
1 mL of bulk solution was sampled and replaced with fresh PBS. Samples were quantified for 
overall protein content using a Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, 
MA). The loss of released material from sampling was accounted for when calculating cumulative 
release over time. 
5.2.6 Retained Antigen-Specificity Analysis 
2:1 mbhGelatin, Blank Gelatin, and PLP139-151-conjugated gelatin constructs were 
embedded and cryosectioned (20 µm sections) onto microscope slides. Each sample was fixed 
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using 10% neutral buffered formalin and blocked with 1% bovine serum albumin. Samples were 
then incubated with mouse serum containing antibodies for PLP139-151. Following the incubation, 
samples were washed, and bound antibody was detected using HRP-conjugated anti IgG. TMB 
substrate was incubated with the slides for 15 minutes, and pictures were taken to visualize PLP-
specific binding. 
5.2.7 Induction of EAE and Therapeutic Study 
Experimental autoimmune encephalomyelitis was induced as previously described15. 
Briefly, 4-6-week-old, female SJL/J mice (n = 4/group) were induced with EAE under 
authorization approved from a protocol passed by the University's Institutional Animal Care and 
Use Committee. Mice were subcutaneously administered the PLP139-151 autoantigen peptide 
epitope in complete Freund’s Adjuvant with the intraperitoneal coadministration of pertussis toxin 
capsid. Intraperitoneal injection of pertussis toxin was repeated on day two post-induction. On day 
4, mice received subcutaneous surgery for the implantation of either mbhGelatin, plpGelatin, 
Blank Gelatin, or Mock Surgery located between the shoulder blades. Over the course of 25 days, 
disease progression was monitored using a 5-point clinical scoring scheme which increases as a 
function of paralysis, including: 0, no clinical evidence of disease; 1, tail weakness or limp tail; 2, 
paraparesis (weakness or incomplete paralysis of one or two hind limbs); 3, paraplegia (complete 
paralysis of two hind limbs); 4, paraplegia with forelimb weakness or paralysis; and 5, moribund.  
In parallel throughout the study, weight change data was collected. 
5.2.8 Detection of Anti-PLP IgG 
PLP-specific IgG titers were assessed using methods previously described19. Briefly, 
Immulon 2HB 96-well plates were coated in an isoelectric PLP solution (pH 9.5) overnight at 4°C. 
Plates were blocked with 1% bovine serum albumin before serum from mice in the therapeutic 
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study was introduced in serial dilution. HRP-Conjugated anti-mouse IgG (Biolegend) was used to 
detect bound anti-PLP IgG as TrueBlue substrate was added as an indicator. The enzymatic 
conversion was stopped with a 2N sulfuric acid solution, and plates were read at 450 and 540 nm 
absorbances on a Spectramax M5 plate reader from Molecular Devices (San Jose, CA). For 
analyzing titer, linear regions across sample titration readings were fitted with linear regressions 
and extrapolated to their 1X concentration for comparison across samples.  
5.2.9 Spleen Harvest and Splenocyte Isolation 
Spleens were resected from mice and placed into 5 mL of sterile PBS. A wire mesh and 
the rubber stopper of a sterile 1 mL syringe was used to grind the spleen.  The unlysed cell 
suspension was centrifuged, and the cell pellet was resuspended in 1 mL red blood cell lysis buffer 
(Sigma Aldrich, St. Charles, MO). The cells were incubated for 7 minutes to lyse splenic red blood 
cells.  The reaction was quenched by adding 10 mL RPMI 1640 media containing 10% FBS to the 
mixture, and the suspension was centrifuged.  The remaining splenocyte pellets were resuspended 
in fresh media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and 
counted for further analysis and experimentation.   
5.2.10 Ex Vivo Screening with EAE Splenocytes 
At peak of disease (Day 12), mixed EAE splenocytes were harvested and plated at 1.5 x 
106 cells per well in a 24-well untreated plate containing either media alone (-PLP), soluble antigen 
rechallenge (+PLP), mbhGelatin sponge, or Blank Gelatin sponge. After 96 hours, sponges were 
minced with microscissors and the culture suspension was collected and passed through a cell 
strainer for further processing and analysis. 
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5.2.11 Fluorescent Staining and Flow Cytometry 
Samples were collected and washed in FACS buffer containing 1X PBS + 5% fetal bovine 
serum + 0.1% sodium azide. Samples were resuspended in a solution containing Zombie Aqua 
viability stain (Biolegend) and were incubated for 20 minutes at room temperature. Following the 
incubation, fluorescent antibodies were added at manufacturer recommended concentrations for 
30 minutes at 4°C. Samples were washed and run on a BD FACSFusion cytometer, where 100,000 
events were collected per sample. Data were analyzed using FlowJo and GraphPad Prism. 
5.2.12 Resazurin Cell Metabolism Assay 
After 96 hours of incubation, samples were incubated with 75 µM resazurin (7-hydroxy-
3H-phenoxazin-3-one 10-oxide) for 3 hours. Metabolic reductive capacity was measured by 
assessing changes in fluorescence (560 excitation, 590 emission, Spectramax M5, Molecular 
Devices, San Jose, CA). Background fluorescence was subtracted out by taking measurements of 
RPMI media alone. 
5.2.13 Statistical Analysis 
Statistical analysis was performed using an ordinary one-way ANOVA with uncorrected 
Fisher’s LSD test. Statistical significance was set beginning at p < 0.05 and was assessed by 
comparing treatment values one group as a control (unless otherwise stated). All analyses were 
performed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA).  
 
5.3 Results 
5.3.1 Fabrication of Complex Decoys 
Complex decoys were designed to recapitulate the phenomenon uncovered by PLP139-151 
peptide-conjugated, microporous collagen sponges in their impressive efficacy against EAE15. We 
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positioned complex decoys as a first translational step toward addressing the polyantigenicity of 
most authentic human autoimmune diseases. By incorporating primary tissue homogenate from 
the compartment implicated in disease, we hypothesized that comprehensive autoantigen coverage 
could be represented by a porous biomaterial for immunotherapeutic benefit. To investigate the 
incorporation of homogenized brain tissue into GelMA microstructures, we prepared mixtures of 
GelMA (7% w/w) with MBH at various Gelatin:Homogenate (G:H) ratios for photocrosslinking. 
Each mixture yielded microporous materials when exposed to UV light and lyophilized (Fig. 1). 
SEM imaging revealed that the homogenate appeared to be incorporated into the architecture of 
columnar pores. Increasing MBH content illustrated a trend of decreasing biomaterial porosity, 
particularly when homogenate composition was in excess to GelMA. Gelatin-alone hydrogels 
were produced with a ~50 µm pore size, and 3:1 G:H and 2:1 G:H closely mirrored this porosity. 
As homogenate was included in excess (1:1, 1:2, 1:3 G:H), pores were less prevalent and were 




Figure 1. SEM of complex decoys for visualizing homogenate incorporation into gelatin 
methacrylate microstructures. The 7% gelatin methacrylate was mixed with varying ratios of 
mouse brain homogenate prior to photocrosslinking and lyophilizing to yield microporous 
biomaterials.  
 
5.3.2 mbhGelatin Decoys are Persistent Depots that Incorporate Primary Tissue 
Homogenate and Retain Antigen-Specificity 
To assess the influence of homogenate inclusion on GelMA material properties, we 
subjected the varied G:H ratio mbhGelatin constructs to a strain-sweep for rheological testing (Fig. 
2). Most mbhGelatin materials exhibited similar deformation response curves excepting 1:3 G:H 
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(the extreme homogenate-containing hydrogel), which showed divergent behavior in its elastic 
modulus (Fig. 2a). Shifts in rheological properties occurred at different strain points among the 
various ratios tested, so we further analyzed measurements at the discrete strain point of 0.32 (Fig 
2b). G’ values did not vary significantly at this point of separation, but a homogenate-dependent 
trend was evident in that increasing homogenate content led to increasing elastic modulus 
measurements. Conversely, changes in the viscous modulus, G”, appeared to indicate that the 
inclusion of homogenate may have led to a similarly decreased readout across G:H contents, 
though 1:1 G:H exhibited a viscosity similar to gelatin-alone. The G”/G’ ratio (tanδ) illuminated 
material propensities for being dominated by elastic or viscous properties. The inclusion of 
homogenate into the gelatin microstructures generally conferred a greater material resilience 
(noted through a G”/G’ ratio of less than 1 across greater strain forces). This observation further 
suggested that the homogenate was successfully integrated into the architecture at some level. 
 To establish mbhGelatin as an implantable decoy therapeutic, it was important to assess 
the irreversibility of homogenate incorporation into the materials. Toward this end, we conducted 
a month-long release study of these constructs across the various G:H ratios (Fig. 2c). Release was 
dependent upon time and homogenate content, as released protein increased gradually over the 
course of the 31 days and was more pronounced in 1:3 G:H than in other groups. There appeared 
to be a slight burst release of unincorporated homogenate, as after 1 day both 3:1 and 1:3 G:H 
released significantly more protein than gelatin alone. After 31 days, however, 3:1 G:H cumulative 
release was statistically similar to gelatin alone while 1:3 G:H continued to increase.  
 Finally, it was necessary to investigate the retained discrete antigenicity of epitopes in 
homogenate after its incorporation into GelMA materials. We cryosectioned blank gelatin, PLP139-
151-conjugated gelatin, and 2:1 G:H gelatin onto microscope slides and used the materials as 
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substrates for an anti-PLP IgG ELISA. No anti-PLP IgG was detected on the blank gelatin sponge, 
and a definitively positive signal was evident with the peptide-conjugated gelatin (Fig. 2d). 
mbhGelatin exhibited an intermediate signal, indicating some binding. PLP represents just one of 
many material constituents of the CNS, so it was rational to observe a lower-intensity reading as 
the result of lower overall abundance.  
 
 
Figure 2. Material characterization of complex decoys of varied homogenate content. a. 
Rheological analysis across a strain sweep yielded storage modulus (G’, left), loss modulus (G”, 
middle), and tanδ (G”/G’, right) information. b. To analyze strain sweep data with greater 
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resolution, G’ (left), G”(middle), and G”/G’ (right) are reported at 0.32 strain, a region of the 
greatest separation. c. A release study was conducted over the course of 31 days, in which data are 
reported for a blank gelatin sponge (1:0 G:H left), minimal homogenate sponge (3:1 G:H, middle), 
and maximal homogenate sponge (1:3 G:H, right). d. ELISA methods were used to detect the 
ability of anti-PLP-containing serum to bind cognate antigen. (Statistical analysis was performed 
against 1:0 G:H as a control. n = 3-4/group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
 
5.3.3 mbhGelatin Decoys Elicit a Cellular Response and Amplify Antigen-Specific B 
cells ex vivo 
2:1 G:H were selected for advancement to biological assays because they facilitated 
retained porosity (Fig. 1) with the most homogenate loading. EAE splenocytes were harvested at 
peak of disease and plated with vehicle, soluble PLP139-151, blank gelatin sponges, or mbhGelatin 
(2:1 G:H) for 96 hours (Fig. 3). After the incubation, cell metabolism in response to the treatments 
was measured with resazurin (Fig. 3a). Both soluble antigen challenge and blank gelatin enabled 
a slight increase in metabolism after the interval, but mbhGelatin elicited over a four-fold increase 
in resazurin, suggesting greater cellular activity. In parallel, cells were harvested from wells and 
sponges and prepared for flow cytometry analysis (Fig. 3b-g). Gelatin biomaterials appeared to 
provide a favorable substrate for B cell viability; both blank gelatin and mbhGelatatin retained 
significantly more CD19+ cells than -PLP and +PLP, where mbhGelatin provided maximal 
retention. This B cell retention logically correlated inversely with CD3+ cell prevalence (Fig. 3c). 
Over 80% of surviving splenocytes in the -PLP and +PLP groups constituted T cells, while slightly 
less were present in blank gelatin and significantly fewer were appreciable after mbhGelatin 
treatment. Antigen presenting cells (CD11c+) were generally consistent among treatment groups 
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(Fig. 3d). CD19+CD11c+ antigen-presenting B cells were analyzed as a subset of interest that is 
implicated in autoimmunity (Fig. 3e), but only subtle differences were observed. mbhGelatin also 
maximally increased CD86 (Fig. 3f). This costimulatory marker was also significantly elevated by 
+PLP and blank gelatin. Finally, FITC-labeled soluble antigen arrays (SAgAs) incorporating 
multivalent PLP were used to detect anti-PLP B cell receptors (Fig. 3g). Few events were detected 
at baseline or after 96 hours with -PLP or +PLP incubation. One replicate of blank gelatin led to 
elevated PLP-specific B cells, but this amplification was not consistent as the other two readouts 
were comparable to other controls. mbhGelatin, however, evoked consistent and statistically 





Figure 3. Ex vivo analysis of EAE splenocyte responses to complex decoys. a. The resazurin assay 
was used to assess changes in cell metabolism after incubating splenocytes for 96 hours with 
vehicle (grey), 25 µM PLP (black), blank gelatin (green), or mbh sponges (blue). After the 
incubation, flow cytometry was used to assess proportionality of populations expressing the 
markers CD19 (b.), CD3 (c.), CD11c (d.) as well as CD19+CD11c+ antigen-presenting B cells 
(e.) and costimulated CD86+ cells (f.). FITC labeled, dendrimeric PLP was used to quantify the 
presence of antigen-specific B cells as well (g.). (Statistical analysis was performed against –PLP 




plpGelatin, but not mbhGelatin Decoys Suppress EAE in vivo. EAE mice were implanted with 
either mock surgery, blank gelatin, plpGelatin, or mbhGelatin on day 4 post induction (Fig. 4). 
plpGelatin suppressed disease as evidenced by clinical scoring, weights, cumulative score, and 
disease incidence (Fig. 4a-d, respectively). Only 3 of 4 plpGelatin-implanted mice developed 
EAE, while all mice in other groups exhibited symptoms to some degree (Fig. 4d). mbhGelatin 
did not alter disease course in EAE mice. Homogenate-containing biomaterials may have even 
exacerbated EAE symptoms, as 1 of 4 mbhGelatin mice succumbed to disease and died during the 
study. No mice were lost in the other control groups, and mbhGelatin trended slightly higher in 
cumulative disease score (Fig. 4c), though the increase was not statistically significant. 
 
 
Figure 4. Clinical data from the in vivo implantation of EAE mice with complex decoys. Clinical 
scores (a.) and weights (b.) are reported for mice implanted with either mock surgery (black), 
blank gelatin (green), plpGelatin (red), or mbhGelatin (blue). c. Cumulative scores across 25 days 
are reported. d. the first incidence of disease was tracked across the study as well. (Statistical 
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analysis was performed against -PLP as a control. n = 4/group, *p < 0.05, **p < 0.01, ***p < 
0.001). 
 
5.3.4 EAE splenocytes are largely unchanged by prophylactic mbhGelatin 
implantation 
After the 25-day therapeutic efficacy study, spleens and serum were harvested from mice 
in each group and processed for further analysis (Fig. 5). Spleen weights were measured upon 
harvest, where no significant differences were observed, although the one mouse that did not 
exhibit EAE symptoms in the plpGelatin group did exhibit a more massive spleen that was 
statistically determined to be divergent from the rest of the set (Grubbs outlier test, α = 0.05, Fig. 
5a). Generally, more splenocytes were harvested from plpGelatin-implanted mice, but this 
difference was not statistically significant (Fig. 5b). Serum from mice was used to determine anti-
PLP IgG Titer among each group (Fig. 5c). plpGelatin exhibited a consistently slightly higher titer 
than other groups, and both mock surgery and blank gelatin each had one mouse with higher titer 
than others in the group. Flow cytometry was used to assess changes in cell populations after 96 
hours of vehicle (-PLP, open bars) or antigen challenge (+PLP, solid bars, Fig. 5d-i). CD3+ cell 
proportionality among splenocytes was largely unchanged among groups after 96 hours, though 
they consistently constituted less in the +PLP group than with -PLP (Fig. 5d). CD19+ B cells 
increased with antigen challenge, and plpGelatin and mbhGelatin showed slightly elevated 
proportions, though not statistically significant (Fig. 5e). In terms of antigen-specific B cells, 
however, both blank gelatin and plpGelatin exhibited significantly higher proportions than mock 
surgery after antigen challenge (Fig. 5f). Splenic CD11c+ populations were not notably different 
between groups, however they increased in proportion after antigen challenge in the mock surgery 
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group while other groups showed a decrease after PLP incubation (Fig. 5g). mbhGelatin-implanted 
mice showed significantly higher costimulation than mock surgery controls (Fig. 5h). 
CD19+CD11c+ double positive cells were not different among groups (Fig. 5i). Finally, resazurin 
was used to quantify changes in cell metabolism among harvested splenocytes (Fig. 5j). Trends 
were strikingly similar between groups after 96 hours of incubation with vehicle, PLP, or mitogen 





Figure 5. After the 25 day in vivo study, spleens were harvested and splenocytes were isolated. 
During isolation, spleens were weighed (a.) and harvested splenocytes were counted (b.). c. serum 
was harvested from mice and anti-PLP IgG was quantified. Splenocytes were incubated with (solid 
bars) and without (open bars) PLP rechallenge for 96 hours before being labeled for flow 
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cytometry. Data reflect marker expression for CD3 (d.), CD19 (e.), SAgA+CD19+ cells (f.), 
CD11c (g.), CD86 (h.), and CD19+CD11c+ antigen-presenting B cells (i.). j. resazurin cell 
metabolism is reported after 96 hour challenge with vehicle, PLP, or concavolin A. (Statistical 
analysis was performed against -PLP as a control. n = 3-4/group, *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001). 
 
5.4 Discussion 
 Our previous exploration of the decoy effect employed single epitope-conjugated 
microporous collagen sponges against an analogous single epitope model of autoimmunity 
(PLP139-151-EAE) to illustrate that the antigen-specific exhaustion of autoimmune effector cells 
could prematurely return these populations to lymphoid organs and prevent disease15. Presently, 
we set forth to create a polyantigenic complex decoy as a first step to extrapolate these effects for 
authentic, polyclonal immune-mediated diseases. It was necessary to fabricate a microporous 
biomaterial that was immunologically inert, irreversibly associable with autoantigen, and 
antigenically functional. GelMA was selected as a constituent material for its biocompatibility and 
versatility in biological applications, and gelatin is chemically autologous to the collagen used in 
our previous application20.  
 Photocrosslinkable GelMA was able to incorporate MBH and manifest as a microporous 
architecture (Fig. 1, 2). SEM imaging revealed that porosity was homogenate-dependent in 
determining size. As increasing amounts of homogenate were added prior to crosslinking the 
materials, we logically observed columnar formations of larger sizes and smaller pore diameters 
as a result. We theorized that a minimum pore diameter of 50 µm would be sufficient to facilitate 
unhindered cell and nutrient transfer21, 22, and 2:1 G:H decoys enabled the highest loading of MBH 
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without falling below this threshold. Interestingly, as MBH mass equaled and exceeded that of 
GelMA in the formulation (1:1, 1:2, and 1:3 G:H), pore architecture changed from a thin, spider 
web-like phenotype to one more comparable to interpenetrating sheet-like structures (Fig. 1). In 
rheological testing analysis, it was apparent that the elastic modulus was slightly increased with 
greater inclusion of homogenate (Fig. 2b) 1:1 G:H sponges were consistently divergent from the 
rest of the set; it is unclear why this discrepancy emerged, but perhaps it is indicative of an 
intermediate transition occurring while the material is predominately GelMA versus becoming 
predominantly MBH. Nevertheless, G’ and G” readouts across the strain sweep experiments 
follow the same response trends. This observation was to be expected, as GelMA hydrogels are 
largely fabricated to resemble the viscoelastic properties of authentic tissue. Therefore, both 
GelMA and MBH should conceivably present similar material properties and lead to these 
consistent trends. 
The influence of MBH on the elastic moduli of mbhGelatin variants implies that the 
homogenate was incorporated to the GelMA structure since it contributed some material 
resilience23. However, mechanical testing alone cannot verify that MBH is irreversibly associated. 
To investigate the lasting immobilization of homogenate into the sponges, we conducted a month-
long release study and found that after 31 days, mbhGelatin that is composed of a majority gelatin 
does not differ significantly from gelatin alone (Fig. 2d). This finding suggested that though some 
homogenate is unincorporated (being released early-on), tissue is retained in majority-gelatin 
materials. Combining SEM assertions (Fig. 1) with rheology and release trends (Fig. 2), 2:1 G:H 
materials were selected for further experimentation. Importantly, anti-PLP IgG bound with 2:1 
G:H mbhGelatin to exhibit retained antigen functionality, fulfilling the last of our identified criteria 
for realizing a complex decoy (Fig. 2d).  
166 
 
Seemingly conflicting outcomes emerged between the ex vivo assays and in vivo 
therapeutic study (Fig. 3, 4, 5). Central to the apparent PLP-conjugated decoy mechanism our 
previous report was the activation and overstimulation of PLP-responsive cell subsets. 
Determinants of overstimulation conserved from PLP decoys were elevated cell metabolism and 
expression of costimulatory marker CD86, which were both significantly elevated by mbhGelatin 
during the ex vivo screen (Fig. 3f). However, these increases did not appear to confer exhaustion 
in vivo, as mbhGelatin-implanted mice exhibited the highest cumulative disease score (Fig. 4c) 
and no suppression of effector cells was evident as was the case with PLP-conjugated decoys from 
the previous work. CD86+ costimulation was higher in mbhGelatin splenocytes than in controls, 
but differences were slight and may have contributed to further destructive action rather than being 
substantial enough to cross a threshold into overstimulation and exhaustion.  
Indeed, the line between immune action and exhaustion can be rather fleeting; these 
opposing results that stem from the same stimulus can be driven by a variety of factors24-26. Antigen 
valency is established as a major determinant27-30. Much work has been done to show the 
relationship between characteristics such antigen dose and persistence in tipping the balance 
between action and anergy27, 31, 32. In the present work, it rationally proceeds and was evident from 
Fig. 2d that plpGelatin was substantially more positive for anti-PLP IgG binding than mbhGelatin. 
Such a discrepancy could explain the difference in magnitude of costimulation and ultimately 
immune cell fates between exacerbation or amelioration of disease.  
While included as a control group for the in vivo study, plpGelatin-implanted mice 
illuminate important qualities that the “decoy effect” harnesses to be therapeutically relevant. Mice 
treated with plpGelatin exhibited suppressed disease (Fig. 4), but one of the four mice in the group 
was protected from EAE symptoms altogether (Fig. 4d). Interestingly, this same mouse’s spleen 
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was over twice as massive as nearly all others in the study (Fig. 5a). In the first exploration of 
antigen-specific decoys, engorged lymphoid organs were recognized as a consistent phenomenon 
in implanted mice that showed suppressed or no disease15. The fact that the spleen was engorged 
in this mouse for which disease was prevented illustrates that the phenomenon of premature splenic 
return may be critical to the overall driving mechanism of immune decoys.  
Though mbhGelatin was not therapeutic, the polyantigenic biomaterial demonstrated an 
ability to amplify PLP-specific B cells ex vivo (Fig. 3g). Such functionality has the potential to 
demonstrate utility in characterizing autoimmunity for patients where tracking disease progression 
and status is difficult and expensive. For example, in MS, detectable autoimmune biomarkers are 
largely evidenced exclusively in the central nervous system33. Autoreactive cells are of low-
prevalence in peripheral blood, and blood tests aiming to diagnose MS require elaborate single-
cell and sequencing techniques34. Further development of mbhGelatin biomaterials could offer a 
lower-cost alternative for the amplification and analysis of MS biomarkers in the blood, but future 
studies are needed. Ongoing work would be beneficial in seeking to characterize ex vivo 
amplification in human patient samples and tie phenotypical changes back to discrete epitope 
specificities as a strategy to more precisely monitor and treat MS35, 36.  
There is undoubtedly a clinical need for precise immunotherapies that can selectively target 
aberrant autoimmune cells while preserving healthy host functions37, 38. Antigen-specific 
immunotherapy leads the charge toward this end, but solutions that can accommodate the 
heterogeneity and transience of autoimmunity are still needed. Ideated as an answer to this call but 
ineffective at treating disease, important lessons can be gleaned from immune decoys. Single-
epitope decoys assert that establishing an immunological niche can be of great benefit for directing 
immunity39, 40, but mbhGelatin illustrates that it is critical to consider additional properties such as 
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antigen loading density. Moving forward, perhaps new approaches will do well to deliver and 
retain immunomodulatory signals in disease-implicated compartments as niches of their own to 
confer broader coverage while limiting systemic effects. 
 
5.5 Conclusions 
 MBH-containing, microporous complex decoys were successfully fabricated by mixing 
primary brain tissue with GelMA. Tissue was immobilized within the gelatin architecture and 
exhibited a retained ability to bind anti-PLP IgG. mbhGelatin decoys were able to amplify antigen-
specific B cells among EAE splenocytes ex vivo. plpGelatin, but not mbhGelatin, suppressed 
disease in vivo, highlighting a key discrepancy in the exhaustion threshold needed to ameliorate 
disease. Future work is needed to refine polyantigenic decoys as viable, translatable solutions for 
treating human autoimmunity. 
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6.1  Conclusions 
 In chapter 1, we explored the physical and chemical factors that dictate the transport and 
effects of parenterally delivered autoantigen formulations. Looking at established allergen 
desensitization regimens as a standard for optimal immune interfacing, we illuminated 
discrepancies between these small (10-70 kDa), soluble (GRAVY score <0), and slightly 
negatively-charged (PI ~5-7) entities and autoantigen counterparts, which often embody extreme 
characteristics outside of these ranges. Our conclusion from reviewing antigen-specific 
immunotherapy (ASIT) literature and clinical trials was that delivery systems and biomaterials not 
only enhance autoantigen delivery to secondary lymphoid organs, but are likely necessary to 
format self-antigens in a way to most effectively influence autoimmunity.  This analysis served as 
the foundation from which the experimental works in this dissertation emerged. We leveraged 
three autoantigen delivery formats – soluble, particulate, and depot – to glean meaningful insights 
about physicochemical drivers of effect using experimental autoimmune encephalomyelitis (EAE) 
as a model of autoimmunity.  
 Chapter 2 initiated the scope of this dissertation by adopting the soluble antigen array 
(SAgA) as a platform to enumerate the role of valency in dampening autoimmunity. Prior to this 
work, the SAgA was well characterized to evoke B cell anergy and therapeutic tolerance by 
clustering B cell receptors. Past work had been done to assess delivery system properties such as 
structure, size, and solubility, but more nuanced components like ligand valency had not been 
explored. We hypothesized that by titrating this property, an optimal inhibitory configuration could 
be discovered to inform tailored SAgA design and future iterations. Both one- and two- signal 
SAgAs were evaluated in this analysis, and the inclusion of both revealed that autoantigen valency 
(not overall ligand valency) was the major driver of effect in autoreactive B cells and mixed 
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splenocytes. Antigen valency proved to correlate inversely and strongly with both acute measures 
of inhibition in a B cell line and downstream indicators of tolerogenesis in mixed splenocytes. We 
proposed a more optimally configured SAgA format expressing 4-7 autoantigen epitopes per 20 
kDa hyaluronan backbone rather than the conventionally invoked 10 epitopes per backbone.  
 Particulate ASIT formulations for autoimmunity have been historically appealing for their 
similarities to vaccine formulations and ability to target immune-directive antigen-presenting cell 
populations. However, many of the tools for these approaches have been adapted from vaccine 
development where immunogenicity is desired. As a result, some vehicles for delivering 
autoantigen can cause inflammation which must be overcome by codelivering immunomodulatory 
drug. In chapter 3, we hypothesized that by developing a “functional” ASIT delivery vehicle, 
therapeutic efficacy would be contributed. We selected FDA-approved α-tocopherol emulsions 
(ETPGS) as a delivery system, as vitamin E is capable to mediate immunity through antioxidant 
mechanisms. We were able to deliver antigen with these formulations by developing a recipe to 
produce nanoparticles around 300 nm in diameter. ETPGS inhibited macrophage reactive nitrogen 
and oxygen species production in vitro, suggesting the antioxidant mechanism could inhibit innate 
immune actors.  
We conducted a therapeutic study and discovered that the delivery of ETPGS containing 
autoantigen suppressed EAE in vivo. Following the therapeutic study with ex vivo analyses, 
however, it became apparent that the ETPGS delivery vehicle may not be enacting effect in the 
way we initially hypothesized. Both pro- and anti-inflammatory cytokines were elevated in mice 
treated with these formulations. Flow cytometric splenocyte analysis showed that cell phenotypes 
did not differ from controls. Ultimately, we assessed the production of autoantigen-specific IgG 
between the serum and central nervous system, and we discovered that a majority of IgG was 
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relegated to the periphery in the ETPGS plus autoantigen group. Further, we noted during the 
therapeutic study that the ETPGS formulations seemed to indefinitely persist at the injection site. 
We posited that rather than being tolerized, the autoimmune response may have been simply 
diverted from reaching the central nervous system by prioritizing and persisting near the 
autoantigen-rich subcutaneous depot formed by ETPGS. However, since ETPGS could 
hypothetically be evoking both immunomodulatory and “decoy” effects, we needed a new system 
to enable exploration of these claims. 
Without definitive evidence for a decoy mechanism of therapeutic efficacy in 
autoimmunity, we set forth to design a biomaterial that could isolate and evaluate this 
functionality. Chapter 4 details the invention of the antigen-specific immune decoy (ASID), an 
immunologically inert biomaterial providing a substrate for irreversibly immobilized antigen 
formulation that was designed to persist at the site of implantation. We developed this microporous 
biomaterial by chemically conjugating autoantigen to the surface of collagen sponges. Antigen 
remained functional after conjugation to the surface and was undelivered due to the irreversibility 
of the conjugation scheme. We implanted ASIDs into EAE mice and found the biomaterials 
capable to prevent disease in vivo. ASIDs appeared to intercept disease-causing autoreactive cells. 
Effector immune cells appeared to be severely exhausted by antigen overstimulation within 
ASIDs, evidenced by high levels of costimulatory markers but a similarly high prevalence of 
apoptosis in response to autoantigen rechallenge. These cells did not appear to regain functionality, 
as a subsequent in vivo study revealed that ASID-implanted mice did not exhibit relapsing disease 
while control mice robustly relapsed. In all, ASIDs seemed to intercept and exhaust autoreactive 




 Chapter 5 set forth to advance from compelling validation of the decoy effect outlined in 
chapter 4 by translating the phenomenon to a format that might be conducive for treating authentic 
human disease. Chapter 4 detailed “simple” ASIDs decorated with the same peptide epitope used 
to induce autoimmunity in EAE mice. In human multiple sclerosis, a plethora of ever-changing 
autoantigens are targeted by the immune system. To account for this polyclonality, “complex” 
ASIDs were fabricated by integrating primary brain tissue homogenate into microporous 
collagenous hydrogels. We hypothesized that these decoys would present with the full palette of 
conceivable multiple sclerosis antigens while retaining discrete antigen specificity. To assess the 
latter of this supposition, we evaluated complex ASIDs both ex vivo and in vivo. Ex vivo, complex 
ASIDs behaved similarly to what we observed in simple ASIDs. Complex decoys stimulated 
antigen-presenting cells and led to the amplification of antigen-specific cell populations. These 
events are important precursors to cellular exhaustion. When complex decoys were implanted in 
EAE mice, however, therapeutic effect was elusive. This result indicated that a critical property 
was lost in translating ASIDs from simple to complex. As a result, ongoing work will shed light 
on this essential parameter.  
6.2 Future Directions 
In the midst of unexpected results from a first step in translating the decoy effect for human 
disease, we are brought back full-circle to indelible lessons from the foundational chapters of this 
dissertation. Chapters 1 and 2 illustrated the importance of antigen valency in directing the immune 
response. Indeed, the observation that low-valency SAgAs were most effective at tolerizing B cells 
and splenocytes stems from seminal work by Howard Dintzis. This determinant is a double-edged 
sword, however, as Dintzis taught us that on the other side of tolerogenesis is immunogenicity, 
brought on by high levels of antigen density. Reconciling this observation with the discrepancies 
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between simple and complex decoys, it seems that antigen valency may yet again be playing a 
critical role. Simple decoys consisted of a full surface saturation of autoantigen epitope, as the 
chemistry was carried out in excess. Conversely, complex decoys were ultimately fabricated with 
a half as much primary brain homogenate as gelatin, and the autoantigen epitope content within 
the heterogenous homogenate constitutes yet another vastly small fraction of total protein. While 
complex decoys were able to express some discrete epitope functionality that contributed to 
antigen-specific cell activation ex vivo, it is likely that the stimulatory threshold for cellular 
exhaustion was not met in vivo. As such, we must return to the single-epitope simple decoy system 
to investigate these claims. Future investigation into decoyed immunity should explore the role of 
autoantigen density for causing therapeutic effect. Much like valency was titrated in chapter 2, 
autoantigen conjugation should be discretely varied to evaluate constructs against EAE in vivo. 
We hypothesize that a threshold will become evident where autoantigen content lower in quantity 
will not protect against disease while higher loading will provide sufficient cellular exhaustion to 
prevent disease. 
 The step toward translating decoyed immunity in chapter 5 represents just one 
manifestation of extrapolating the success of the works in chapter 4. Simple decoys illustrate the 
power of engineered microenvironments in leveraging effect against the autoimmune response. 
The translation to complex decoys in chapter 5 strives toward accounting for the heterogeneity and 
polyclonality of human disease. While there is still promise for this platform with more 
intelligently-designed material properties, we may also be well-served to exploit immunological 
microenvironment engineering in alternate ways. One such avenue of interest could be to target 
the tissue compartment implicated in autoimmune destruction for delivering immunomodulatory 
factors to directly to instill an instructive depot at the site of inflammation where yet again, all 
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autoantigen epitopes are present. Advances in protein engineering have paved the way for 
opportunities such as the production of monoclonal antibodies consisting of specificities for 
regions such as the lesion microenvironment in multiple sclerosis or locales of islet destruction in 
type 1 diabetes. These specificities could be leveraged to deliver inhibitory factors or drugs to 
reestablish the microenvironment in a tolerogenic context to ultimately confer bystander effects 
and protection from disease.  
 The works presented in chapters 3 through 5 proceed in tandem and intuitively, however 
the lessons learned in chapter 2 provide the foundation for substantial future work within the SAgA 
platform as well. By elucidating that lower-valency conjugates (4-7 epitopes/backbone rather than 
10) are most ideal for pursuing B cell anergy as a therapeutic mechanism, new research 
opportunities have emerged. To date, SAgAs have consisted of autoantigen grafted onto linear 
hyaluronan backbones. The utility of this material has been favorable the conjugation of arrays 
ranging from 10-20 ligands. However, taking to heart the low-valency design parameter outlined 
by chapter 2, new manifestations of these constructs can be ideated with similar size and solubility 
properties. Multi-armed polymers such as 4-arm poly(ethylene)-glycol backbones can provide a 
discrete number of functional handles for conjugation that overcomes heterogenous linear 
polymers in terms of scale-up manufacturability. Ongoing work around the SAgA platform may 
benefit from evaluating multi-arm configurations against classical linear ones to assess whether 
additional value may be grasped through adopting multi-dimensional backbones with similar 
molecular weights and hydrodynamic radii.  
 
 
